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Abstract 
The characterization of the  protein, eventually renamed to Escherichia coli 
Topoisomerase I (EcoTopoI), by Prof. James C Wang opened the door to the previously 
unknown world of molecular machines that manipulate DNA topology. Since then, 
topoisomerases have been demonstrated to be vital instruments of the cellular machinery in a 
wide array of processes that are essential for life such as DNA synthesis, DNA repair and 
chromosome segregation. Their essentiality is further exemplified through the fact that these 
molecular machines have been identified in every species sequenced to date regardless of 
domain. As a result, they remain to be a therapeutic target of interest with numerous drugs in 
various stages of development. 
Each class of topoisomerase has its own phylogenetic distribution. The focus of this study 
is the type IA topoisomerase III (TopoIII). From mice to men, higher order eukaryotes contain 
two TopoIII enzymes while lower order eukaryotes such as yeast contain a single TopoIII. 
Sequence examination and biochemical studies reveal that this is not the result of gene 
duplication. Instead, these enzymes have distinct biological roles. Methanosarcinales is the only 
sequenced archaeal order with this distinct distribution of two TopoIIIs. And yet, there is little 
information currently available on archaeal TopoIII. 
Here we report on Methanosarcina acetivorans TopoIIIα (MacTopoIIIα) as the first 
biochemically characterized mesophilic archaeal topoisomerase. The ensuing study delves into 
the biochemical properties of a singular topoisomerase from a relatively unexplored domain and 
utilizes a large-scale phylogenomic approach to illustrate the therapeutic potential of the specific 
class to which it belongs. This report provides the first analysis of over 2000 topoisomerase 
sequences from the type IA class. 
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Chapter 1. Introduction 
The revelation that the dichotomy of life is a trinity was discovered by Prof. Carl Woese 
on June 11, 1976 (1). While examining preliminary results of a Sanger Pattern from what was 
then considered a methanogenic bacterium, Prof. Woese realized that it was not in line with 
results for any of the previously characterized organisms in the domain Bacteria or Eukarya. 
Once published, his data would begin an uphill battle with the scientific community for 30 years 
to adopt this concept (2). 
We have since learned that Archaea are distinct from Bacteria and Eukarya while sharing 
certain traits with one or both domains.  For example, some genes are located in similar physical 
locations to Bacteria with the proteins often having a primary sequence that more closely 
resembles the counterpart in Eukarya (3). Like Bacteria, Archaea lack a nuclear envelope (4). 
However, unlike Bacteria, Archaea contain histones (5). In other ways, Archaea are completely 
unique such as having no fatty acids in their lipids (6). Archaeal membranes contain glycerol 
covalently linked to long chain carbons via ether linkages in place of the ester linkages observed 
in both Eukarya & Bacteria. Not only is this domain of life interesting to study, useful 
biochemical applications have been developed from the study of Archaea. For example, 
commercially available DNA polymerase with the highest fidelity and processivity originate  
from an archaeon (7). 
From the discovery of the three domains of life to developing novel transformation 
techniques, researchers at the University of Illinois have been at the forefront of discovery within 
the domain Archaea. Basic research on anaerobic archaea has led to important discoveries that 
have expanded the available molecular biology toolkit and our knowledgebase (2, 8, 9) 
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While the focus of this body of work is type IA DNA topoisomerases (specifically 
TopoIII), our scientific query begins with the archaeon Methanosarcina acetivorans C2A (Mac). 
This organism is an obligate anaerobic methanogen with the largest cocci reported to be about 2 
microns (10). It is a mesophile with the largest sequenced archaeal genome (11). With a 5.7 Mb 
genome and over 4500 genes, this organism is well-adapted to survive in diverse environments. 
Like other organisms, Methanosarcina acetivorans C2A has a serious genomic problem 
to address. The big problem is maintaining DNA topology during replication. If the double helix 
genome maintains a B-form structure with 0.34 nm between each base pair and it were laid out 
across the table, then it would be about 2 mM long (12).  This means that the linearized genome 
is about 1000x longer than the diameter of the largest identified cells. Through biochemical 
studies, we have learned that eukaryotic DNA is compacted into chromatin with a repeating 
structure of about 150 base pairs wrapped around a repeating tetramer of histones (13, 14). Once 
condensed, another issue arises as to how information is accessed and regulated for gene 
transcription. Topoisomerases are a class of enzymes intricately involved in addressing this 
problem (15). 
Topoisomerases are a diverse class of molecular machines that manage DNA topology 
(16). There are topoisomerases that relax positive and negative DNA supercoils without the use 
of ATP. There are also topoisomerases that use ATP to introduce either positive or negative 
supercoils. Chapter 2 provides a general overview of topoisomerase mechanism, structure and 
function. From the characterization of the first enzyme to the first crystal structure to the most 
innovative experiments, this chapter provides a general outline for the field. There is also an 
emphasis on novel discoveries. For example, the identification of a unique type II topoisomerase, 
DNA gyrase, with the ability to introduce supercoils and a unique phylogenetic distribution, has 
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led to the development of novel antibiotics (17, 18). DNA topoisomerase inhibitors are also the 
focus of a subset of medications that are prescribed to Cancer patients (19). These drugs can 
have serious side effects ranging from nausea to secondary malignancies.  
And while type IB and type II topoisomerases are the targets of various therapeutic 
agents, patients prescribed these anti-topoisomerase drugs often develop resistance within a 
small time frame (20). As a result, natural defense mechanisms limit their therapeutic utility. 
And while every sequenced organism has at least one type IA topoisomerase, there are currently 
no medications available that specifically inhibit this enzyme. 
One possible explanation for the lack of drugs that target type IA topoisomerases is the 
paucity of research conducted in this area in contrast to the other classes of topoisomerases. 
Though limited, the study of type I TopoIII has already benefitted our understanding in humans. 
The potential for human application from such endeavors is illustrated in yeast where scientists 
provided the first biochemical evidence that a helicase and a topoisomerase interact as a complex 
(21). These experiments provided the foundation for future experiments to demonstrate that 
human TopoIIIα has direct interaction with BLM, a helicase involved in Bloom syndrome, both 
in vitro and in vivo (22). Through studies in non-human systems, researchers provided the 
foundation for future studies in humans to probe the role between helicases and topoisomerases 
in order to advance our understanding of aging and diseased states (23).  
And while topoisomerase has been implicated in the interaction with premature aging 
genes, only recently have investigations turned to topoisomerase III as a potential therapeutic 
target of value (24). In one study in zebrafish, a TOP3A deletion was implicated in the 
development of T lymphocytes suggesting a potential role in human primary immunodeficiency 
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syndromes (25). In another study of breast cancer markers, TopoIIIβ expression was noted to be 
a useful independent marker in assessing the prognosis of patients with breast cancer. As 
evidence for the role of TopoIII in human disease grows, the number of therapeutic agents is at a 
relative standstill. 
Nonetheless, investigation into the physiologic role of TopoIII in eukaryotic development 
has also pointed to the essentiality of this class of enzymes. Originally discovered in yeast, the 
top3 gene encodes a protein which could not recover the phenotype of slow growth, but could be 
recovered with the expression of EcoTopoI. Only one type III enzyme was discovered in 
Schizosaccharomyces pombe - topoisomerase III (top3) and it forms a covalent linkage with the 
5’-end of the DNA backbone as every type IA topoisomerase does (26). Top3 knockout was able 
to germinate, but demonstrated a variety of growth defects such as abnormal chromosome 
segregation. The data suggests that faithful nuclear division requires a functional TopoIII.  
Research on eukaryotic TopoIII is sparse and it is even more limited in the area of 
archaeal type III topoisomerases. The first archaeal topoisomerase characterized, 
Desulfurococcus amylolyticus topoisomerase III (DamTopoIII), is from an extremely 
thermophilic archaeon (27). Like its eukaryotic and bacterial counterparts, DamTopoIII is an 
ATP-independent enzyme but has a unique temperature profile. It relaxes negatively supercoiled 
DNA at 60-80°C, but does both positive and negative supercoiling at 95°C. The salt dependence 
profile reveals that it is inhibited at NaCl concentrations ranging from 170 to 250 mM while 
Dam Reverse Gyrase is optimal in this range. The authors propose that this complementary 
activity may be important in vivo. 
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An acidophilic thermophile, Sulfolobus solfataricus, is the organism with the only other 
topoisomerase III (SsoTopoIII) characterized (28). SsoTopoIII is another ATP-independent 
enzyme that only relaxes negatively supercoiled DNA in a Mg2+-dependent fashion while being 
inhibited by M13 ssDNA. SsoTopoIII relaxation activity is optimal at temperatures above 65°C. 
The enzyme demonstrates unique sequence specificity. The equilibrium for cleavage-religation is 
disrupted at low temperatures (25°C) and high enzyme/substrate ratios such that cleavage is 
favored and a covalent adduct accumulates (29).  These studies demonstrate that more research is 
needed to determine what properties are valid across all domains to provide insights to the 
properties of the archetypal TopoIII.  
Archaeal type IA TopoIII topoisomerases represent an underexplored area with great 
scientific potential. Interestingly, all sequenced eukaryotes have a TopoIII topoisomerase while 
higher order organisms have two TopoIII topoisomerase genes. Though originally believed to be 
only one topoisomerase III in humans, there are two human TopoIII topoisomerases named 
topoisomerase IIIα (hTopoIIIα) and topoisomerase IIIβ (hTopoIIIβ) (30). Methanosarcinales 
represent the only sequenced archaeal order with two type I TopoIII enzymes and share greater 
sequence homology with humans than bacteria. Given the ubiquitous nature of type IA 
topoisomerases, it is necessary to further probe the fundamental properties and differences of 
each class of topoisomerase to improve upon our current array of medications. 
In Chapter 3, we investigate the fundamental biochemical properties of an archaeal 
TopoIII from a mesophilic archeon. A basic attribute of type IA topoisomerases is the 
requirement of Mg2+, a divalent cation, in the catalytic mechanism, but other divalent cations can 
substitute (31). While the role of Mg2+ is usually well examined, other divalent cations have not 
been systematically analyzed. For example, EcoTopoI was demonstrated to have DNA relaxation 
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activity after being examined in the presence of 0-10 mM Mg2+ or 2 mM Ca2+ while there was 
little or no activity observed in the presence of 2 mM Co2+, Mn2+ or Zn2+ (32). In another study, 
while the activity of hTopoIIIα was evaluated in the presence of a range of MgCl2 
concentrations, hTopoIIIα was deemed inactive based on data from a singular concentration of 
other divalent cations (30). In another divalent cation dependent assessment, SsoTopoIII  was 
demonstrated to have maximal activity in the presence of Mg2+ at 10 mM while Ca2+ was slightly 
able to substitute (28). The authors determined that Cu2+, Co2+, Mn2+ and Ni2+ could not elicit 
DNA relaxation activity. The divalent cation profile can act as a tool to distinguish 
topoisomerases and the potential to influence how topoisomerase inhibitors are packaged. In 
Chapter 3, we explore this fundamental property and others using MacTopoIIIα. 
Prior work has illustrated the value of systematic phylogenomic analysis of all 
topoisomerases (33). In Chapter 4, we build upon this approach through a focused evaluation of 
the type IA topoisomerases within over 2000 sequenced NCBI genomes across all domains of 
life. We narrow our analysis on some of the most conserved motifs (active site, DxD motif, 
GxxQ motif) in order to reveal previously unobserved domain-wide and domain-specific 
attributes of these enzymes. The data demonstrates that useful biochemical information can be 
uncovered with a brand new schema for classification along with genetic properties of the 
archetypal TopoIII within each domain. We provide observations about unique aspects within 
each domain that lay the foundation for future scientific investigation and that may provide the 
basis for the future development of novel pharmacological agents.  
In the final chapter, we discuss future studies on type IA topoisomerases. We examine 
novel investigations and emphasize efforts that would enhance our understanding of the 
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physiologic role of this enzyme in vivo. In producing this body of work, it is our anticipation that 
the field of type IA topoisomerases will be advanced and the knowledgebase further expanded. 
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Chapter 2. Literature Review 
2.1 Topoisomerase Overview 
The characterization of the  protein, eventually renamed to Escherichia coli 
Topoisomerase I (EcoTopoI) by Prof. James C Wang opened the door to the previously 
unknown world of molecular machines that manipulate DNA topology (1). Since then, 
topoisomerases have been demonstrated to be vital instruments of the cellular machinery 
in a wide array of processes that are essential for life such as DNA synthesis, DNA repair 
and Chromosome Segregation (2-4). Their essentiality is further exemplified through the 
fact that these molecular machines have been identified in every species sequenced to 
date regardless of domain (5). As a result, they remain to be a therapeutic target of 
interest with numerous drugs in various stages of development (6). 
2.2CLASSIFICATION 
Before we discuss some of the major milestones for topoisomerase research, we 
must understand that the different subfamilies of topoisomerases are distinct in function 
and structure. In reality, the classification of topoisomerases along with the nomenclature 
has over 40 years of history embedded. As luck would have it, the two main classes are 
easy to distinguish based on name and the localization of the topoisomerase. 
Topoisomerases are classified according to the molecular mechanism by which the 
topology of DNA is manipulated (5, 7-9). Generally speaking, topoisomerases catalyze 
the cleavage of one DNA strand (type I or odd numbered) or two strands (type II or even 
numbered) creating a gate through which either another DNA strand or strands are 
transported before reversing the initial transesterification and producing a religated DNA 
backbone.  
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Type I topoisomerases are able to transiently cleave one strand of DNA in the 
absence of ATP. The energy stored in the super coiled DNA is utilized to pass the other 
strand through this gap before the strands are re-ligated changing the linking number of 
DNA in increments of 1. Type I enzymes can be further subdivided according to the 
covalent intermediate formed during cleavage. Type IA topoisomerases form covalent 
intermediates with the 5’-end of the cleaved phosphate backbone (Fig. 2-1). A catalytic 
tyrosine performs a nucleophilic attack on the phosphodiester backbone of a single strand 
of DNA as part of a transesterification reaction. In the presence of Mg2+, the 3’-hydroxyl 
reverses the reaction and the DNA is re-ligated releasing the enzyme. There is a 
cleavage-re-ligation equilibrium for this reaction. As a result, no energy is required.  
While type IA topoisomerases do not utilize energy to relax positive or negative 
supercoils, reverse gyrases seemingly amend this rule and require ATP to introduce 
positive supercoils (10). The exact role of reverse gyrase in vivo has yet to be determined. 
However, the enzyme has been deemed a signature of hyperthermophiles and may be 
function to maintain DNA in a positive or relaxed state as an adaptation to elevated 
temperatures (11).  
Type IB topoisomerases form a phosphotyrosine covalent adduct with the 3’-end 
and release a 5’-hydroxyl. No cofactors (divalent cation or ATP) are necessary for this 
reaction. These enzymes are structurally distinct and lack much sequence homology to 
type IA topoisomerases, but bear mechanistic and structural similarity to tyrosine 
recombinases. Type IB is noticeably absent in E. coli and many bacteria.  
In the presence of Mg2+ and ATP, type II topoisomerases form covalent 
intermediates with the 5’-end of the cleaved phosphate backbone. Type IIA 
topoisomerases, which encompasses DNA gyrase, form a covalent intermediate through 
 13 
the catalytic tyrosine on each protomer introducing a staggered 4 nucleotide overhang. In 
a similar fashion, type IIB topoisomerases introduce a staggered 2 nucleotide overhang. 
Upon examination of the topoisomerases present across various life forms, it 
appears that the minimum cellular requirement for topoisomerases is one type IA and one 
type II enzyme (8). This literature review will focus primarily on type IA topoisomerases 
and the crystal structures across the three domains of life while discussing some of the 
major findings for other classes of topoisomerases. As will be revealed, these structures 
have gone hand in hand with impacting studies past and present. They have also revealed 
much about the mechanism of action. A brief timeline is provided as a reference with a 
focus on the most historically significant and novel studies conducted (Fig. 2-2). 
 
2.3 BRIEF HISTORY OF FIRSTS 
The fact that Type IA enzymes are present in every domain and in every organism 
highlights their significance as ubiquitous enzymes. As the first topoisomerase reported, 
Escherichia coli topoisomerase I (EcoTopoI) is the best characterized of the type IA 
topoisomerases (1). Originally named -protein, EcoTopoI was shown to relax 
supercoiled DNA changing the linking number in increments of one in a Mg2+-dependent 
manner, a property that would later become a defining property of type I topoisomerases. 
EcoTopoI is encoded by a 4071 base-pair long segment named the topA (12). While 
EcoTopoI only relaxes negatively supercoiled DNA, it was shown that it has the ability to 
relax positively supercoiled DNA when a heteroduplex substrate containing artificial 
ssDNA regions is presented (13). 
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Initial biochemical investigations utilized indirect evidence to hint at a 
transesterification between a catalytic tyrosine residue and scissile phosphates within the 
backbone of DNA to form a covalent bond and thereby exclude the possibility of a serine 
or threonine as part of the mechanism (14). The first direct evidence came with the 
proteolytic cleavage and sequencing of E. coli gyrase covalently linked to DNA revealing 
that Tyr122 of the gyrase A subunit was responsible for the catalytic activity (15). Based 
on sequence homology, these authors predicted Tyr783 of S. cerevisiae TopoII 
(SceTopoII) to be the putative catalytic residue. This hypothesis was verified with tryptic 
digestion and sequencing (16). Shortly thereafter, similar methods were utilized to 
identify the catalytic residue in EcoTopoI (Tyr319) and in SceTopoI (Tyr727) (17, 18). 
Once the question of the residue responsible for the covalent adduct formation was 
identified, researchers began to investigate the role of other amino acid residues based on 
sequence conservation while characterizing novel topoisomerases (19).  
Dr James Champoux of the University of Wisonsin was the first to illustrate that 
rat liver nuclear topoisomerase is covalently linked to the 3' end of DNA nick, the 
hallmark of type IB enzymes (20). Along with that, his work proved that the intermediate 
complex is NOT formed via a phosphoamide linkage using acidic hydroxylamine as 
proof. These experiments utilized alkaline CsCl centrifugation to assay complex 
formation and cleavage of radioactively labeled SV40 DNA. 
Fairfield et al. provided the first evidence of a mitochondrial topoisomerase I 
(mtTopoI) isolated from rat liver (21). They utilized the drugs Berenil and ethidium 
bromide to inhibit activity and illustrate that the protein purified was not the same as 
nuclear topoisomerase since mtTopoI had a significantly lower Km. As a type IB enzyme, 
mtTopoI has no Mg2+ requirement and was able to relax positively supercoiled DNA.  
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In a seemingly forgone era where DNA sequencing and BLAST searches were 
not readily available, EcoTopoIII was discovered twice after topA KO strains were shown 
to maintain DNA topology (22, 23). This curious finding led the authors to search for 
another protein capable of fulfilling this critical cellular function. The mutants were 
shown to contain fractions of protein that were still able to decatenate form I:I dimers at a 
rate 70x greater than DNA gyrase. This would be the first evidence that a TopoIII has the 
ability to decatenate DNA. 
The overwhelming majority of crystal structure research has focused on bacterial 
and eukaryotic topoisomerases such that few conclusions can be made about the 
principles that overlap between the three domains of life. Nonetheless, their discovery is 
invaluable to the expansion of our knowledge of these vital enzymes. Collaboration 
between the Mondragon & Wang labs led to the crystallization of a 67K fragment of 
EcoTopoI at a 3.0 Å resolution followed shortly thereafter by one of 2.2 Å resolution (24, 
25). These structures provided a significant advancement in the understanding of type I 
family of enzymes. The toroidal structure revealed a 27.5 Å DNA binding groove with 
little homology to any other known DNA binding motifs with four distinct domains. It is 
important to note that this 596 amino acid structure contained the ability to cleave 
oligonucleotides, but was not able to relax negatively supercoiled DNA. 
In an effort to elucidate the catalytic mechanism, initial studies sought to modify 
highly conserved residues with E. coli topoisomerase I as the prototype. In one study, 12 
Alanine mutants were selected based on the 67K crystal structure to discern what, if any, 
role there might be for these residues (19). This study yielded several points worth 
noting. First, mutants E9A and R321A were the only two mutants found to have no 
relaxation activity while E9A was the only mutant without DNA cleavage activity on a 
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radiolabeled 388 bp EcoRI-NcoI restriction fragment. This study also revealed that salt 
alone could shift the cleavage-religation equilibrium such that cleaved substrates were 
religated even without Mg2+. These results indirectly implicated Mg2+ in the 
conformational changes necessary for relaxation, but not in religation. Finally, the 
Y319A mutant was found to have minimal cleavage activity versus the expected 
complete lack. The authors speculated that water molecules could intercalate the active 
site pocket with the truncated side chain thereby permitting cleavage of a scissile 
phosphate, but not to the point of relaxation illustrating the requirement for that covalent 
linkage. 
The addition of Mg2+ to a reaction mixture produces the large conformational 
changes necessary for the DNA relaxation activity of EcoTopoI as evidenced with the 
decrease in the absorbance at 295 nM (10 Trp residues & 8 Trp in 67K N-terminal 
fragment) (26). In this study, the authors utilized ICP-MS to determine that there are two 
Mg2+ binding sites when preparations were preincubated with Mg2+. They were able to 
extract Mg2+ from one of these sites when the dialysis buffer included EDTA leaving one 
Mg2+ strongly bound and presumably buried deeper within the structure. Interestingly, 
these enzymatic preparations were able to relax negatively supercoiled DNA without the 
addition of MgCl2. However, adding MgCl2 to the reaction elicited greater 
oligonucleotide cleavage activity of diUA7 suggesting that there is another binding site or 
mechanistic role for the increased MgCl2 in the reaction. 
In an effort to study the role of pH dependence, mutants of an invariant EcoTopI 
His365 were generated to study its role in acid/base catalysis (27). H365Q and H365A 
mutants appear to be pH independent. Crystal structures reveal that His365 is too far from 
the catalytic tyrosine to directly interact with active site, but the authors believed that 
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His365 plays a role relaying a positive charge from Asp111 to Glu9. Mutating this residue 
does not abolish activity, but it does change the binding affinity for ssDNA (diUA7 with 
first Uracil base iodinated), rate of cleavage and shifts the pH dependence to be more 
basic for relaxation. For these mutants, high concentrations of salt (>120 mM KCl) 
inhibit relaxation activity. Ironically, H365A has greater cleavage activity than all other 
forms (including wild type) at any pH. While these studies did not directly reveal the 
contribution of the histidine to the catalytic mechanism, the authors illustrate the process 
of systematically mutating a residue implicated in the hydrogen network of a known 
crystal structure. 
In another study, authors utilized this same crystal structure to examine the basic 
and acid residues adjacent to the catalytic tyrosine through a mutation to alanine (19). 
While mutating some residues abolished DNA relaxation activity, there was still cleavage 
activity present. Furthermore, many of the mutations still maintained partial relaxation 
activity suggesting that much is left to be understood about the residues responsible for 
conformational changes in the catalytic mechanism. 
In an effort to take further snapshots of the type IA mechanism, Feinberg et al. 
crystallized a 30 kDa fragment consisting of E. coli topoisomerase I domains II and III 
(residues 214-477) (28). They obtained two crystals each with two monomers (named A, 
B, C and D) which the authors suggest may be viewed as different stages of the catalytic 
mechanism. In comparison to the 67 kDa crystal originally obtained, there are no large 
rearrangements observed and the secondary structure is preserved. The authors highlight 
residue Arg321 which is disordered in monomers A, B and D, but ordered in C as a 
potential interaction partner with the catalytic Tyr319. 
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Our view of type IA topoisomerases was expanded with the crystallization of the 
aforementioned E. coli 67 kDa fragment (residues 1 to 596) in the presence of mono- and 
tri-nucleotides (29). Using 5’pT, Tp3’, 3’5’ADP and a combination of both 5’pT and 
Tp3’, the authors were able to identify 5 potential DNA binding sites within the enzyme. 
The authors suggest that Arg396 located near site II may facilitate ssDNA binding such 
that the phosphates point away from the protein and the bases towards the protein to 
minimize duplex formation. This structure represented the first DNA-protein interaction 
demonstrated in a topoisomerase.  
The validity of these binding sites would be brought into question when Perry et 
al. attempted to crystallize the original 67 kDa EcoTopoI with a catalytically inactive 
mutation (Y319F) or a mutant with a high binding affinity for DNA (H365R) (30). The 
authors were only able to crystallize the latter in the apo form and in complex with an 11 
base oligomer, 5’-ACTTC↓GGG↓ATG-3’, where ↓ indicates the site of topoisomerase-
induced DNA cleavage. The authors obtained the apo form to draw comparison with the 
original 67 kDa structure obtained and found little difference (overall rmsd of 0.97 Å). 
The bound structure contains electron density for 7 nucleotides with six fitting on a 
positively charged groove leading from the active site. The authors note that Arg321 
blocks the oligo from contacting Tyr319 while making contact with the Gua7 phosphate. 
There are many stacking interactions, but the authors highlight Cyt2 and Trp184 indole 
ring interaction based on homology with Cyt1 and Trp61 in the EcoTopIII/ssDNA 
complex. The authors note that this seems to be a conserved interaction across type I 
topoisomerases. The authors also suggested that the structures obtained by the Feinberg 
et al. (1999) study represent nonspecific binding of nucleotides to topoisomerase I. This 
study provided another snapshot of the elusive catalytic cycle of type I topoisomerases.  
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With 609 of the 653 residues in the structure, the 3.0 Å crystal structure of E. coli 
topoisomerase III represented the first fully intact topoisomerase (31). As with EcoTopoI, 
it forms a torus with an approximately 25 Å pore. In this central cavity, there are 17 
lysines and arginines facing the interior yielding a positive surface potential with which 
DNA can interact. A major difference with the EcoTopI structure is the presence of two 
novel loops not present in the sequence of EcoTopI. The first is at the interface between 
domains III and IV (502-519) and has been demonstrated to be required for decatenation. 
The other loop consists of residues 241-255 in domain II. The authors suggest that these 
loops may play a role in selecting for DNA substrates with different topologies. 
When crystallized with an 8nt ssDNA (5’-CGCAACTT-3’) at 2.05 Å resolution, 
the EcoTopIII-Y328F mutant (full length with C-terminal His Tag) was found non-
covalently bound and poised for cleavage between the 6th and 7th nucleotide based on the 
3.6 Å distance of Phe328 from this phosphodiester linkage (32). Oddly, the ssDNA was 
identified in an alignment akin to that of B DNA based on the phosphate backbone and 
six bases. The authors note that highly conserved residues interact with the phosphate 
backbone while non-conserved residues interact with the bases. For example, Arg330 and 
Lys8 serve to coordinate non-bridging oxygen. It appears that Domains II, III and part of 
IV swing 20 Å away from the protein to accommodate the protein-nucleotide interaction. 
Through this structure, the authors suggest that there is no general base to abstract a 
proton from the catalytic tyrosine. As a result, the authors posit that a water molecule 
plays this function in the same manner that it does for Type II topoisomerases. The 
authors suggest that Glu7 has a role in the donation/abstraction of a proton upon cleavage 
of the 3’- hydroxyl group and religation, respectively. Worthy of mention is the fact that 
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no Mg2+ is present in this structure despite efforts to soak co-crystals in magnesium 
containing solution. 
The structure of EcoTopoIII complexed with an 8 nt ssDNA (5’-CGCAACTT-
3’) shed light on the mechanism and raised new questions (33). Unlike previous 
structures, the active site tyrosine was not mutated to phenylalanine and is covalently 
linked to ssDNA at pH ranging from 5.5-8.0. One of the crystals shows the toroidal 
structure closed with the clamp of Domain III (with active site Tyr) inaccessible while 
Domain IV and Domain I are interacting with 6 of the 8 nt. Another crystal shows the 
open conformation with the ssDNA fully interacting with Domain IV and I. Domain II is 
the least clear in the crystal structure implying that it is a mobile linker region or that it is 
the most mobile. 
At pH 5.5, the structure reveals Tyr328 poised to attack a scissile phosphate. The 
authors believed that increasing the pH would shift the equilibrium toward religation and 
not the cleavage structure. They raised the pH in the hopes that the equilibrium will be 
shifted, but to no avail. Curiously, there is no Mg2+ in the active site, which begs the 
question as to its role in the mechanism. The closed complex with ssDNA reveals that 
Domain IV moved the most to accommodate the ssDNA with major movement 
specifically localized to Helix O (residues 525 to 539). 
The first crystal structure information on the CTD of topoisomerases came from 
NMR studies on the 14 kDa C-terminal fragment (residues 745-865) of E. coli (34). With 
the largest observed amide chemical shifts, the first -sheet of this fragment is thought to 
facilitate DNA binding with positively charged arginine residues and aromatic residues 
for stacking interactions. The authors obtain a micromolar KD value that is largely 
influenced by salt concentration. Increased salt was shown to decrease protein-DNA 
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interaction while reinforcing the notion that electrostatic interactions are involved in 
binding. 
The structure of Thermotoga maritima topoisomerase I revealed a toroidal 
structure analogous to EcoTopoI with a central cavity having a diameter of 25 Å (35). 
Based on initial characterizations of EcoTopoI, most type IA topoisomerases are believed 
to have 5 domains (I-V). The fifth domain is widely varied or absent in some 
topoisomerases and usually contains a zinc-binding motif (Cys-X-Cys-X16-Cys-X-Cys in 
this case). In this structure, the contact area between Domain IV and V is 1300 Å2 (about 
¼ of the total surface area of Domain V) suggesting that it may actually be an extension 
of Domain IV. TmTopI Domain V is a “4-stranded antiparallel Beta sheet” with 
dimensions of 25x20x15 Å. The binding cleft is peppered with many conserved and 
positively charged amino acids. Domains I and III maintain intimate contacts such that 
the enzyme is said to be in a closed conformational state. 
 
2.4 TOPO III 
Originally discovered in yeast, TOP3 encoded a protein which could not recover 
the phenotype of slow growth, but could be recovered with the expression of EcoTopoI 
(36, 37). And from its initial discovery, TopoIII has been demonstrated to be essential for 
normal growth. Only one TopoIII enzyme was discovered in Schizosaccharomyces 
pombe - topoisomerase III (top3), and it forms a covalent linkage with the 5’-end of the 
DNA backbone as any type IA topoisomerase does (38). TOP3 knockout was able to 
germinate, but demonstrated a variety of growth defects such as abnormal chromosome 
segregation. Thus, the enzyme was required for faithful nuclear division. 
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One study demonstrated that Top3α is essential in a higher order eukaryote, but 
the precise cellular function is elusive since knockout mice are embryonically lethal (39). 
Initially, TOP3β−/− mice were reported to develop normally, but with shorter lifespans 
over a 25 month period (40). In this case, there were no differences in size, weight, and 
agility relative to the wild-type, but post-mortem biopsies revealed lesions in multiple 
organs. Further study of this phenotype revealed that there was increase in antibodies 
against IgG while maintaining normal populations of lymphocytes (41). There were 
anomalous chromosome numbers in somatic cells and a high incidence of condensed 
nuclear morphology, suggestive of apoptosis. Longer term studies revealed that older 
TOP3β−/− mice become infertile with a high frequency of aneuploidy (42).  
Though originally believed to harbor one topoisomerase III, humans have two 
TopoIII topoisomerases named topoisomerase IIIα (hTopoIIIα) and topoisomeraseIIIβ 
(hTopoIIIβ) (43). With a tetracysteine motif in the C-terminal domain, it is structurally 
more akin to EcoTopoI than EcoTopoIII. While the activity of hTopoIIIα was tested in 
the presence of a range of MgCl2 concentrations, it was deemed inactive in the presence 
of other divalent cations based on one concentration (5 mM) of other divalent cations. 
These studies reinforce the importance of type IA topoisomerases in the normal 
development of eukaryotes. 
A closer examination of the phylogenetic distribution within domain Eukarya 
reveals that some eukaryotes have two type III topoisomerases while others have one. 
While the biological significance of this phylogenetic distribution has not been proven, it 
has been noted that duplication is a distinct property of higher order eukaryotes (Forterre 
et al. 2007; Wang 2002; Viard et al 2007; Champoux 2001). In Archaea, there is also a 
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distinct distribution of two Reverse Gyrase and TopoIII genes. (Chapter 4, Table 2 and 
Table 3) 
There is a dearth of information published on archaeal topoisomerase III. The first 
archaeal topoisomerase characterized, Desulfurococcus amylolyticus topoisomerase III 
(DamTopoIII), is an ATP-independent enzyme that relaxes negatively supercoiled DNA 
at 60-80°C, but does both positive and negative at 95°C (44). It is inhibited at NaCl 
concentrations ranging from 170 to 250 mM, while DamRG is optimal in this range. The 
authors theorize that this complementary activity may be important in vivo. 
Sulfolobus solfataricus topoisomerase III (SsoTopoIII) is another ATP-
independent enzyme that only relaxes negatively supercoiled DNA in a Mg2+-dependent 
fashion while being inhibited by M13 ssDNA. SsoTopoIII relaxation activity is optimal 
at temperatures above 65°C (45). In another example of systematic error in divalent 
cation dependent assessment, the authors in this study demonstrated that only Mg2+ 
elicited maximal activity at 10 mM while Ca2+ was slightly able to substitute (Cu2+, Co2+, 
Mn2+ and Ni2+ could not). The enzyme demonstrate sequence specificity for 
G(A/T)CA(T)AG(T)G(A)X↓XX. The equilibrium for cleavage-religation is disrupted at 
low temperatures (25°C) and high enzyme/substrate ratios such that cleavage is favored 
and a covalent adduct accumulates (46).  As with other type I topoisomerases, SsoTopo 
III has a strong preference for ssDNA.  
It is important to note that both of these enzymes are from hyperthermophiles and 
that they are from the archaeal subdomain Crenarcheota. There are no crystal structures 
currently available for archaeal type III topoisomerases. 
 
2.5 TYPE IB 
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Type IB topoisomerases contain four domains broken down into an N-terminal, 
linker, core region containing the catalytic tyrosine and a C-terminal that is dispensable 
for activity. As will be described later, these topoisomerases contain a “catalytic pentad” 
that coordinates cleavage and religation using a hydrogen bonding network for catalysis. 
No specific residue or molecule has been identified as the catalyst for the mechanism 
although tyrosine forms the covalent intermediate. Human topoisomerase I is the main 
target of inhibitors for cancer treatment. The catalytic mechanism is one of controlled 
rotation which involves clasping DNA in a semi-circle fashion while cleavage, relaxation 
and religation occur. 
These enzymes share sequence similarities and function to tyrosine recombinases. 
Both utilize a 3’-phosphotyrosine intermediate to manipulate DNA topology. Eukaryotic 
and virus topoisomerases share sequence similarity. Virus topoisomerases are 
significantly smaller (30-36 kDa). 
In a novel study, Pla et al. utilized optical tweezers to measure the force of 
stretching-relaxing cycles of linear dsλDNA 3’-labeled at each end with biotin and 
attached to streptavidin beads in the presence of wheat germ topoisomerase I (47). They 
obtained different distance versus force measurements when starting with highly nicked 
in place of barely nicked substrates. When starting with DNA containing few nicks and 
placed in the presence or absence of Lamellarin D, a topoI inhibitor, the authors found 
that TopoI could not religate the substrate entirely as determined through the presence of 
hysteresis in the graph after 20 min. When starting with a highly nicked substrate, the 
topoisomerase was able to religate the substrate and remove the hysteresis within 18 min. 
These authors demonstrate a new method to characterize topoisomerases-DNA 
interactions in the presence of inhibitors. 
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The Mondragon lab paved the way with an important contribution consisting of a 
1.6 Å structure of the vaccinia virus DNA topoisomerase IB (48). While only a 9 kDa N-
terminal fragment consisting of 77 amino acids, this crystal represented the first type IB 
structure published. The fragment was obtained from a purified tryptic digest of the intact 
topoisomerase. The authors sequenced the first five amino acids for verification. 
Composed of 5 beta-strands, vaccinia virus topoIB has hydrophobic residues exposed on 
the surface which the authors propose may interact with another domain of the full length 
enzyme. It is important to note that this fragment did not have any relaxation activity or 
the ability to bind DNA. 
In vitro assays with relaxed dsDNA yielded negative supercoils in the presence of 
wheat germ TopoI and EcoRecQ with SSB (49). The authors went on to illustrate that 
TopoI, RecQ and SSB could convert sc pUC19 into multimers that could withstand 
alkaline conditions in an ATP-dependent fashion. The authors treated purified multimers 
with HindIII in the presence of EtBr (to prevent thermal branch migration) to 
demonstrate that these multimers were actually fully catenated DNA. The same reaction 
with Norfloxacin or involving Topo III substituted with Topo III-F, Topo IV, DNA 
Gyrase or Topo I could not yield catenated products. TopoIII (with SSB) was only 
minimally able to stimulate catenation of DNA containing single stranded regions in 
comparison to its activity in the presence of RecQ. The authors state that EcoHelicase II 
was unable to substitute for RecQ while yeast TopoIII was able to substitute for 
EcoTopoIII in the catenation assay with EcoSSB or yeast RPA. 
With yet another contribution, the Mondragon lab & Wang lab provided a 
glimpse into the first eukaryotic topoisomerase with the crystallization of the 26 kDa 
fragment of Saccharomyces cerevisiae topoI (residues 135 to about 363) (50). With the 
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clarity of a 1.9 Å resolution, this crystal was structurally distinct from the 
aforementioned. Although this truncated enzyme was unable to catalyze relaxation or 
DNA binding, the authors demonstrated that Cys232 was likely involved in DNA binding 
using photocrosslinking experiments with radiolabeled components. The authors suggest 
that the distribution of lysines and their high positive potential are ideally located for 
interaction with negatively charged DNA. Finally, the authors propose that the drug 
resistant mutants Phe293 and Gly295 map to the CL loop (a long beta-pin-like loop) and 
exert influence based on proximity to the DNA binding surface. 
In another study, Perry et al. attempted to crystallize the original 67 kDa 
EcoTopoI with a catalytically inactive mutation (Y319F) or a mutant with a high binding 
affinity for DNA (H365R) (30). The authors were only able to crystallize the latter in the 
apo form and in complex with an 11 base oligomer, 5’-ACTTC↓GGG↓ATG-3’. The 
authors obtained the apo form to draw comparison with the original 67 kDa structure 
obtained and found little difference (overall rmsd of 0.97 Å). The bound structure 
contains electron density for 7 nucleotides with six fitting on a positively charged groove 
leading from the active site. The authors note that Arg321 blocks the oligo from contacting 
Tyr319 while making contact with the Gua7 phosphate. There are many stacking 
interactions, but the authors highlight Cyt2 and Trp184 indole ring interaction based on 
homology with Cyt1 and Trp61 in the EcoTopIII/ssDNA complex. The authors note that 
this seems to be a conserved interaction across type I topoisomerases. The authors further 
suggested that the structures obtained by the Feinberg et al. (1999) study represent 
nonspecific binding of nucleotides to topoisomerase I. This study provided another 
snapshot of the elusive catalytic cycle of type I topoisomerases.  
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In an effort to determine how oxidative damage impacts topoisomerase activity, 
Lesher et al. crystallized hTopoIB (residues 175-765) in the presence of a 22 bp DNA 
substrate containing a 7,8-dihydro-8-oxoguanine (8-oxoG) base at the +1 position on the 
scissile strand (51). In this 3.1 Å structure, the authors note that the docking of this DNA 
substrate would clash sterically with Thr-718 based on previous structures. As such, the 
enzyme shifts this residue away from that position 2.6 Å to produce overall changes that 
lead to an “inactive conformation”. In essence, the Y723F is rotated 64º away from the 
scissile phosphate in comparison to previous structures with analogous substrates 
demonstrating a physical basis for decreased cleavage of DNA damaged substrates. 
In another 3.1 Å structure, the authors identified a covalent complex between 
hTopoI and 1-β-D-Arabinosefuranosylcytosine (Ara-C), a potent anticancer therapeutic 
(52). Using a 22 bp sequence analogous to previous structures, except with an Ara-C in 
the +1 position of the intact strand and a sulfhydryl group at the scissile linkage, the 
authors demonstrate that there is little change in the enzyme structure, but there are subtle 
and significant differences in the DNA structure. They note that the ribose ring C3’-endo 
pucker is stabilized by a hydrogen bond between the 2’-hydroxyl and the O4’ of the -1 
adenine. They utilized NMR to confirm this conformation and bonding interaction.  The 
authors suggest that the cleavage-religation equilibrium is disrupted because the 5’-
sulfhydryl group is now 3.7 Å away from the 3’-phosphotyrosine linkage instead of the 
2.5 Å seen in a previous structure. A reorientation of the 5’-sulfhydryl to poise it for 
religation is not possible without significant conformational changes reinforcing the 
induced conformational changes. 
From previous structures of human topoisomerase I, it was noted that Lys532 is the 
only residue with base specific contacts through interaction with O-2 atom of the -1 
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thymine base in the minor groove. Seeking to probe the role of Lys532 in catalysis, 
Interthal et al. modified this residue to a lysine and arginine to observe the effects on 
activity and to determine the structure (53). The authors used DNA substrates in all 
experiments analogous to the 22 bp DNA sequence from previous crystal structures. 
Based on equilibrium cleavage assays, the authors hypothesize that K532R inhibits 
cleavage while K532A inhibits religation. When a suicide substrate (dsDNA with top 
strand containing 14 bases and bottom strand containing 25 bases) was utilized, neither 
mutant reached equilibrium within 22.5 hrs (unlike the equilibrium cleavage assays) 
suggesting a role for a duplex downstream of the cleavage site in the mechanism. 
Overexpression of K532A in yeast proved toxic with limited growth suggesting that 
covalent complexes accumulate and lead to cell death as with camptothecin. When a 5’-
bridging phosphorothioate containing DNA substrate is utilized in the suicide cleavage 
assays, the mutant cleavage rates are comparable to that of WT. Given that this 
modification lowers the requirement for a general acid, the authors use this information to 
suggest that Lys532 acts as a general acid in WT cleavage to protonate the 5’-oxygen. The 
authors obtained a crystal of hTopoIB Y723F/K532R with DNA and noted that arginine 
was able to maintain the DNA contact with the -1 thymine base although the scissile 
phosphate shifts 1.20 Å. Hydrogen bonding with Arg590 is lost due to this shift while 
His633 bonding is lost due to a reorientation of helix 17. 
The field was advanced with structural data on human topoisomerase IB 
covalently bound to a 22 bp Tetrahymena-like sequence (2.1 Å) and a Y723F inactivated 
mutant in a noncovalent complex (2.5 Å) (54). Between the two structures, there is little 
difference except the location of the active site residue and scissile phosphate group as 
the protein completely wraps around 10 bp (4 bp upstream and 6 bp downstream). These 
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structures consisted of a core sequence (58 kDa fragment consisting of residues 175 to 
659) expressed in a baculovirus-insect cell system mixed in a 1:1 ratio with an E. coli 
over expressed 6.3 kDa C-terminal fragment (residues 713 to 765). The authors utilized a 
5’-bridging phosphorothioate substitution to stabilize and trap the covalent complex for 
crystallization. In the closed form, the protein complex contains a central DNA-binding 
pore that is 15 to 20 Å in diameter and composed predominantly of positively charged 
residues (15 lysines and 8 arginines). The authors note that, while there are 20+ protein 
contacts with the primarily B-form DNA, the vast majority interact with the phosphate 
backbone. There is only one basic specific interaction between Lys532 and the O-2 
carbonyl oxygen of the -1 thymidine base on the scissile strand. Interestingly, the authors 
note significant structural homology with HP1 integrase. 
In the same issue of Science, the authors published another crystal structure at 2.8 
Å resolution of a slightly different fragment of hTopoIB Y723F (residues 175 to 764) 
(55). Top70, as it was named, was expressed in a baculovirus-insect cell system and 
found that it formed a clamp around a 22 bp sequence akin to the other publications (53, 
54). The authors found that the previously unpublished linker region (Ser643 to Arg708) 
was structurally homologous to the coiled coil of E. coli repressor of primer (Rop<2aa>) 
and transcript cleavage factor GreA. Based on the data available, the authors propose that 
a controlled rotation model where strand cleavage is followed by interactions between 
the positively charged linker domain and helices juxtaposed to the duplex to facilitate 
rotation. This is in stark contrast to the free rotation model where the non-covalently 
bound strand would be released and allowed to rotate freely about the unbroken strand or 
the strand passage model where the unbroken strand would be passed between the 
cleaved strands. 
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As with the DNA-bound hTopoIB structure, Patel et al. discovered that the 
Deinococcus radiodurans topoisomerase IB enzyme was poised for cleavage in the 
absence of DNA (56). In essence, the catalytic pentad residues (Arg137, Lys174, Arg239, 
Asn280 and Tyr289) are in positions equivalent to those of hTopoIB whereas the structure 
of Vaccinia apoenzyme only displays two out of the five residues ordered and in 
comparable positions. 
Perry et al. successfully obtained two TopoIB structures of Variola virus, the 
infectious agent of small pox, covalently and noncovalently bound to a 13 bp sequence 
containing the recognition sequence (5’-(T/C)CCTT-3’) (57). In the noncovalent 
structure, the authors note that Tyr274 is ~8 Å from the scissile phosphate suggesting that 
relatively large conformational changes must occur during cleavage. The N-terminus of 
Variola virus TopoIB is comparable to that of Vaccinia virus TopoIB. The data does 
reveal a potential structural basis for the strong sequence specificity of this viral 
topoisomerase. The amino terminal β5 strand makes direct contacts with the major 
groove of DNA substrate using Tyr70 and Tyr72 to make both hydrogen bond contacts 
with the phosphate backbone and base stacking interactions with DNA sugars and base. 
Another direct contact from this strand is the Gln69 interaction with Ade+2. The C 
domain of α5 interacts with positions +4 and +5 in the major groove of the core 
recognition sequence and position +6 outside of it. From this study, we gain a deeper 
understanding of topoisomerase sequence specific DNA binding. 
Novel human topoisomerase I-DNA complexes were obtained at 2.6 Å resolution 
of the same fragment (residues 175-765) that contains Phe723 in place of the catalytic 
Tyr723 (58). In comparison to the shift seen in DNA, there was little deviation of the 
protein structure from previously obtained crystals. The DNA was again primarily B-
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form, but contained Cytosine at the -1 position. With a water molecule within 3.0 Å of 
the theoretical catalytic tyrosine hydroxyl, the authors propose that it is ideally positioned 
to function as a general base for catalysis. The authors note the 75° rotation of the 
nonbridging oxygens of the scissile phosphate and expand on how this orientation 
permits Lys532 ε-amino group to be within hydrogen bonding distance of the pyrimidine 
O2 atom. Given this new structure, the authors propose that the active site is composed of 
Tyr723, Arg590, Arg488, His632, Lys532 and a catalytic water molecule. 
 
2.6 VIRUSES (TYPE IB) 
In the same month, the crystal structure of the Vaccinia virus topoisomerase IB 
fragment (residues 81 to 314) was solved (59). It consists of 10  helices and 3  sheets 
with a catalytic pentad (Arg130, Lys167, Lys220, Arg223 and His265) that is structurally 
conserved as compared with HP1 integrase, lambda integrase and other site specific 
recombinases. Despite little sequence homology, the authors view these structures in 
combination with the mechanistic parallels as evidence of a common ancestor. The 
structure reveals that the catalytic Tyr274 is oriented in such a way that it is not properly 
positioned for cleavage. The authors interpret this data to suggest that there must be a 
reorientation of the catalytic site upon DNA binding. 
Initially, Broccoli et al. cloned a gene for a topoisomerase IB-like protein from 
Leishmania donovani lacking the canonical “SKXXY” motif (60). In the hopes of 
characterizing this protein, the authors overexpressed recombinant protein in E. coli and 
purified it. Using various techniques such as complementation rescue experiments and 
relaxation assays with hTopoIB as a control, the authors eventually determined that the 
enzyme was catalytically inactive. Among other possibilities, the authors postulated that 
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another subunit may contain the catalytic activity. It would take another lab to discover 
the dimeric nature of this unique topoisomerase (61). In this subsequent study, the 
authors clearly identified that there is a single gene copy for each subunit and that the 
enzymatic complex is expressed as a heterodimer with the second subunit containing the 
catalytic activity and canonical “SKXXY” motif. 
Further characterization of this topoisomerase from Leishmania donovani would 
reveal that high KCl concentrations (> 300 mM) inhibit this enzyme and that it is Mg2+ 
independent although Mg2+ can enhance the reaction (62). As with other type IB 
topoisomerases, they found that it binds the canonical hTopoIB sequence. Compared to 
rat liver topoisomerase IB, the authors found that Leishmania donovani TopoI is less 
processive and relaxes supercoiled DNA 2x faster. Interestingly, they produced rabbit 
antibody for each subunit and observed that this topoisomerase is associated with both 
the nucleus and the kinetoplast. 
 In a creative effort, Davies et al. crystallized topoisomerase I from Leishmania 
donovani in the presence of a 22 bp “nicked” DNA duplex substrate (canonical type IB 
sequence) consisting of a top strand that is non-contiguous and composed of two strands 
lacking a phosphate on either terminus at the interface junction (63). The authors 
successfully crystallize the structure covalently linked to both ends of each top strand via 
a vanadate that has intercalated the nick. Thus, the authors dub this structure a transition 
state mimic. Upon observing a molecule of water 2.5 Å from Tyr222, the authors suggest 
that this is the first conclusive evidence for a specific base in the mechanism and further 
propose that Arg410 is a key player in stabilizing the tyrosine phenolate ion for attack 
based on distance. As with previous structures for type IB topoisomerases, the authors 
find a conserved catalytic pentad consisting of Tyr222, Arg314, Lys352, Arg410 and His453. 
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Authors would find that another kinetoplastid, Trypanosoma brucei, contains a 
heterodimeric type IB topoisomerase (64). Again, the data revealed inhibition of 
topoisomerase activity at high KCl concentrations (> 200 mM). This finding suggests that 
catalysis requires ionic interactions between the large and small subunit. Despite 
discovering two small subunits on SDS-PAGE, the authors propose that one subunit may 
be a phosphorylated form or a proteolytic fragment. The authors find that the predicted 
masses are 80 and 30 kDa, but the native enzyme migrates as a 207 kDa protein in gel 
filtration. Given that the SDS-PAGE suggests masses of 90 and 36 kDa, the authors 
postulate on the potential nonglobular nature of the protein or the subunit organization. 
This enzyme falls in line with other type IB topoisomerases in that it relaxes positive and 
negative supercoils and it is Mg2+ independent although Mg2+ does enhance activity.  
 
2.7 TYPE IC (or UNIQUE TYPE IB) 
Methanopyrus kandleri topoisomerase V (MkaV) is the first topoisomerase IC 
characterized. It was able to relax negatively and positively supercoiled DNA in the 
absence of ATP and Mg2+ and in the presence of KCl or NaCl (65). The enzyme was 
initially suspected to be homologous to hTopoIB based on reactivity with an antibody 
raised against hTopoIB. Later, the MkaV was shown to have a preference for positively 
supercoiled DNA (66). Slight inhibition using Camptothecin was demonstrated, but it 
was not as pronounced as the inhibition of eukaryotic topoisomerase I at such high 
concentrations. 
The MkaTopoV C-terminal would subsequently be demonstrated to contain a 
helix-hairpin-helix (HhH) DNA-binding motif with homology to human and Taq DNA 
Polymerase amongst other proteins (67). The N-terminal region of MkaTopoV contains 
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sequence homology to eukaryotic type IB topoisomerases and tyrosine recombinases. 
Only 3 out of the 5 conserved catalytic residues in type IB topoisomerases are present in 
this unique enzyme. And with thermophilic origins, this enzyme demonstrated higher 
activity at 60°C vs 37°C. Most importantly, MkaTopoV was the first topoisomerase 
demonstrated to contain DNA repair activity with both AP lyase and dRP lyase activity. 
This study led to the notion that this enzyme may occupy another branch of the 
topoisomerase tree. 
Tanjea et al. characterized and crystallized an N-terminal fragment of 
Methanopyrus kandleri topoisomerase V (residues 1-532) called Topo-61 (68). The 
structure of this unique type IB consists of two domains – an N-terminal topoisomerase 
domain that is predominantly α-helical with a C-terminal helix-turn-helix (HTH) motif 
and a C-terminus consisting of 8 helix-hairpin-helix (HhH) [or four (HhH)2 domains]. 
Interestingly, alanine mutation of residues in the core “catalytic pentad” including an 
active site Tyr226 still demonstrates relaxation activity albeit markedly reduced for three 
out of the five. This pentad is not spatially conserved with three out of the five active site 
residues located in the N-terminal HTH domain. Using spectroscopic means, the authors 
observe a blue shift in tryptophan fluorescence in topo-61 from heating but not in topo-
44. This data suggests that a change in a (HhH)2 domain may occur at higher 
temperatures which may facilitate DNA binding. This structure reinforces the notion that 
topoisomerase V is a unique archaeal protein with little to no homology to other known 
topoisomerases. 
2.8 REVERSE GYRASE MECHANISM (ATP-DEPENDENT TYPE IA) 
The discovery of reverse gyrase in Sulfolobus introduced the scientific community 
to this unique enzyme that can introduce positive supercoils in an ATP and Mg2+ 
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dependent fashion (10). Interestingly, the structure of Sulfolobus acidocaldarius DSM 
639 reverse gyrase revealed a monomer consisting of a C-terminal region with structural 
homology to type IA topoisomerases and an N-terminal region with helicase motifs, an 
ATP binding site and a zinc finger domain (Cys-X2-Cys-X14-Cys-X2-Cys) (69). The 
sequencing and cloning of the rgy gene for Pyrococcus furiosus reverse gyrase (PfuRG) 
illustrated that PfuRG also contained an amino-terminal helicase-like module and a C-
terminal topoisomerase module. PfuRG was able to make pTZ17 completely positively 
supercoiled within 2 minutes at 90°C (70). Shortly thereafter, four strains of 
Thermotagales would be demonstrated to contain analogous reverse gyrase activity (71). 
Methanopyrus kandleri revealed a dimeric structure with 50 and 150 kDa subunits 
containing the catalytic and ATP binding activity, respectively (72). 
The only type IA topoisomerase crystallized is that of Archaeoglobus fulgidus 
reverse gyrase (AfuRG) and it contains a topoisomerase ‘hole’ that is significantly 
smaller (16 Å) in diameter such that the authors suggest it may play a role in its 
thermostability (73). These high resolution structures provided the first insight into a 
topoisomerase with positive supercoiling ability in the presence [3.2 Å] and absence 
[2.7Å] of cofactor (ADPNP). AfuRG is broken up into an N-terminal helicase-like 
module with an ATP binding core (folds H1 and H2) and a C-terminal topoisomerase 
module (folds T1-T4 analogous to domains I-IV in EcoTopoI) with a latch-like insertion 
(H3) that is postulated to facilitate DNA binding and communication between the 
modules. While the N-terminal contains a pair of RecA folds that has been identified in 
all helicase structures, AfuRG lacks many of the residues associated with the ATP-
dependent movement along ssDNA. It is worth noting that the apo containing crystal is a 
 36 
monomer while the nucleotide bound structure is a dimer. No conclusive evidence is 
provided for the actual mechanism of positive supercoiling. 
Despite the fact that it is the only protein specific to hyperthermophiles, reverse 
gyrase has been demonstrated to not be a prerequisite for growth at high temperatures. A 
knockout strain of Thermococcus kodakaraensis KOD1 was generated and demonstrated 
to have retarded growth, but growth nonetheless (74). As such, the exact physiological 
role of this topoisomerase remains unanswered and more research is needed to clarify its 
function. 
 
2.9 ROLE OF ZINC BINDING 
Zinc fingers represent small domains of proteins that can influence protein 
interaction with other molecules (75). However, previous studies have yielded 
confounding results regarding the role of Zn2+ in the catalytic mechanism of 
topoisomerases.  
Using inductively coupled plasma-atomic emission analysis, EcoTopoI was 
shown to contain three tetracysteine motifs (Cys-X2-Cys-Gly-X2-Met-X12-13-Cys-X4-10-
Cys) responsible for coordinating 3 to 4 zinc ions that were so tightly bound that 10 mM 
EDTA, 2.5 mM o-phenanthroline and other treatments did not change the amount of zinc 
detected (76, 77). Zinc depletion through chemical agents such as PMPS or MMTS, 
rendered the enzyme inactive while DTT treatment followed by incubation in zinc sulfate 
recovered activity. Partial activity was seen without zinc sulfate incubation. 
T. maritima TopoI has previously been shown to coordinate one Zn2+ ion, but 
there is none in the crystal structure with two disulfide linkages in place of the potential 
Zn2+ ion (35). The authors suggest that it was lost during the crystallization process from 
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aerial oxidation. Detected strong fluorescence signal in absorption edge scan prior of 
mother crystal liquor suggested the presence of Zn2+ as well.  
While a double mutant (C559A/C561A) or truncation abolishes Zn2+-binding, T. 
maritima TopoI (TmTopoI) relaxation activity is minimally affected (78, 79). Truncation 
of TmTopoI also still maintained moderate activity in comparison to the full-length 
protein albeit at a temperature much lower than its ideal growth temperature (79). This 
data has led some authors to suggest that the Zn2+-binding domain may have some as yet 
undetermined function in vivo and/or act as the gain for relaxation activity, because 
EcoTopoI/TmTopoI chimeras were able to augment activity. 
When the EcoTopo67 fragment was reconstituted with the Zn2+-binding domain 
(ZBD), researchers were able to illustrate that Topo67 had similar cleavage and 
catenation activity with or without the 14 kDa ZBD (80). The main difference was that 
EcoTopo67 could not promote relaxation with the Zinc binding domain at a reasonable 
rate. Interestingly, Mycobacterium smegmatis TopoI & EcoTopoIII do not contain a 
homologous Zn2+-binding motif (81, 82). It is clear that more research is needed to clarify 
the role of Zinc binding on the catalytic mechanism. 
 
2.10 OTHER CATIONS 
The potential role that other divalent cations may play has been elusive due to 
asystematic flaw in testing divalent cations other than Mg2+. As a result, it is currently 
believed that Mg2+ is the only divalent cation capable of eliciting DNA relaxation activity 
across domains except for Ca2+ for specific enzymes. For example, EcoTopoI was 
demonstrated to have a preference for Mg2+ and Ca2+, but no other divalent cation (83). It 
should be noted that these ions were only tested at a final concentration of 2.5mM. And 
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yet, another study revealed that SsoTopoIII had no activity in the presence of any divalent 
cation tested except Mg2+ (45). In this study, the authors only tested these ions at a final 
concentration of 10 mM in the reaction vessel. In another study, hTopoIII was tested in 
the presence of various cations and the authors demonstrated that only Mg2+ was a viable 
cofactor (84). Once again, the authors tested for activity only at a singular concentration 
of 5 mM. The lack of standardized analysis has impaired our ability to elucidate the 
potential role of other divalent cations in DNA relaxation across all domains. 
 
2.11 TOPOSOMES: TOPOISOMERASE IA PROTEIN-PROTEIN 
INTERACTIONS 
While studies in recombinant systems provide a wealth of information pertaining 
to structure and function, the reality is that the native state of proteins may not directly 
correlate with in vitro findings. Along with that, interactions with other molecules 
(cofactors, proteins, DNA, etc) may regulate the activity in a manner not well understood. 
In the following section, experiments are highlighted that illustrate the fact that protein-
protein interactions are common and require better characterization. 
E. coli RecA has been demonstrated to enhance the catalytic activity of EcoTopoI 
(85). It was deduced that an active filament of RecA is required based on the fact that a 
cofactor such as ATP, dATP or ATPγS was required while ADP was not. RecA was 
unable to catalyze the activity of S. aureus TopoI or EcoTopoIII, but B. cereus Topo I 
activity was slightly enhanced (2-fold). RecA was unable to enhance the activity of DNA 
gyrase. 
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The EcoTopoI C-terminal domain has been demonstrated to interact directly with 
RNA Polymerase ’ subunit (86). Hypernegative supercoils were observed in vivo when 
a plasmid containing the 14 kDa fragment was overexpressed. This result can be 
interpreted as demonstrating that 14 kDa fragment is competing with full length native 
TopoI for RNA Polymerase binding and preventing TopoI from being recruited to relax 
supercoils produced during transcription. In the presence of a toxic electrophile N-
ethylmaleimide (NEM), E. coli strains expressing TopoI with a truncation of the 20 kDa 
(Top67) or 14 kDa (Top85) C terminal fragment were shown to have impaired survival 
rates as compared to strains expressing the full length protein. The authors suggest that 
transcription is vital in response to toxic agents and, as such, the direct interaction 
between EcoTopoI and RNA Polymerase may be critical to generating a fast cellular 
response for survival. 
Under the control of doxocycline, chicken TopIIIα and TopoIIIβ DT40 cells 
single and double knockout mutants were monitored for their cell growth (87). Top3α 
deficient cells arrested in G2, but aberrant M-phase cells were visible. Double mutants in 
BLM and TopIIIα yielded a significant increase of annexin V-positive cells and 
suppressed the occurrence of large nuclei. In essence, a mutant in BLM could rescue 
some of the phenotypes of a TopoIIIα knockout, but did not suppress the lethality. 
One of the most important findings was produced in yeast where authors provided 
the first evidence that a helicase and a topoisomerase interact as a complex (88). The 
authors began with experiments showing that yeast Top3 deficient strains are more likely 
to be stuck in S/G2 phase as evidence by large-budded cells with an undivided nucleus. 
They went on to isolate strains that could counteract this topA- phenotype (slow growth 
suppressor 1) and demonstrated that Sgs1 is epistatic to Top3 with Top3 Sgs1 deficient 
 40 
strains that are indistinguishable from wild-type yeast cells. The authors go on to identify 
the SGS1 gene on chromosome XII as a homologue to EcoRecQ, a helicase, using a Gal4 
activating fusion library that interacted with Top3 fusion protein. Using a two hybrid 
cloning system, it was shown that the Sgs1 N-terminal 500 amino acids alone could 
interact with Top3. The authors hypothesize that Sgs1 produces lesions which Top3 
repairs. They go one step further to postulate that this helicase/topoisomerase activity 
may be ubiquitous and is supported with the discovery of reverse gyrase. 
In another study, hTopoIII was demonstrated to have a direct interaction with 
BLM in vitro and in vivo (89). The proteins were immunoprecipitated from whole cell 
extracts of HeLa cells using antibodies for either BLM or hTopoIII After extraction, 
the authors demonstrate that complexes are present using the complementary antibody in 
the Western. The authors generate a nitrocellulose bound recombinant form of either 
BLM or hTopoIII and incubate it with the complementary protein. They probe with an 
antibody specific for either to illustrate interaction. The authors also demonstrate that 
there is a genetic interaction between yTop3 and the two BLM interaction domains 
(residues 1-212 or 1266-1417). They went on to show that hTopoIII may be 
mislocalized in the absence of BLM suggesting that BLM has a role in directing 
hTopoIII to the proper site of action. 
BLM and hTopoIII were demonstrated to colocalize in meiotic spreads of 
human testes synchronized in the phases G1, S and G2, but not when the cells were 
starved indicating that the cell cycle is important for association (90). hTopoIII co-
immunoprecipitated and co-localized with both RECQL and BLM individually, but did 
neither with WRN. To eliminate the possibility that RECQL/hTopoIII or 
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BLM/hTopoIII were complexed to DNA, lymphoblastoid whole-cell extracts were 
exposed to ethidium bromide and 37°C with or without nucleases. In each instance, an 
hTopoIII immunoprecipitate yielded interaction with BLM as measured with antibody 
specific for BLM. It should be noted that BLM binding to the complex was reduced 
suggesting that DNA either stabilizes the complex or that some other factor may be 
involved in complex formation. 
As with EcoTopoIII, human topoisomerase IIIβ was actually discovered twice. 
The first published result was an incidental finding during sequence analysis of the gene 
locus for human immunoglobulin lambda (91). As a result, the only noteworthy remark 
was the modest sequence homology to hTopoIIIα (46%) and yeast topoIII (43%). The 
presence of two human topoisomerase II enzymes and a human topoisomerase III with 
greater C-terminal sequence homology to EcoTopoI than to yeast TopoIII prompted a 
separate set of researchers to search for a second human topoisomerase III (92). The 
results yielded the same topoisomerase III in humans (hTopoIIIβ). Interestingly, the 
authors discovered three DNA transcripts for each topoisomerase III along with the 
expression of tissue specific 3’-sequence ends. A yeast two hybrid system was utilized to 
illustrate that the largest gene product for htopoIIIβ co-immunoprecipitated with yeast 
SGS1 protein. Subsequently, that particular isoform of hTopoIIIβ was transfected into of 
a top3 mutant yeast strain under the control of a GAL1 promoter and shown to partially 
rescue the slow growth phenotype. The results provide further evidence for 
topoisomerase and helicase in vivo interaction. 
Given these studies and the functional organization of reverse gyrase as a 
helicase-like module, it is tempting to infer that the interplay between topoisomerases and 
other enzymes namely helicases is evolutionarily conserved. However, many questions 
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remain about the significance of these interactions in vivo and more studies must be 
conducted to clearly determine their importance. 
2.12 TYPE II TOPOISOMERASES 
Type II topoisomerases are able to cleave two strands of DNA while permitting 
another pair of strands to pass through this gate. These enzymes change the linking 
number in increments of II. Originally believed to be a monophyletic group, the 
discovery of type IIB topoisomerases in Sulfolobus shibitae (topoVI) and Methanopyrus 
kandleri, changed our perception of their distribution (93). Within each family of 
topoisomerases and organism, there are interesting nuances that biochemical studies have 
begun to tease out.  
E. coli gyrase (type II topoisomerase) has the unique ability to produce negative 
supercoils in closed circular DNA in the presence of ATP (94).  The interplay between 
EcoTopoI and DNA gyrase to manage DNA topology is so critical that deletions of the 
topA gene, which produces EcoTopoI, result in the slow (or nonexistent) growth of 
mutant strains unless compensatory mutations in gyrA or gyrB are generated (95). DNA 
Gyrase is the target of many drugs. Gyrases are heterotetramers with a gyrase B subunit 
N-terminal containing the ATP activity. The C-terminal of the B subunit and the N-
terminal of the A subunit contains the core catalytic activity. The ATPase domain in the 
B subunit is inhibited by a class of drugs such as novobiocin while the A subunit is 
inhibited by oxalidinic acids. 
E. coli topoisomerase IV bears structural and sequence homology to gyrase except 
for one stretch of amino acids that is thought to be responsible for the ability to be 
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responsible for introducing supercoils. TopoIV is expressed from the ParC and ParE 
gene. Par C is homologous to GyrA gene and ParE gene is homologous to the GyrB gene. 
Subunit B is able to carry out ATP binding and hydrolysis. The authors assayed 
the ATPase activity of E. coli DNA gyrase A subunit alone and in the presence gyrase B 
subunit with and without DNA (96). Whether it was untreated, treated with 2.5 M Urea or 
heated at 43°C for 5 min, the B subunit demonstrated a dramatic increase in relative 
ATPase activity in the presence of both the A subunit and DNA only. The authors do 
note that the absolute ATPase activity of the B subunit alone does increase dramatically 
under these treatments, but that the relative activity remains the same. The authors 
illustrate that there is no sequence dependence for the relaxation, but there is length 
dependence given that any duplex DNA below 100 bp does not act as an efficient 
substrate for ATPase activity (using  phage and fragments). The authors do not exclude 
the possibility that there are DNA sequences that gyrase will preferentially bind. 
The utility of topoisomerase sequence specificity was best demonstrated in a 
single-molecule study of eukaryotic Drosophila topoisomerase II (97). The authors 
utilized Alexa Fluor 488 and Alexa Fluor 555 to produced short oligonucleotide sequence 
with a known topo II cleavage site for this particular enzyme (98). The authors 
demonstrated that Drosophila topo II was able to bind this 28 bp substrate and proceeded 
to provide some of the first measurements for the dynamics of DNA gate opening and 
closing. The specificity of the results was confirmed using a restriction enzyme specific 
for the DNA substrate and a topo II inhibitor, teniposide, to illustrate that the 
fluorophores did not perturb normal topoII-DNA interaction. 
Using gel retardation, nitrocellulose filter binding and DNase I footprinting 
assays, Reece et al. investigated the roles of the gyrase A subunit domains produced from 
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a tryptic digest (99). The authors compared the wild type A subunit to the product from 
the digest directly (A’) and SDS-PAGE purified proteolytic products – a 64 kDa (N-
terminal) and 33 kDa (C-terminal) fragment. It was found that the A’ subunit in 
combination with the B subunit was able to accomplish all of the known activities of 
wild-type protein (supercoiling, relaxation, decatenation, DNA cleavage, DNA-
dependent ATPase activity and DNA binding), albeit with reduced efficiencies in some 
instances. Only the 64 kDa fragment was able to demonstrate some supercoiling and 
DNA cleavage while the 33 kDa fragment yielded no activity. The authors interpret this 
data to mean that the N-terminal 571 amino acids of the gyrase A subunit contain the 
ability to carry out DNA breakage and reunion.  
The authors conducted another study where they examined the C-terminal portion 
of GyrA (572-875) and determined that it is responsible for stabilizing the protein-DNA 
complex (100). Using a 147 bp DNA fragment containing a strong Topoisomerase-
binding site derived from pBR322, the authors used gel retardation assays to illustrate 
that GyrA(572-875) alone was able to bind this substrate while GyrA(1-572) could not. 
While GyrA(572-875) bound DNA without Mg2+, this was a strict requirement for the 
association of A2B2 or the A subunit alone with the substrate DNA. 
Given the poor resolution, the 4.5 Å crystal report of the aforementioned 64K 
fragment of GyrA yielded little information (101). The 2.5 Å crystal structure of the N-
terminal fragment of DNA gyrase B subunit published shortly thereafter provided the 
first glimpse at DNA gyrase (102). Obtained in the presence of a nonhydrolyzable ATP 
analogue (ADPNP), this C-terminal domain of this 43K fragment forms a 20 Å hole 
when dimerized and contains Mg2+ and 2 water molecules. The authors note that every 
arginine in this domain protrudes into this cavity. A previous study demonstrated that 2’-
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deoxy-ATP will not support supercoiling and this structure shows that binding may 
require Tyr5 interaction which is not possible with this analogue. The authors note that 
proline residues are critical to the tight folding observed. They indicate that, at four 
positions within the structure, there are 2 proline residues spaced apart within 5 residues 
in places where there is a sharp turn in the protein fold. 
When Thermotoga maritima DNA gyrase was purified, it became the first 
example of reverse gyrase and a DNA gyrase identified within a single species (103). The 
authors noted that the subunits GyrA & GyrB were more tightly associated. It was not 
stable at temperatures above 90ºC which falls in line with the fact that this organism does 
not grow above 90C in vivo (104). The authors went on to examine Thermotoga sp. RQ7 
to examine the state of DNA in Thermotogales. Hyperthermophiles with Reverse Gyrases 
were initially thought to have genomes that are relaxed or positively supercoiled. The 
discovery that pRQ7 is negatively supercoiled provided the first direct evidence to 
contradict this notion. The authors incubated Thermotoga sp. RQ7 with novobiocin and 
demonstrated that the plasmid was positively supercoiled. This data was interpreted to 
mean that DNA gyrase is responsible for the negative supercoiling of the pRQ7. The 
discovery that pGS5 in Archaeoglobus profundus was negatively supercoiled illustrated 
that hyperthermophilic archaea do not all adhere to DNA that is either relaxed or 
positively supercoiled (105). In contrast to Thermotoga sp. RQ7, high concentrations of 
the gyrase inhibitor did not influence the supercoiling result. The authors speculate that 
the presence of DNA gyrase and histones provide a potential explanation for this 
topological result. 
The gyrase 59K fragment (residues 2 to 523 of E. coli) revealed a second 
snapshot of a type II topoisomerase to complement that of S. cerevisiae (106). This 
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structure contained a large positively charged surface for DNA interaction with tyrosine 
residues that are 7 Å apart in the head-dimer interface and many of the quinolone 
resistant residues map to this area. Even though there is ~20 degree angle between the 
long axis dimer face and DNA duplex, the authors note that either the protein or the DNA 
must conform further for the cleavage-ligation in order to overcome the distance between 
the catalytic residues. The authors highlight the fact that 2 conserved positively charged 
residues (Arg46 and Arg47) are positioned to interact with the non-covalently bound 3’ 
end during cleavage. 
 
2.13 TYPE IIA 
In a recent in vitro study of hTopoII, the authors utilized a dsDNA 50-mer to 
illustrate that two divalent cations are required in the catalytic cycle for cleavage (107). 
The top strand of this oligomer consisted of two strands to simulate a nick. The authors 
used a bottom strand sequence that was unmodified and also ones that contained a 3’-
bridging phosphorothiolate or a racemic mixture of the phosphorothioate in place of the 
non-bridging scissile bond oxygens. Utilizing these substrates, the authors demonstrated 
that Ca2+, Mg2+ and Mn2+ individually elicited varying degrees of cleavage and compared 
combinations of these cations. Using the results of this study, the authors postulate that 
there is a high affinity divalent cation binding site that interacts with the scissile 3’-
bridging oxygen and a low affinity binding site that interacts with the non-bridging 
oxygen in the proposed two metal ion mechanism. 
Using S. cerevisiae type II topoisomerase, another structure was captured at 2.5 Å 
resolution with a hole through the center that has a maximum diameter of 48 Å (108). 
The two active site tyrosines (Tyr782) are ~26 Å apart from one another. The authors 
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suggest that this structure is an intermediate to the previously captured type II structures 
(gyrase DNA closed form and type II DNA open form). The authors note that there is a 
large conformational change (~170° rotation) of the B’ fragment from the previously 
obtained yeast topoII fragment to this one. 
S. cerevisiae topoisomerase II crystal structure reveals a dimer that consists of 
two crescent shaped monomers forming a heart shaped cavity with dimensions 25 and 55 
Å at its two widths (109). With the catalytic tyrosines initially 27 Å apart, the authors 
suggests that this enzyme undergoes large conformational changes of 35-40 Å to 
facilitate the staggered cleavage of a duplex DNA strand. Based on the crystal structure 
of this 92K fragment 
The first archaeal topoisomerase structure obtained was that of Methanococcus 
jannaschii topoisomerase VI A subunit (residues 69–369) which bears sequence 
homology with the S. cerevisiae meiotic recombination factor Spo11 (110). With a 
resolution of 2 Å, this dimeric structure contains motifs (toprim and CAP-like domain) 
that are essential for catalysis that are ordered differently, but still conserved as compared 
to EcoTopoI and S. cerevisiae topo II. This structure consists of a ‘U’-shaped dimer in 
which the tyrosine from one protomer is closer to the Mg2+ bound toprim domain of 
another protomer (9.6 Å) as compared to its own (>30 Å). With bound Mg2+ in the toprim 
domain, this structure represents the first direct structural evidence of Mg2+ in the 
mechanism. The authors suggest a role in the mechanism based on other metal-assisted 
enzymes outside of the topoisomerase family despite having no direct evidence. 
While attempting to crystallize the full length B subunit of Sulfolobus shibitae 
topoisomerase VI, the authors identified a truncated contaminant consisting of residues 2-
470. They purified this polypeptide and obtained structures of it in the presence and 
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absence of AMP-PNP (111). The 2.0 Å structure contains a GHKL domain whose lateral 
sides facilitate dimerization in the presence of the AMP-PNP. The 20 Å hole seen in 
GyrB is not present in this structure between the inner sides of the transducer. 
Comparison of the unliganded monomer to the cofactor-bound dimer demonstrates a 
rearrangement of the transducer domains such that Lys427 flips 180º and inserts in the 
ATP-binding pocket of the GHKL domain. Asn42 is captured bound to a Mg2+ ion which 
is also coordinated by two water molecules and the three phosphates groups of the 
cofactor. The authors utilize the comparable dimerization geometry between GyrB and 
this structure as evidence for mechanistic homology amongst type II topoisomerases. 
In another study, full length S. cerevisiae Type IIA topoisomerase was 
crystallized bound to a prospective G-segment dsDNA (112). In obtaining this 3 Å 
structure, the authors observed that each subunit of the protomer bends the nucleic acid 
complex approximately 75 degrees in what appears to be a configuration poised for 
catalysis. The authors postulate that a surface exposed isoleucine (Ile 833) intercalates the 
minor groove of the bound DNA between the +8 and +9 position such that it significantly 
increases the rise and roll of the duplex while simultaneously decreasing the local twist. 
The bent conformation is further stabilized by the positively charged groove formed near 
winged helix domain (WHD). In comparison to the apo form where there is a 25-30 Å 
distance between the catalytic tyrosines, this structure contains a nearly contiguous 
surface between the WHD subunit tyrosines illustrating the large conformational changes 
that this enzyme undergoes. The authors indicate that the 80 degree rotation of the 
TOPRIM domain and reorganization with the WHD gives rise to an active site 
configuration that hints at evolutionarily conservation amongst type IA and type IIA 
topoisomerases. 
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2.14 DRUG INHIBITION: STRUCTURE-FUNCTION 
Camptothecin is a type IB topoisomerase inhibitor that was originally discovered 
through a systematic analysis of drugs on cancer cell lines (113). However, camptothecin 
has low solubility and is hepatotoxic. As a result, homologues named 
homocamptothecins have been developed with greater solubility (114, 115). Interestingly, 
the mechanism for camptothecin was originally postulated through molecular modeling 
prior to crystallization (54, 116). 
The mechanism for a water soluble homocamptothecin, topotecan, has been 
resolved. Topotecan, a camptothecin analog, intercalates DNA at the site of hTopoIB 
induced cleavage between +1 and -1 forming base stacking interactions (117). In this 
way, it acts as an uncompetitive inhibitor. The authors capture two structures – a binary 
complex (3.2 Å) of hTopoIB-DNA and a ternary complex (2.1 Å) of hTopoIB-DNA-
Topotecan. Topotecan (20-(S)-hydroxyl of both lactone and carboxylate) has a hydrogen 
bond interaction with Asp533 which means that if this residue is mutated it may result in a 
drug resistant mutant. Given the electron density observed in the structure, both the open 
and closed form of the E-ring of Topotecan may fit. Arg364 and Lys532 make contacts with 
the bases at the -1 position of the intact and cleaved strand, respectively. This drug 
directly interacts with the cleaved intermediate through base stacking and coordinated 
water interactions with various amino acid residues. It pushes the 5’-OH end (or 5’-SH in 
this case) 8 Å farther away from the phosphotyrosine linkage disrupting the 
cleavage/religation equilibrium. This structures answers why the enzyme complex is the 
target and NOT the enzyme alone. Basically, the drug increases the distance between the 
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3’ and 5’ end preventing the equilibrium between cleavage and religation from being 
established.  
Lewis et al. collected native data on the crystallization of a gyrase B fragment in 
the presence of novobiocin (2.5 Å) and GR122222X (2.0 Å) (118). Once those structures 
were published, the authors noted that one of the main differences in the GyrB structures 
(residues 1-220) in complex with an inhibitor is that both complexes are monomeric in 
comparison to the previously obtained dimer in the presence of ADPNP (119). The 
authors note that binding of ATP to the 24 kDa N-terminal is akin to that of novobiocin 
and GR122222X, a cyclothialidine, in that it is mediated in part by ordered water 
molecules. Even though there is little structural homology between these compounds, 
both act as competitive inhibitors in the sense that binding to the B subunit impinges 
upon cofactor binding on account of overlap in the region of interaction. With 
GR122222X, there are several water mediated contacts but both polar and apolar contacts 
appear to be important. With novobiocin, there is an extensive hydrogen bonding network 
with the coumarin ring forming two hydrogen bonds with Arg136. These structures 
represented the first structures of a topoisomerase interacting with a drug inhibitor. 
In a later study, Tsai et al. were able to determine the structure at 1.9 Å of this 
same gyrase B subunit fragment with clorobiocin (a natural antibiotic produced by 
several Streptomyces strains) independently in two laboratories (120). The authors used 
ITC to compare the thermodynamic parameters for novobiocin and clorobiocin 
complexes. Given that ordered water molecules and novobiocin are in one structure 
versus clorobiocin alone in the other, the authors noted that there was not the anticipated 
large entropic gain for the preclusion of the water molecules. Clorobiocin makes two 
hydrogen bonding contacts with Arg136 and several polar and apolar contacts akin to 
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novobiocin. The sugar moiety of clorobiocin appears to be in the chair conformation. The 
authors illustrate again that the drug and ATP binding site are not identical, but that there 
is overlap sufficient to inhibit binding of both substrates. 
Interestingly, another group went on to publish another crystal for the same 24 
kDa gyrase B subunit–clorobiocin complex (121). The authors note that the previous 
structures obtained were not deposited into the PDB and used this as an opportunity to 
crystallize the 24 kDa fragment with RU 64135 as well. In this publication, two synthetic 
coumarin analogues - RU 64135 and RU 64136 – were utilized to determine the 
contributions of the hydroxybenzoate isopentenyl moiety and the 5’-methyl group on the 
activity of the noviose. The authors utilized ITC with a displacement method to illustrate 
why clorobiocin binding is thermodynamically favored over novobiocin and provided the 
first real data to explain this empirical finding. Clorobiocin, RU 64135 and RU 64136 
binding was demonstrated to be entropically and enthalpically favored. Meanwhile, 
Arg136 was again illustrated to play a key role in the protein-inhibitor complex 
formation. 
Further probing gyrase B, Lamour et al. would publish a crystal structure of gyrB 
from the thermophilic bacteria Thermus thermophilus in the presence of novobiocin 
(122). Given that the 24 kDa crystals were a monomer in the presence of novobiocin, the 
authors were surprised to find their 43 kDa structure as a dimer. The authors point out 
that the regions primarily involved in the dimeric contacts were not present in the 24 kDa 
structure and these same residues represent a subset of the dimeric contacts involved in 
the analogous E. coli gyrase B-ADP-PNP dimeric interface. The authors verified that this 
structure acts as a monomer via gel filtration in the presence or absence of novobiocin 
and as a dimer in the presence of ADP-PNP. They utilized native gels to illustrate that 
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dimers are present in the presence of novobiocin albeit at lower concentrations. The 
authors note that loop 98-118 occupies a different conformation in the presence of 
novobiocin as compared to ADP-PNP. The authors reveal that Arg136 interaction with this 
inhibitor is conserved with another strong hydrogen bond from Asp80, which appears to 
be a T. thermophilus specific interaction. 
In a comparative study of three common hTopoIB inhibitors, the authors obtain 
the crystal structures (3.0 Å) of a ternary complex featuring either bound camptothecin or 
a representative member of indolocarbazoles or indenoisoquinolines (123). Interestingly, 
the planar structure of these compounds permitted all to intercalate the cleaved DNA 
substrate while there are no conserved base stacking interactions. The only conserved 
protein-drug interaction between all three structures is that of a lone electron pair of the 
drug with that of the adjacent ε-Nitrogen of Arg364. The authors note that the relative 11° 
twist of camptothecin compared to topotecan suggests that there is some flexibility in 
how this class of drugs fit into the cleaved pocket. The hTopoIB fragment utilized was 
that of top70 with a 22 bp phosphorothioate containing DNA duplex while the 
indolocarbazole resolved best with a mutant containing N722S and the same duplex. 
In a subsequent structure-activity study of topoisomerase inhibitors, Ioanoviciu et 
al. synthesize and characterize norindenoisoquinolines before obtaining a crystal 
structure of the therapeutic with most potential (compound 14) (124). With over 40 
compounds to compare, the authors test for the proliferation inhibition using 
approximately 55 cancer cell lines that are National Cancer Institute (NCI)-maintained. 
After determining the cytotoxicity, the authors selected the three compounds with the 
lowest GI50 values (13, 14, 18) to further characterize. The authors compare the cleavage 
properties of these compounds (13, 14 and 18) with camptothecin using 3’-end labeled 
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PvuII/HindIII fragment of pBluescript SK(-) in a DNA cleavage assay. The result is that 
only compound 14 produces appreciable accumulation of cleavage products with some 
noticeable differences in specificity than camptothecin and at appreciably higher 
concentrations of drug. The authors go on to obtain a crystal structure at 3.1 Å resolution 
of this novel compound 14 with a 22 bp DNA substrate previously described that 
contains the phosphorothioate linkage. In this structure, the authors identify two 
hydrogen bonds with hTopoIB – Arg364 and Asn722 – that ensure stabilization in the 
ternary complex. This study reaffirms the notion that slight modifications of known 
therapeutics can result in drastically different antitumor specificities. 
Discovered for resistance conferred through an R462C mutation, GyrA is the 
target of coupled cell division protein B (CcdB), a bacterial toxin located on plasmid F 
(125). Using surface plasmon resonance, Dao-Thi et al. demonstrated that a truncated 
form of the gyrase A subunit with the same mutation (GyrA14R462C) was unable to bind 
CcdB while wild type GyrA14 could (126). The authors demonstrate that cells 
overexpressing GyrA14 in a system containing CcdB and wild type GyrA without the 
antitoxin coupled cell division protein A (CcdA) were still viable while GyrA14R462C in 
the same system yielded no protective effect. This in vivo assay illustrates the molecular 
basis of CcdB inhibition of GyrA and the potential of a peptide fragment as a therapeutic 
agent. The authors move on to obtain a crystal structure in which both GyraseA14 and 
CcdB are dimers with global symmetry with an asymmetric center. The interface consists 
of a Trp99 residue from each CcdB contacting a single subunit GyrA14 Arg462 residue that 
also contacts the same CcdB at Asn95. Furthermore, Asn92 of the second CcdB subunit 
forms a different contact with the second GyrA14 subunit at residue Arg462. The authors 
go on to produce 33 CcdB mutants and assess cell viability when expressed in vivo 
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without CcdA. The authors found that most loss-of-killing mutants mapped to the binding 
interface of GyrA14-CcdB. The rest map to potential binding sites of GyrA59, but were 
not confirmed with a crystal structure. From the available data, the authors suggest that 
CcdB binds to a state that is short lived such as when the DNA gate is opened, but no 
passage of the T-segment has occurred. 
In an effort to tease out the differences between TopoIV and DNA gyrase in terms 
of drug interaction, the authors crystallized TopoIV fragments in the presence of either 
ADPNP or novobiocin (127). The 2.1 Å 43 kDa TopoIV structure in the presence of 
ADP-PNP is a dimer, binds Mg2+ and maintains a C-terminal cavity that is approximately 
20 Å and lined with arginines. Despite having 35% sequence identity between the two 
type II topoisomerases, the active site crystals bound to ADPNP are structurally similar 
and have a largely conserved architecture. In the presence of novobiocin, the authors 
discovered that the 24 kDa structure of both enzymes bind in a similar conformation with 
the main difference being the residues Met74 and Asp77 in ParE of Topo IV (Ile78 and 
Gly81 in GyrB, respectively). The authors utilize mutagenesis of full length proteins to 
explore the role of these residues and others on the novobiocin IC50 difference between 
these two topoisomerases. The authors note that GyrB Ile78 γ1 carbon interacts with the 
oxygen on the novobiose sugar while the γ2 carbon interacts with the isopentyl group 
while the corresponding Met74 is only able to interact with γ1 with the oxygen of the 
novobiose sugar. Examination of the GyrB I78M mutant revealed a 22-fold increase in 
the IC50 while the ParE M74I mutant was able to decrease the IC50 from 210 nM to 12 
nM. Other mutations (GyrB G81D and Gyr B flexible loop swaps for S. aureus GrlB and 
E. coli ParE) showed marginal effects on the novobiocin IC50. The authors examined 
other type II topoisomerase protein sequences and found that Methionine and Isoleucine 
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were the only two amino acid residues at this position. They conclude that the interaction 
of a single residue influences observed difference between novobiocin and type II 
topoisomerases, specifically TopoIV and DNA gyrase. 
Classen et al. obtained a 1.75 Å resolution crystal of a complex consisting of 
adenosine 5’-[β,γ-imino]-triphosphate-bound yeast topoII in the presence and absence of 
ICRF-187, a bisdioxopiperazine inhibitor (128). With 12 potential hydrogen bonding 
contacts, the drug only makes 2 with the carbonyl oxygen of Gln365 on each protomer. 
The two piperazinedione rings are surrounded by a “tyrosine dome” whose ceiling and 
walls consist of Tyr144 and Tyr28, respectively, on each protomer. The authors note that 
the interior cavity is much more constricted than in the GyrB structure (6 Å vs 20 Å). 
From this structure, the authors decipher the potential physical basis behind some 
empirical findings of drug resistant mutations. For example, the Y165S mutation is 
inhibitory based on the fact that the “tyrosine dome” would be completely disrupted 
along with the delocalization of the π electrons. A L169F mutation is thought to introduce 
a bulky side group which may disrupt the local architecture and subsequently impact the 
Gln365 and drug binding. It is important to note that the authors submitted an erratum in 
which they indicated that the compound ICRF-186 was inadvertently utilized in place of 
ICRF-187 so that some of the other mutant interpretations may not bear as much weight. 
As with a previous effort, Corbett el al were only able to crystallize the S. shibitae 
TopoVI-B’ in the presence of an inhibitor, radicicol, in the monomeric state (129). The 
authors postulate that binding of radicicol does not maintain the same base pairing 
contacts as AMP-PNP since they lack structural similarity so the conformational changes 
necessary for dimerization. The authors compare the binding specificities of three type II 
topoisomerase II - GR122222X, novobiocin and radicicol - to illustrate how the same end 
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result can be produced. All three drugs share specific contacts with 2 conserved residues 
– Asp76topoVI-B’/Asp73GyrB and Thr170topoVI-B’/Thr165GyrB. Noticeably, only radicicol almost 
entirely fits into the ATP-binding pocket while the other two have large portions outside 
of it. The authors demonstrate how drug binding directly blocks dimerization, but cannot 
explain how the GHKL family member yeast HSP90 is 1000x more inhibited than Topo 
VI-B’ based on these structures. This study reveals that radicicol is a competitive 
inhibitor of S. shibitae TopoVI-B’ subunit. 
Chrenkik et al. sought to further characterize the protein-drug interactions of 
hTopoIB and topotecan through crystal structures of two drug-resistant mutants (P361S 
and N722S) (130). The authors use the same 22 bp DNA sequence as in previous 
structures with a 5’-bridging phosphorothioate in the scissile strand. In the 2.3 Å N722S 
hTopoIB structure, the authors found that a key water-mediated hydrogen bond was 
destabilized. This water molecule exhibits a thermal displacement parameter that 
suggests it is highly mobile and, thus, less effectively coordinated for interaction with the 
drug and amino acid side chain. Most of the other contacts remain the same. In the 2.6 Å 
Phe361Ser structure, the authors found that a well-ordered water molecule is buried in 
place of the hydrophobic side chain and likely imparts drug resistance. The authors 
speculate as to why other mutations contribute to drug resistance with an emphasis on the 
influence of water-mediated contacts. 
In the archaeon S. shibatae, a 3.55 Å crystal was recently characterized of the 
Topoiomerase Ss-topo VI A2B2 heterotetramer in the absence and presence of radicol, a 
topoisomerase inhibitor (131). As with a previous crystal structure of the Ss-topo VI-B’ 
subunit lacking the 60 C-terminal residues, radicol was shown to interact with the 
ATPase site. In the presence of radicol, the ATPase domains remain approximately 70 Å 
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apart in comparison to the dimerization induced by ATP and its analogues suggesting that 
radicol-induced inhibition is accomplished through competitive binding of the ATPase 
domain. The N-terminal residues that were missing in previous structures were shown to 
be at the interface between the heterodimer subunits constituting a major portion of the 
1300 Å2 area. With an overall “V” shape, the apo and inhibitor bound conformation 
reinforce the belief that type II topoisomerases are highly flexible with Lys450 of the B-
subunit helix 11 acting as the potential hinge in Ss-topo VI. 
Hsieh et al. determined the 1.8 Å crystal structure of ParC CTD of Bacillus 
stearothermphilus (132). Surprisingly, the structure maintains a similar β-propeller 
structure with a key difference being the no close contacts observed between blade 1 and 
blade 6. This results in a broken form of the six-bladed propeller that features no ring 
closure. The authors report that the lack of ring closure in this structure may play a 
critical role in distinguishing the activity of the ParC-CTD with that of the GyrA-CTD. 
For example, the lack of ring closure may play a role in the previously noted decreased 
efficiency in DNA bending. The authors do not rule out the possibility that ring closure 
occurs upon DNA binding. 
In one study, the Corbett et al. sought to characterize the complete nucleotide 
hydrolysis mechanism of subunit B from S. shibitae topoisomerase VI (133). Using 
cofactor analogs such as ADP˖AlF4-, ADP˖Pi and ADP, the authors crystallize 
intermediate stages of the dimer in this crucial process to enzyme turnover with a 2.0-2.2 
Å resolution. Prior to hydrolysis, Gln34 stabilizes Glu38 to coordinate a water molecule for 
attack on the γ-phosphate. The only GHKL domain residue that interacts with the Pi 
phosphate after hydrolysis is Glu38. The transducer region residue Lys427 appears to play 
a role in stabilizing the γ-phosphate both before and after hydrolysis. Once Pi has been 
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released, Lys427 and Glu38 hydrogen bond each other. Topoisomerase VI is said to be in a 
restrained state when Lys427 is interacting with the γ -phosphate or Glu38. Once these 
interactions are abolished and the transducer region changes conformation, it is said to be 
in a relaxed state. The authors were unable to obtain a structure containing a relaxed form 
of the enzyme bound to ATP (or analog) suggesting that ATP hydrolysis is a prerequisite 
(among others) for return to the relaxed state. 
Unsuccessful at crystallizing the GyrA CTD from E. coli, Corbett et al. turned 
their attention to a homologous region in the Borrelia burgdorferi gyrase A subunit 
(residues 499-810) and yielded a 1.75 Å crystal (134). The authors found that this 
fragment adopts a β-propeller-like structure with six four-stranded β-sheets coordinated 
in a closed circle. Importantly, the organization is different from all previous β-propeller 
structures such that it is not four antiparallel β-sheets in an A-B-C-D strand order. 
Instead, there is an “antiparallel Greek key structure” such that there is an inner-to-
outermost strand arrangement of D-A-B-C that they named a β-pinwheel. Then, they 
went on to test whether the CTDs of the E. coli GyrA and ParC could bend DNA using 
FRET. The authors found that both a 40 bp and 45 bp end-labeled DNAs yielded similar 
dye-dye distances. This data fit the notion that the β-pinwheel non-specifically binds 
DNA and bends it over 180º through interaction with four of the six blades. It is 
important to note that ParC yielded similar results at ~10-fold the protein concentration. 
The authors utilize this data to suggest a mechanism by which DNA gyrase introduces 
negative supercoils to positively supercoiled substrates. 
Surprisingly, Ruthenberg et al. found that the structure of E. coli GyrA-CTD 
contains a β-pinwheel fold whose blades are spiral in a fashion comparable to B. 
stearothermophilus Par-CTD (135). This is in contrast to the flat structure of B. 
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burgdorferi GyrA-CTD. To assess the structural effect of DNA wrapping by E. coli 
versus B. burgdorferi GyrA-CTD in the presence of hTopoIB, the authors compare the 
results on gels with and without chloroquine to determine the increase in linking 
numbers. The authors found that E. coli GyrA-CTD had significantly more influence and 
increase in positive supercoiling based on pBR322 plasmid mobility post treatment. The 
authors purport that the rise of the positively charged midriff on the protein surface 
directs the binding of right-handed DNA and promotes the introduction of (-) supercoils. 
In effort to further elucidate the differences between type IIA topoisomerases, 
Corbett et al. crystallize two structures of E. coli ParC (136). In this structure, the authors 
find the dimer in the most open configuration to-date with a 40 Å distance between each 
active site Tyr120. The authors propose that this open conformation may account for the 
rearrangement noted in some regions such as residues 102-124 as compared to GyrA. As 
anticipated, the CTD does consist of a B-pinwheel with a spiral shaped structure that 
lacks an entire blade (only 5). After comparing the activities of wild-type to CTD 
truncated enzyme, the authors find that the CTD is responsible for the pronounced 
preference of decatenated and positively supercoiled substrates. The only caveat is that 
activity on negatively supercoiled is also amplified but to a lesser extent. From this data, 
the authors propose that small differences in the CTD account for the functional 
differences amongst type IIA topoisomerases. 
Wei et al. obtained the structures for human topoisomerase IIα ATPase domain in 
the presence of either AMPPNP (non-hydrolyzable ATP analogue) or ADP at a 
resolution of 1.86 and 2.51 Å, respectively (137). They found that superposition of the 
individual modules within the nucleotide binding domain revealed nearly identical 
structures (adenine ring direct contact with Asn120 and via water mediated contacts to 
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Asn120, Thr215 and Tyr34’). While the sugar pucker appears C4’-exo in the AMPPNP 
structure versus C3’-endo in the ADP structure, many of the contacts within the binding 
pocket remain. Even the coordination of the Mg2+ is near identical with the exception 
that, in the ADP structure, a water molecule participates in the octahedral coordination 
shell in place of the oxygen from the γ-phosphate. The main difference amongst the two 
structures is Lys378. In the ADP structure, Lys378 from the transducer region is retracted 
from the nucleotide as compared to the AMPPNP structure where the Nε bonds the γ-
phosphate. The transducer region appears to swing open 10° upon hydrolysis, increasing 
the channel from 6 to 17 Å at its narrowest. From this, the authors implicate this residue 
as a potential sensor for nucleotide binding. 
 
2.15 Conclusion 
While the overall role of DNA topology maintenance is shared, each class of 
topoisomerases has a unique structure, function and mechanism. The cofactors, 
interaction partners and inhibitors further reflect this delineation. Exhaustive 
investigation of type IB and type II topoisomerases has yielded targets for the treatment 
of various tumors and bacterial infections, respectively. Unfortunately, drug resistance 
has proven to be a serious limitation. 
Less is known about type IA topoisomerases relative to type IB and type II. While 
tissue specific expression of the isoforms of hTopoIIIα and hTopoIIIβ provides a strong 
case for increased scrutiny of this class of topoisomerases, TopoIII topoisomerases have 
received little attention in spite of their interaction with enzymes involved in diseased 
states. So while type IA topoisomerases are ubiquitous and indirectly implicated in 
pathology, there are currently no drugs specifically targeting these enzymes or any in 
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clinical trials. With drug resistance becoming a greater issue for known classes of 
topoisomerase inhibitors and so many gaps remaining in our understanding of the 
mechanism of type IA topoisomerases, there is a need to further investigate TopoIII 
topoisomerases as a potential therapeutic target. 
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Figure 2-1 Mechanism Of Action. The formation of a transient covalent adduct is the 
hall mark of the topoisomerase family of enzymes. Based on the type intermediate 
formed, the enzymes are further classified. (a) Type IA topoisomerases form a covalent 
adduct with a 5’-phosphotyrosine linkage. (b) Type IB topoisomerases form a 3’-
phosphotyrosine linkage. (c) Type IIA and IIB topoisomerases maintain dyad symmetry 
and induce a staggered cleavage of the backbone with a 5’-phosphotyrosine intermediate 
formed. 
 
DNA is illustrated in black. Catalytic tyrosine of the topoisomerase is illustrated in blue 
and orange. The break in the DNA sequence is clearly delineated with the hydroxyl and 
phosphate denoted. Drawing is not to scale. 
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FIGURE 2-2 Brief Timeline of Major Topoisomerase Discoveries. Eco, Escherichia 
coli; mt, mitochondrial; RG, reverse gyrase; Mka, Methanopyrus kandleri; ss, single 
stranded. 
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Chapter 3. Methanosarcina acetivorans C2A topoisomerase IIIα, an archaeal enzyme with 
promiscuity in divalent cation dependence1 
ABSTRACT 
Topoisomerases play a fundamental role in genome stability, DNA replication and repair. 
As a result, topoisomerases have served as therapeutic targets of interest in Eukarya and Bacteria, 
two of the three domains of life. Since members of Archaea, the third domain of life, have not 
been implicated in any diseased state to-date, there is a paucity of data on archaeal 
topoisomerases. Here we report Methanosarcina acetivorans TopoIIIα (MacTopoIIIα) as the 
first biochemically characterized mesophilic archaeal topoisomerase. Maximal activity for 
MacTopoIIIα was elicited at 30-35°C and 100 mM NaCl. As little as 10 fmol of the enzyme 
initiated DNA relaxation, and NaCl concentrations above 250 mM inhibited this activity. The 
present study also provides the first evidence that a type IA Topoisomerase has activity in the 
presence of all divalent cations tested (Mg2+, Ca2+, Sr2+, Ba2+, Mn2+, Fe2+, Co2+, Ni2+, Cu2+, Zn2+ 
and Cd2+). Activity profiles were, however, specific to each metal. Known type I (ssDNA and 
camptothecin) and type II (etoposide, novobiocin and nalidixic acid) inhibitors with different 
mechanisms of action were used to demonstrate that MacTopoIIIα is a type IA topoisomerase. 
Alignment of MacTopoIIIα with characterized topoisomerases identified Tyr317 as the putative 
catalytic residue, and a Y317F mutation ablated DNA relaxation activity, demonstrating that 
Tyr317 is essential for catalysis. As the role of Domain V (C-terminal domain) is unclear, 
MacTopoIIIα was aligned with the canonical E. coli TopoI 67 kDa fragment in order to construct 
an N-terminal (1-586) and a C-terminal (587-752) fragment for analysis. Activity could neither 
                                                 
1 This chapter appeared in its entirety in the journal PLoS ONE.  
Morales R, Sriratana P, Zhang J, Cann IKO (2011) Methanosarcina acetivorans C2A Topoisomerase IIIα, an 
Archaeal Enzyme with Promiscuity in Divalent Cation Dependence. PLoS ONE 6(10): e26903. 
doi:10.1371/journal.pone.0026903 
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be elicited from the fragments individually nor reconstituted from a mixture of the fragments, 
suggesting that native folding is impaired when the two fragments are expressed separately. 
Evidence that each of the split domains play a role in Zn2+ binding of the enzyme is also 
provided.  
3.1 INTRODUCTION 
Topoisomerases manage DNA supercoiling and are classified according to the 
mechanism of action employed (1-4). In general, topoisomerases form a phosphotyrosine 
intermediate while cleaving one strand (type I or odd-numbered) or two strands (type II or even-
numbered) of DNA. Before the initial transesterification is reversed and a ligated DNA backbone 
regenerated, type I and II enzymes change the DNA linking number (Lk) by 1 and 2, respectively. 
Type I topoisomerases are ascribed further distinction based on the polarity of the covalent 
intermediate formed. Type IA (like Type II) forms a 5’-phosphotyrosine adduct while type IB 
forms 3’-phosphotyrosine covalent adduct. Thus, the structure and mechanism of each class are 
distinct.  
The characterization of the first topoisomerase E. coli TopoI (EcoTopoI), originally titled 
ω protein, was an earnest exploration into a field that has grown to be of burgeoning biological 
importance (5). Since then, topoisomerases have been demonstrated to be vital components of 
the cellular machinery in a wide array of processes that are essential for life, such as DNA 
replication, DNA repair and chromosome segregation (6-8). While these molecular machines 
have been identified in every genome sequenced to date, irrespective of domain, eukaryotic and 
bacterial topoisomerases have received greater scrutiny given their role in diseased states such as 
Cancer and infections (9, 10). 
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Interestingly, studies from bacteria and both lower and higher eukaryotes have 
demonstrated that ablation of TopoIII (a subfamily of type IA) activity in vivo without some 
compensatory mechanism leads to genomic instability and/or abnormal growth (11-16). In spite 
of this direct evidence that TopoIII is vital for normal development, the majority of archaeal 
studies have focused on the non-essential Reverse Gyrase (a subfamily of type IA) given its 
unique phylogenetic distribution in thermophiles and hyperthermophiles (17-20). Furthermore, 
the only data published on archaeal TopoIII are from hyperthermophilic organisms of the 
archaeal subdomain Crenarchaeota (21-23). 
The archaeal subdomain Euryarchaeota contains a large group of economically important 
organisms, including both the mesophilic and hyperthermophilic methane-producing organisms. 
The methane-producing genus Methanosarcina is known to harness all known substrates 
(including acetate, H2 and CO2, formate, methylamine and methanol) to produce methane, a 
greenhouse gas (24). Recent reports also demonstrate that methanogens may be important in 
human health, especially from the nutritional standpoint (25, 26). With the largest sequenced 
archaeal genome, Methanosarcina acetivorans C2A provides a fertile ground for studies on 
archaeal DNA metabolism. This organism has four putative topoisomerases (six genes) 
tentatively named MacTopoIIIα [NP_617416], MacTopoIIIβ [NP_616715], MacTopoVIA 
[NP_616519, NP_616520], MacTopoVIB [NP_616517, NP_616516] (24). Based on sequence 
homology, MacTopoIII is classified as a type IA topoisomerase III protein. In the present 
report, we characterize MacTopoIIIα, as the first mesophilic archaeal TopoIII studied. The 
attributes shared with orthologs from the other domains and those potentially specific to Archaea 
are discussed. 
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3.2 RESULTS 
3.2.1 Expression and purification of MacTopoIIIα In order to characterize MacTopoIIIα, 
the encoding gene was amplified, cloned, expressed, and purified from E. coli cells as a fusion 
protein with an N-terminal hexa-Histidine (6-His) tag. Purification of the recombinant protein 
was achieved through affinity chromatography, ion-exchange chromatography and size-
exclusion chromatography. Based on the polypeptide sequence, the recombinant protein has an 
estimated molecular mass of ~86 kDa. As expected, the highly purified MacTopoIIIα migrated 
between the 66 and 116 kDa molecular mass markers via a 12% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) according to the method of Laemmli (Fig. 3-
1A, lane 2) (27). 
3.2.2 Catalytic properties of MacTopoIIIα The putative topoisomerase was tested for the 
ability to relax negatively supercoiled pUC18 (300 ng). As little as 10 fmol of enzyme initiated 
relaxation upon addition to the reaction mixture (Fig. 3-2A). Whereas 200 fmol of enzyme 
showed modest activity, 5 pmol of enzyme elicited maximal activity under standard assay 
conditions. Analysis of aliquots of samples collected from the last step (gel filtration column) 
demonstrated similar activities in all fractions.  
Maximal relaxation activity was observed around 30 °C, and at temperatures of 50 °C 
and above, no relaxation was observed (Fig. 3-2B). M. acetivorans C2A is an anaerobic 
mesophile that grows optimally at 35-40 °C. Therefore, the optimal temperature for activity of 
MacTopoIIIα falls within the expected range of activity (28). Both Na+ and Mg2+ are required for 
growth of this archaeon, and the optimal concentration of NaCl required was 200 mM. In the 
present study, at NaCl concentrations of 400 mM or higher, the activity of MacTopoIII was 
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almost not observable (Fig. 3-2C). A similar observation was made for the effect of KCl 
concentration on MacTopoIII activity. Initiation of activity by the enzyme was observable as 
early as 15 seconds after addition of MacTopoIIIα to the reaction mixture, and maximal activity 
was observed within 5 min (Fig. 3-2D).  
3.2.3 The effects of different divalent cations on MacTopoIII activity Topoisomerase 
activity was assessed as a function of divalent cation concentration in a semi-logarithmic range 
of concentrations from 50 μM to 10 mM (Fig. 3). We observed that each divalent cation elicited 
a unique activity profile. As in previous studies on topoisomerases, Mg2+ was able to elicit 
maximal activity at concentrations greater than or equal to 1 mM. Ca2+ was the only other cation 
that maintained a profile comparable to Mg2+, with concentrations greater than 1 mM showing 
near maximal relaxation. In fact, relaxation activity of MacTopoIII at concentrations above 1 
mM appeared to be higher for Ca2+ compared with Mg2+.  Ba2+ and Sr2+ profiles were similar, 
but were not able to relax the supercoiled substrate as effectively as Mg2+ and Ca2+. The ability 
of these Group II alkaline metals to elicit DNA relaxation activity at low cation concentration 
was, therefore, as follows: Mg2+ > Ca2+ >> Ba2+ > Sr2+.  
In the presence of Zn2+, activity was observed in a narrow window of 100 μM. Zn2+ 
concentrations of 50 μM or less and 500 μM or more elicited no activity even when the reaction 
was performed in a 1:1 enzyme:DNA molar ratio (data not shown). To a lesser extent, Cd2+ was 
also able to elicit activity within a similar narrow range. Relaxation activity was observed at 0.1 
mM and 0.5 mM concentrations of Co2+, and at a concentration of 1 mM or higher, either no 
activity was detectable or divalent cation-catalyzed DNA degradation was observed. Fe2+ 
required a concentration of 1 mM or higher for activity. However, DNA degradation was also 
78 
 
significant at concentrations above 1 mM. These results are consistent with metal catalyzed DNA 
degradation seen with certain transition metals that are capable of promoting the Haber-Weiss 
reaction. (29, 30). Relaxation activity in the presence of Mn2+ or Ni2+ or Cu2+ was also elicited 
under a narrow range (100 μM – 1 mM). 
3.2.4 Classification of MacTopoIIIα To determine the class of MacTopoIIIα in the 
topoisomerase family, its response to known topoisomerase inhibitors, with different 
mechanisms of action, was investigated. Table 3-1 shows a summary of the inhibitors tested. 
Ethidium bromide (EtBr) and M13 ssDNA inhibited activity. The type I prokaryotic inhibitor 
spermidine and the type I eukaryotic inhibitor camptothecin were unable to inhibit the activity of 
MacTopoIIIα. Furthermore, the type II inhibitors (etoposide, nalidixic acid and novobiocin) also 
had no effect on the relaxation activity of MacTopoIIIα. Relaxation activity was, however, 
inhibited by high concentrations of KCl and NaCl (>400 mM). Based also on preliminary 
analytical gel filtration experiments, MacTopoIIIα was estimated to exist as a monomer in 
solution, which is consistent with the oligomerization state of type 1A topoisomerases (3).  
3.2.5 Catalytic Tyrosine of MacTopoIIIα is Tyr317 A sequence alignment using 
Sulfolobus solfataricus topoisomerase III (SsoTopoIII) and the entire archaeal TopoIII subfamily 
II (of which MacTopoIIIα is a member) was created to provide a hint at the potential catalytic 
tyrosine (Fig. 3-1C), because SsoTopoIII is the only archaeal TopoIII with a characterized active 
site tyrosine (9, 22). The alignment suggested Tyr317 as the potential active site residue of 
interest. Site-directed mutagenesis was used to create a Y317F mutant. Size exclusion 
chromatography of MacTopoIIIα Y317F yielded similar elution volume to that of the wild-type 
protein, suggesting that the mutant also exists as a monomer in solution (data not shown). The 
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purified wild-type and mutant proteins (Fig. 3-1A, lanes 2 and 3) were subjected to circular 
dichroism scan to determine whether the mutation grossly impacted the structure of 
MacTopoIIIα Y317F (Fig. 3-1C). No gross differences between the structures could be discerned, 
suggesting that the secondary structures of both enzymes are comparable, outside of the point 
mutation. By subjecting the purified mutant protein to the relaxation reaction, it was revealed 
that MacTopoIII Y317F was unable to relax the negatively supercoiled substrate under the 
same conditions where the wild-type protein demonstrated activity (Fig. 3-4A). The products 
seen in Lane 5 are likely to be due to iron catalyzed DNA degradation via the Haber-Weiss 
reaction (refer to Fig. 3-3, last lane under Fe2+). 
3.2.6 Truncation mutants Two truncations of MacTopoIII were constructed based on 
sequence alignment with the 67 kDa fragment of EcoTopoI (31). Based on this sequence 
alignment, the MacTopoIIIα sequence was spliced at a position between two small aliphatic 
residues (A586 and I587) where no secondary structure was apparent based on secondary 
structure prediction (PredictProtein: http://www.predictprotein.org/). We constructed two 
fragments, N1-586 and C587-752, containing the N-terminal 586 amino acid residues and the C-
terminal 166 amino acid residues, respectively. Both truncations were cloned, overexpressed and 
highly purified. Neither the N1-586 nor the C587-752 fragment was able to relax the same 
substrate as the wild-type under standard assay conditions (Fig. 3-4B and 3-4C). To determine 
whether relaxation activity could be reconstituted by mixing the two fragments, they were 
incubated briefly prior to addition to the reaction mixture at varying ratios (50:1, 5:1 and 1:1). 
However, no relaxation activity was observed (Fig. 3-4C). To determine whether higher 
concentrations of the two fragments will elicit topoisomerase activity, we examined 
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concentrations up to five times the maximum concentration used for the wild-type protein; 
however, no relaxation of the substrate was observed either by the individual polypeptides or 
their mixture (Fig. 3-5). The polypeptides, especially the C587-752 polypeptide demonstrated 
DNA binding activity at high concentrations. Further experiments will be designed to 
characterize this property of the split MacTopoIII.  
3.2.7 Zinc Content Measurements In an effort to assess the Zn2+ binding ability of this 
enzyme, samples of wild-type and the two truncation mutants were subjected to ICP-MS analysis. 
The wild-type enzyme was found to contain 1.29 ± 0.01 mol of Zn2+. The MacTopoIII N1-586 
truncation was found to contain 0.62 ± 0.02 mol, and the C587-752 truncation mutant was found 
to contain 0.49 ± 0.01 mol of Zn2+ (Fig. 3-6).  
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3.3 DISCUSSION 
3.3.1 MacTopoIII is promiscuous A fundamental property of type IA topoisomerases is the 
absolute requirement of Mg2+ for the large conformational change required during DNA 
relaxation, but other divalent cations can substitute (5, 32). Recent publications have proposed a 
two metal mechanism for type IA and type II topoisomerases wherein one may bind acidic 
residues within the TOPRIM motif causing the necessary large conformational changes while the 
other may play a transient role in stabilizing the transition state in preparation for attack on the 
scissile phosphate (33, 34). Fluorescence and ICP-MS measurements on E. coli TopoI 
(EcoTopoI) reveal that one Mg2+ plays a role influencing the overall structure of the enzyme, 
while a second Mg2+ is required to achieve full catalytic activity (35). Mutation of three acidic 
residues of EcoTopoI within the TOPRIM domain only partially inhibited activity (36). But even 
when crystals were soaked in MgCl2, no Mg2+ was detected in the crystal structures of 
EcoTopoIII whether the wild-type was covalently linked or whether the wild-type or mutant 
were primed for attack at a scissile bond of ssDNA in a manner akin to S. cerevisiae TopoII 
(SceTopoII) (37, 38). The data in total suggests that two transient divalent cations are required 
for maximal activity with the one divalent cation binding in order to prime the enzymatic 
structure for large conformational changes while the second cation primes the phosphate linkage 
of interest for attack before immediate removal from the active site. 
And while the role of Mg2+ is usually well examined, it is commonplace for other 
divalent cations to receive less scrutiny (Table 3-2). As one example, EcoTopoI DNA relaxation 
activity was investigated in the presence of 0-10 mM Mg2+ while Ca2+ , Co2+, Mn2+ and Zn2+ 
were investigated at 2 mM only (39). In another study, while the activity of human 
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topoisomerase IIIα (hTopoIIIα) was again tested in the presence of a range of MgCl2 
concentrations, hTopoIIIα was deemed inactive in the presence of other divalent cations based 
on one concentration (5 mM) (40). We demonstrate for the first time that MacTopoIIIα is 
promiscuous with regard to divalent cation (Ba2+, Ca2+, Cd2+, Co2+, Cu2+, Fe2+, Mg2+, Mn2+, Ni2+, 
Zn2+) and that each elicits a unique activity profile. Unlike results with other topoisomerases, we 
observe DNA relaxation activity in the presence of Zn2+ albeit under a narrow range (22, 32). 
These results are not plasmid-specific as confirmed in the presence of 300 ng of either pUC18 or 
pGEM-T (data not shown). While further studies are needed to determine if all divalent cations 
may substitute in the mechanism for all topoisomerases, our data clearly demonstrates that there 
is a need to assess bivalent metal ion profiles and not simply examine activity at a singular 
concentration. As a result, it is possible that different divalent cations not previously reported to 
elicit activity for any given topoisomerase indeed do elicit activity, although it may be under a 
narrow range of concentrations. It also remains to be seen whether these divalent cation profiles 
can act as a tool to distinguish topoisomerases or whether this activity is specific to Archaea or to 
this particular archaeon in the present study. 
3.3.2 MacTopoIII is a type IA topoisomerase Nalidixic acid, etoposide and novobiocin are 
specific inhibitors of type II topoisomerases with different mechanisms of action (10). 
Camptothecin is a known eukaryotic type I inhibitor that stabilizes the binary protein-DNA 
complex intermediate thereby impeding DNA relaxation (41). None of these inhibitors were able 
to inhibit the DNA relaxation activity of MacTopoIII. Ethidium bromide induces positive 
supercoiling (42). Type IA topoisomerases have a preference for ssDNA and preferentially relax 
negatively supercoiled DNA. Ethidium bromide and M13 ssDNA were each able to inhibit 
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activity. Thus, the sequence homology in combination with the results from the inhibitor studies 
clearly demonstrates that MacTopoIII is a type IA topoisomerase. 
Spermidine had no effect on MacTopoIIIα at concentrations up to 100 mM. Spermidine 
was initially posited as a prokaryotic polyamine topoisomerase inhibitor given its inhibitory 
effect on both EcoTopoI and EcoTopoIII at physiological concentrations (43, 44). However, the 
data actually suggests that it is a case by case scenario within the domain Bacteria and the only 
archaeal TopoIII tested to-date, SsoTopoIII, demonstrated no susceptibility (22, 45-49). The data 
reveal that there is no definite trend for polyamine susceptibility amongst bacterial type IA 
topoisomerases and no demonstrated effect to-date in the domain Archaea. 
3.3.3 Catalytic tyrosine is located at Tyr317We assayed the Y317F mutant of MacTopoIII for 
activity under conditions that were demonstrated to elicit relaxation activity for wild-type. After 
analyzing the CD spectra of MacTopoIII Y317F to ensure that there were no gross structural 
differences compared to the wild-type, we demonstrated that MacTopoIII Y317F was inactive 
under conditions where wild-type had activity. This result confirmed our prediction that Tyr317 
is indeed essential in the mechanism of DNA relaxation by MacTopoIIIα.  
3.3.4 Novel N-terminal Zn2+-binding activity An open question about TopoI and TopoIII 
is the role that the C-terminal (Domain V) plays in the context of Zn2+-binding. While lacking 
the C-terminal (Domain V), the EcoTopoI fragment (Domains I-IV) retained the ability to cleave 
oligonucleotides, but was not able to relax negatively supercoiled DNA (31). With three Zn2+-
binding sites in Domain V (the domain absent in the original crystal structure),  methyl 
methanethiosulfonate (MMTS)-treated EcoTopoI abolished Zn2+-binding and rendered the 
enzyme incapable of catalyzing DNA relaxation (32). Meanwhile, a double mutant 
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(C559A/C561A) or truncation that abolished Zn2+-binding in Thermotoga maritima TopoI 
(TmTopoI) only minimally affected DNA relaxation activity (4). No TopoI crystal structures 
have been identified with Zn2+ positioned even when it was detected in the mother crystal liquor 
(50). The story is further confounded by the fact that there are several bacterial type IA 
topoisomerases that contain no homologous Zn2+-binding motif or Zn2+-binding ability (37, 48, 
51). A reasonable conclusion from the current data available is that type IA topoisomerase Zn2+-
binding motifs, when present in a given bacterial organism, play a structural role that may or 
may not be essential for DNA relaxation activity. 
Given that MacTopoIIIα contains a C-terminal Cys-X2-Cys-X17-Cys-X5-Cys motif and 
that there have not been any studies to date examining the role of Zn2+-binding in archaeal 
TopoIII, we set out to determine whether MacTopoIIIα contains Zn2+ in order to delineate any 
potential differences with the well-characterized bacterial topoisomerases. The results 
demonstrated that MacTopoIII binds to approximately one mole of Zn2+ per mole of protein. 
We then constructed, expressed and purified N-terminal and C-terminal fragments to assess the 
Zn2+-binding ability of each segment. To our surprise, both the C-terminal fragment and the N-
terminal fragment demonstrated the ability to chelate approximately a half mole of Zn2+. To our 
knowledge, this is the first report of an N-terminal fragment of a TopoIII or TopoI having this 
ability to coordinate Zn2+. It is likely that residues in the two fragments coordinate Zn2+ in the 
wild-type. Mutational studies are currently underway to investigate the Zn2+-binding role that 
any of the eight His residues in the N-terminal and eleven Cys/His residues in the C-terminal 
may play.  
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In this report, MacTopoIII, a mesophilic archaeal TopoIII, was biochemically 
characterized in the context of well-established properties of eukaryotic and bacterial type IA 
topoisomerases. We demonstrate that MacTopoIII is a monomer in solution, binds Zn2+ and 
exhibits susceptibility to inhibitors in a manner similar to other type IA topoisomerases. 
MacTopoIII  is a distributive topoisomerase that has a high affinity for ssDNA and is inhibited 
by high salt concentrations. Properties that may be unique to this enzyme are the ability of all 
divalent cations tested to elicit DNA relaxation activity and the ability of this enzyme to bind 
Zn2+ via the N- and C-terminal. Further studies are needed in the domain Archaea and beyond to 
determine if these attributes are domain or organism specific.  
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3.4 MATERIALS AND METHODS 
3.4.1 Cloning and expression of M. acetivorans C2A TopoIII (MacTopoIII) gene The 
gene for the putative topoisomerase, MacTopoIIIα (NP_617416), was amplified from the M. 
acetivorans C2A genomic DNA using PCR primers containing restriction sites for NdeI and 
XhoI in the forward (5'-CATATGCACCTTATCGTAACGGAAAAAAATATA-3') and reverse 
(5'-CTCGAGCTATAGGTCCTCAACTATGCCGCCGTTACA-3') primers, respectively. The 
size of the PCR product was verified through agarose gel electrophoresis and cloned into pGEM-
T, TA-cloning vector (Qiagen). The recombinant plasmid was purified using a Qiagen gel 
extraction kit, and after confirming the integrity of the sequence of the DNA insert, the 
MacTopoIIIα gene was transferred into a modified pET28a expression vector. The pET28a 
vector has its kanamycin resistance gene replaced with an ampicillin resistance gene (52). 
Therefore, the ligated products were transformed into E. coli JM109 cells and transformants 
were selected on lysogeny broth (LB) plates supplemented with ampicillin at a final 
concentration of 100 μg/mL. The plates were incubated overnight at 37C, and a single colony 
was picked and cultured in 10 mL LB containing the same antibiotic and grown at 37C for 8 
hours. The plasmid was extracted from the E. coli culture and examined for the presence of the 
MacTopoIIIα gene through DNA sequencing. The recombinant plasmid was named 
pET28a/MacTopoIIIα. All DNA sequencing in the present report were carried out at the W. M. 
Keck Center for Comparative and Functional Genomics (University of Illinois at Urbana-
Champaign). 
The recombinant plasmid MacTopoIIIα was used in transforming E. coli BL21 codonplus 
RIPL cells (Stratagene) and plated on LB plates supplemented with ampicillin (100 μg/mL) and 
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chloramphenicol (50 μg/mL). A transformant was cultured at 37 °C in 10 ml LB medium 
supplemented with both antibiotics at the same concentrations stated above until the optical 
density (O.D.) at 600 nm reached 0.3. The expression of the MacTopoIIIα gene was then induced 
by adding isopropyl β-D-thiogalactopyranoside (IPTG) at a final concentration of 1 mM.  The 
temperature was decrease to 16 °C and cell culturing was continued for 12-16 hours. The 
recombinant E. coli cells were then collected through centrifugation at 6500 rpm for 10 minutes.  
3.4.2 Site-directed mutagenesis Site-directed mutagenesis was carried out using the 
Quikchange site-directed mutagenesis kit (Stratagene) according to the instructions of the 
manufacturer. The PCR primer (5’-AACGGGTATATATCTTTTCCCAGGACCGACAAT-3’) 
was utilized to convert MacTopoIIIα Tyr317 into Phe317. Mutagenized plasmid was 
transformed into JM109 cells after digestion of the parental plasmid with DpnI. The E. coli 
transformants were selected on LB agar plates supplemented with ampicillin [100 μg/mL] 
overnight at 37°C. Plasmids were extracted from individual colonies after growth in liquid 
cultures supplemented with ampicillin [100 μg/mL]. Plasmids were sequenced as described 
above, and the desired plasmid containing the Y317F mutation was selected for gene expression 
as described above for the wild-type gene.  
3.4.3 Truncation Mutagenesis A truncated gene containing the DNA sequence for the N-
terminal 586 amino acids (N1-586) was generated using an iProof™ High-Fidelity PCR kit with 
a forward primer (5'-CATATGCACCTTATCGTAACGGAAAAAAATATA-3') and reverse 
primer (5’-CTCGAGCTATGCCTGCAGGGACTCTATGATTTTGTC-3’) according to the 
manufacturer’s instructions. A truncated gene containing the DNA sequence for the C-terminal 
166 amino acids (C587-752) was generated in the same manner with the forward primer (5’-
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CATATGGGTCTCAGGGAAGACAAGATCATAGGCAAC-3’) and the reverse primer (5'-
CTCGAGCTATAGGTCCTCAACTATGCCGCCGTTACA-3'). The size of the PCR product 
was verified through agarose gel electrophoresis and cloned into the pGEM-T vector (Qiagen). 
Plasmids were transformed into JM109 cells after ligation. The E. coli transformants were 
selected on LB agar plates supplemented with ampicillin [100 μg/mL] overnight at 37 °C. 
Plasmids were extracted from individual colonies after growth in liquid cultures supplemented 
with ampicillin [100 μg/mL]. Plasmids were sequenced as described above, and the correct 
inserts of N1-586 and C587-752 were transferred to the modified pET28a for expression as 
described above. 
3.4.4 Purification of MacTopoIIIα and mutant proteins For MacTopoIIIα wild-type protein 
and the Y317F mutant, the harvested recombinant E. coli cells were resuspended in Buffer A (50 
mM Sodium phosphate, pH 7.0, 300 mM NaCl), and the cell contents were released by a French 
pressure cell (American Instruments Co). The cell debris was removed through centrifugation at 
9500 rpm for 15 min at 4°C. The supernatant was subsequently filtered using a 0.22 μm filter 
and applied to a His-TrapTM HP column (GE Healthcare) pre-equilibrated with 90% buffer A and 
10% buffer B (50 mM Sodium phosphate, pH 7.0, 300 mM NaCl, 500 mM imidazole), and 
eluted using a step-wise gradient of Buffer B.  
Fractions containing the protein of interest were pooled and dialyzed against buffer A (50 
mM Sodium phosphate, pH 7.0, 300 mM NaCl) overnight at 4°C. Samples were applied to a 
HiTrapTM SP column (GE Healthcare) pre-equilibrated with buffer A, and to elute the bound 
protein, a linear gradient using 100% buffer C (50 mM Sodium phosphate, pH 7.0, 1 M NaCl) 
was utilized. Concentrated fractions of each protein were directly applied to a size exclusion 
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column (Superdex HR 200 HR 10/30 column) pre-equilibrated with buffer GF (50 mM sodium 
phosphate, 150 mM sodium chloride, pH 7.0), and the chromatography was developed with the 
same buffer. Highly purified proteins were dialyzed against a storage buffer (50 mM Tris-HCl 
pH=7.5, 200 mM NaCl, 2 mM DTT and 50% Glycerol) and stored at -80 °C until used.  
In the case of MacTopoIIIα C587-752 truncated mutant, the harvested recombinant E. 
coli cells were re-suspended in Buffer A, and the cell contents were released by a French 
pressure cell (American Instruments Co). The cell debris was removed through centrifugation at 
9500 rpm for 15 min at 4°C. The supernatant was subsequently filtered using a 0.22 μm filter 
and applied to a His-TrapTM HP column (GE Healthcare) pre-equilibrated with 70% buffer A and 
30% buffer B (50 mM Sodium phosphate, pH 7.0, 300 mM NaCl, 500 mM imidazole), and 
eluted using a linear gradient of buffer B.  
The protein fractions from the HisTrapTM HP column were pooled and dialyzed against 
buffer A (50 mM Sodium phosphate, pH 7.0, 300 mM NaCl) overnight at 4°C. Samples were 
applied to a HiTrapTM SP column (GE Healthcare) pre-equilibrated with buffer A and eluted with 
a linear gradient of 100% buffer C. Highly purified fractions were dialyzed against the storage 
buffer and stored at -80 °C until used.  
In the case of MacTopoIIIα N1-586 truncated mutant, the harvested recombinant E. coli 
cells were re-suspended in Buffer A, and the cell contents were released by a French pressure 
cell (American Instruments Co). The cell debris was removed through centrifugation at 9500 rpm 
for 15 min at 4°C. The supernatant was subsequently filtered using a 0.22 μm filter and applied 
to a His-TrapTM HP column (GE Healthcare) pre-equilibrated with 75% buffer A and 25% buffer 
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B (50 mM Sodium phosphate, pH 7.0, 300 mM NaCl, 500 mM imidazole), and eluted using a 
linear gradient of buffer B.  
The fractions of the MacTopoIIIα N1-586 truncated mutant from the His-Trap column were 
pooled and dialyzed against buffer A overnight at 4°C. Samples were then applied to a HiTrapTM 
heparin HP column (GE Healthcare) pre-equilibrated with 90% buffer A and 10% buffer C. The 
MacTopoIIIα N1-586 truncated mutant was eluted with a step gradient using 75% buffer A and 
25% buffer C. Highly purified fractions were dialyzed against the storage buffer and stored at -
80°C until used. Aliquots of eluted fractions from all chromatographies were examined through 
SDS-PAGE.  
3.4.5 Preparation of DNA substrates for topoisomerase assays E. coli JM109 cells were heat 
shocked to uptake the pUC18 plasmid, and transformants were cultured in ampicillin 
supplemented (100 μg/mL) LB medium to amplify the plasmid. The pUC18 plasmid was 
purified from cell pellets with a commercial kit (Qiagen), and electrophoresed on a 1.5% agarose 
gel containing 1X TBE (89 mM Tris, 89 mM Boric acid, 2 mM EDTA). Subsequently, the gel 
was stained with ethidium bromide and imaged with a UV illuminator. The plasmid DNA 
migrating the fastest was excised and purified utilizing a gel extraction kit (Qiagen) according to 
the manufacturer’s specifications. The purified negatively supercoiled DNA was verified using a 
2-Dimensional gel with EcoRI linearized pUC18 and ethidium bromide treated pUC18 as 
standards. The M13 ssDNA was from a commercial source (New England Biolabs).  
3.4.7 DNA relaxation assay Unless otherwise stated, the method is the same as previously 
described (22). Briefly, reaction volumes contained 300 ng negatively supercoiled pUC18 DNA 
in the presence of 5 pmol of MacTopoIIIα wild-type (or its mutants) in 50 mM Tris-HCl, pH 8.8, 
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1 mM DTT, 0.1 mM EDTA, 90 mM NaCl, 30 μg of BSA/ml, and 12% (vol/vol) ethylene glycol 
with the indicated divalent cation. After 30 min incubation at 37°C (unless indicated otherwise), 
reactions were terminated by adding 4 μL of DNA loading dye (25% Glycerol, 0.2% 
Bromophenol Blue, 50 mM EDTA) and the products were resolved with 1.5% agarose gel in 
0.5X TPE (44.6 mM Tris, 0.13% Phosphoric Acid, 1 mM EDTA) buffer. DNA bands were 
visualized through ethidium bromide staining and imaging with a UV illuminator. 
The levels of negatively scDNA that remained or were relaxed (partially and completely) were 
determined by densitometry using AlphaEaseFCTM software. For each divalent ion, the values 
for a given lane were normalized to that obtained without any divalent cation present (Fig 3-3, 
Lane 1). Activity for each ion was assessed according to the maximal percentage of substrate that 
was relaxed (partially and completely) relative to the percentage of negatively scDNA when no 
ion was present. High activity (Y) was utilized to denote greater than or equal to 95% activity 
while medium activity (M) denotes activity falling below 95%. 
3.4.8 Determination of zinc content by ICP-MS The zinc content in purified wild-type 
MacTopoIIIα and variants was determined at the University of Illinois Microanalysis Laboratory 
using the SCIEX ELAN DRCe ICP-MS (PerkinElmer Life Sciences). Briefly, two aliquots of 
purified protein, 1 mL each, at a concentration of approximately 0.5 mg/mL, were digested in 
nitric acid. The resulting solutions were diluted to 25 mL and analyzed.  Two isotopes of zinc, 
64Zn and 66Zn, were analyzed with gallium as the internal standard.  
3.4.9 Estimation of subunit organization by gel filtration Since MacTopoIIIα was expressed 
with an N-terminal 6-His tag, the protein eluted from the HiTrapTM SP column was incubated 
with the protease thrombin (1 unit/mg/mL) during dialysis in buffer GF (50 mM sodium 
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phosphate, 150 mM sodium chloride, pH 7.0) in order to remove the tag. The dialyzate was 
loaded onto a Superdex 200 HR 10/300 gel filtration column pre-equilibrated with buffer GF.  
The chromatography was developed with the same buffer at a flow rate of (0.5 ml/min) and 
fractions of 0.5 ml were collected and analyzed by SDS-PAGE. To generate a standard curve, the 
column was calibrated by analyzing a set of gel filtration standards (thyroglobulin, 669 kDa; 
bovine γ-globulin, 158 kDa; chicken ovalbumin, 44 kDa; equine myoglobin, 17 kDa; and 
vitamin B12, 1.35 kDa) under the same conditions as the MacTopoIIIα. 
3.4.10 Materials Methanosarcina acetivorans C2A genomic DNA was used for 
amplification of the topoisomerase. E. coli JM109 competent cells were used as host cells for 
amplification of the plasmids pGEM-T and pUC18. The negatively supercoiled pGEM-T and 
pUC18 DNA were isolated with the Qiagen Mini Plasmid kit according to the specification of 
the manufacturer and used in the topoisomerase assay as substrate DNA. Reagents for SDS–
PAGE, 1 protein molecular weight standards, 1 DNA molecular weight standards, etoposide, 
camptothecin, EDTA, nalidixic acid, novobiocin, spermidine, ethidium bromide and DTT were 
purchased from Sigma. BSA was obtained from NEB. HiTrap Q HP, HiTrap S HP, and 
Superdex 200 HR 10/30 columns were from GE Healthcare. Single-stranded M13 ssDNA was 
from New England BioLabs. Gel Filtration Standards were obtained from Bio-Rad. 
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Tables and Figures 
 
Figure 3-1. 
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Figure 3-1. (cont.) Purification and domain analysis of MacTopoIIIα. (A) SDS-PAGE of the 
purified recombinant proteins. Samples were loaded as follows: 1, Protein molecular mass 
markers (Fermentas); 2, MacTopoIIIα wild-type; 3, MacTopoIIIα Y317F; 4, MacTopoIIIα N1-
586; 5, MacTopoIIIα C587-752. (B) Schematic representation of MacTopoIIIα wild-type, mutant 
(MacTopoIIIαY317F) and truncation (MacTopoIIIα C587-752 and MacTopoIIIα N1-586) 
proteins, showing the five canonical domains with Domains I-IV distinguished from the C-
terminal Domain V. The red asterisk indicates location of the Y317F mutation. The domains are 
not drawn to scale. (C) Alignment of the active site of Archaeal TopoIII SubFamily II 
Topoisomerases with Sulfolobus solfataricus P2 TopoIII. MacTopoIIIα, Methanosarcina 
acetivorans C2A TopoIIIa [NP_617416]; MmaTopoI, Methanosarcina mazei TopoI 
[AAM32772]; MbaTopoI, Methanosarcina barkeri str. Fusaro TopoI [YP_305910]; MbuTopoI, 
Methanococcoides burtonii DSM 6242 TopoI [ABE51114]; MthTopoIII, Methanosaeta 
thermophila PT TopoIII [EAR48366]; HalTopoI, Halobacterium sp. NRC-1 TopoI [NP_444190]; 
AfuTopoIII, Archaeoglobus fulgidus DSM 4304 TopoIII [AAB89443]; MhuTopoIII, 
Methanospirillum hungatei JF-1 TopoIII [ABD40761]; RxyTopoI, Rubrobacter xylanophilus 
DSM 9941 TopoI [ABG04911]; PtoTopoI, Picrophilus torridus DSM 9790 TopoI [YP_023525]; 
TvoTopoI, Thermoplasma volcanium GSS1 TopoI [NP_110538]; SsoTopoIII, Sulfolobus 
solfataricus P2 TopoIII [NP_342400]. The GenBank accession numbers are in brackets. The 
conserved and similar amino acids are shaded black and gray, respectively. The putative catalytic 
residue is shaded red. (D) Circular Dichroism (CD) spectra of purified MacTopoIIIα wild-type 
and the Y317F mutant. Triplicate data sets were collected from samples at a concentration of 0.5 
µg/µl in a buffer containing 50 mM Tris-HCl pH 7.5, 200 mM NaCl, 2 mM DTT. All data sets 
were normalized against baseline readings from buffer containing no protein. EV, elution volume.
95 
 
 
Figure 3-2.  
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Figure 3-2. (cont.) Characterization of activity based on protein concentration, salt and time. (A) 
Concentration dependent relaxation of negatively supercoiled pUC18 DNA by MacTopoIIIα 
wild-type. Standard reaction mixtures with 90 mM NaCl were incubated with 0.3 μg of pUC18 
for 30 min at 37°C with 10 mM MgCl2. From right to left, lanes contain increasing amounts of 
enzyme as labeled. fI, form I; fII, form II. (B) Temperature dependent relaxation of negatively 
supercoiled pUC18 DNA by MacTopoIIIα wild-type. Standard reaction mixtures containing 5 
pmol of enzyme were incubated with 0.3 μg of pUC18 for 30 min with 10 mM MgCl2. Lane C 
contains no divalent cation and was incubated at 37°C. The remaining lanes were incubated for 5 
min at the indicated temperature prior to the addition of enzyme. (C) Salt dependent relaxation of 
negatively supercoiled pUC18 DNA by MacTopoIIIα wild-type. Standard reaction mixtures 
containing 5 pmol of enzyme were incubated with 0.3 μg of pUC18 for 30 min at 37°C with 10 
mM MgCl2. Lane C contains 90 mM NaCl.  From right to left, remaining lanes contain 
increasing amounts of NaCl as labeled. (D) Time dependent relaxation of negatively supercoiled 
pUC18 DNA by MacTopoIIIα wild-type. Standard reaction mixtures of enzyme were incubated 
with pUC18 at 37°C with 10 mM MgCl2. Lane C contains no divalent cation.  Time points of the 
reaction were taken as indicated.   
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Figure 3-3. 
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Figure 3-3. (cont.) Cation-dependent DNA relaxation activity profiles of MacTopoIIIα wild-
type. Relaxation of negatively supercoiled pUC18 DNA by MacTopoIIIα wild-type. Standard 
reaction mixtures with 90 mM NaCl containing 5 pmol of enzyme were incubated with 0.3 μg of 
pUC18 for 30 min at 37°C with the corresponding divalent cation. Lane 1-8 contain increasing 
amounts of the indicated divalent cation: Lane 1, 0 μM; Lane 2, 50 μM; Lane 3, 100 μM; Lane 4, 
500 μM; Lane 5, 1 mM; Lane 6, 2.5 mM; Lane 7, 5 mM; Lane 8, 10 mM.  fI, form I; fII, form II. 
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Figure 3-4.  
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Figure 3-4. (cont.) Mutant and truncation DNA relaxation assays. (A) Standard reaction 
mixtures with 90 mM NaCl were incubated in the presence of 5 pmol of MacTopoIIIα Y317F 
with 0.3 μg of pUC18 for 30 min at 37˚C unless stated otherwise. Lane PC contains 10 mM 
MgCl2 and 5 pmol of wild-type enzyme only. Lane NC contains MacTopoIIIα Y317F only. Lane 
1, 500 μM CoCl2; Lane 2, 100 μM CuCl2; Lane 3, 2 mM FeCl2; Lane 4, 10 mM MgCl2; Lane 5, 
50 μM MnCl2; Lane 6, 500 μM NiCl2; Lane 7, 100 μM ZnCl2. fI, form I; fII, form II. (B) 
Relaxation of negatively supercoiled pUC18 DNA by MacTopoIIIα N1-586. Standard reaction 
mixtures with 90 mM NaCl containing 5 pmol of enzyme were incubated with 0.3 μg of pUC18 
for 30 min at 37°C. Lane 1 contains 10 mM MgCl2 and 5 pmol of MacTopoIIIα wild-type only. 
Lanes 2-9 contain increasing amounts of MgCl2: Lane 2, 0 μM; Lane 3, 50 μM; Lane 4, 100 μM; 
Lane 5, 500 μM; Lane 6, 1 mM; Lane 7, 2.5 mM; Lane 8, 5 mM; Lane 9, 10 mM.  fI, form I; fII, 
form II. (C) Relaxation of negatively supercoiled pUC18 DNA by MacTopoIIIα C587-752. 
Standard reaction mixtures with 90 mM NaCl containing 5 pmol of enzyme were incubated with 
0.3 μg of pUC18 for 30 min at 37°C. Lane 1 contains 10 mM MgCl2 and 5 pmol of MacTopoIIIα 
wild-type only. Lanes 2-9 contain increasing amounts of MgCl2: Lane 2, 0 μM; Lane 3, 50 μM; 
Lane 4, 100 μM; Lane 5, 500 μM; Lane 6, 1 mM; Lane 7, 2.5 mM; Lane 8, 5 mM; Lane 9, 10 
mM.  Lanes 10-14 contain varying ratios of MacTopoIIIα C587-752 to MacTopoIIIα N1-586 
ranging from 50:1, to 5:1 to 1:1 to 1:5 to 1:50, respectively. 
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Figure 3-5. In depth truncation DNA relaxation assays. Relaxation of negatively supercoiled 
pUC18 DNA by MacTopoIIIα N1-586 and C587-752 at higher concentrations. Standard reaction 
mixtures with 90 mM NaCl were incubated with 0.3 μg of pUC18 for 30 min at 37°C with 10 
mM MgCl2. The only exception is Lane 1 which contains no divalent cation. Lanes 1 and 2 
contain 5 pmol of MacTopoIIIα wild-type only. Lane 3 contains 50 pmol of N1-586 only. Lane 4 
contains 50 pmol of C587-752 only. Lanes 5-11 contain varying ratios of MacTopoIIIα C587-
752 to MacTopoIIIα N1-586 in pmol ranging from 50:1, to 50:5 to 50:10 to 50:50 to 10:50 to 
5:50 to 1:50, respectively. Lanes 12-18 contain varying ratios of MacTopoIIIα C587-752 to 
MacTopoIIIα N1-586 in pmol ranging from 10:0.5, to 10:1 to 10:5 to 10:10 to 5:10 to 1:10 to 
0.5:10, respectively. 
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Figure 3-6. ICP-MS analysis of MacTopoIIIα wild-type and its truncation. Purified 
recombinant MacTopoIIIα wild-type and truncation (MacTopoIIIαN1-586 and 
MacTopoIIIαC587-752) proteins were submitted for zinc content analysis.  The error bars 
represent standard deviations for two independent measurements.  
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Table 3-1. Summary of inhibition assays conducted with MacTopoIIIα wild-type. Three 
independent trials were conducted to determine the ability of different agents to inhibit DNA 
relaxation activity at increasing concentrations. 
Chemical Inhibition 
Ethidium Bromide Yes 
M13 ssDNA  Yes 
Spermidine No 
Camptothecan No 
Etoposide No 
Nalidixic acid No 
Novobiocin No 
High [KCl] Yes 
High [NaCl] Yes 
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Table 3-2. Summary divalent cation studies. A literature review was conducted on previously 
published studies where divalent cations other than Mg2+ were utilized in type IA topoisomerase 
DNA relaxation assays. The findings are summarized herein. Methanosarcina acetivorans C2A, 
Mac; Drosophila melanogaster, Dme; Escherichia coli, Eco; Fervidobacterium islandicum, Fis; 
Homo sapiens, Hsa; Methylophaga sp. strain 3, Met; Nicotiana tabacum, Nta; Rhodobacter 
capsulatus, Rca; Staphylococcus aureus, Sau; Saccharomyces cerevisiae mitochondria, Scemt; 
Sulfolobus solfataricus, Sso; D, data not shown; S, M2+SO4 used in place of M2+Cl2; Y, high 
activity; M, moderate activity; L, low activity; N, no activity.  
 
Enzyme Mg2+ Ca2+ Sr2+ Ba2+ Mn2+ Fe2+ Fe3+ Fe4+ Co2+ Ni2+ Cu2+ Zn2+ Cd2+ Ref 
MacTopoIIIα Y Y M M Y Y - - Y M Y M M 
This 
paper 
DmeTopoIIIβ Y Y - - Y - - - N - NS NS - (53) 
EcoTopoI Y YD - - ND - - - LD - - LD - (32) 
FisTopoI Y ND - - ND - - - - - ND - ND (45) 
HsaTopoIIIα Y - - - N - - - N N N NS - (40) 
MetTopI Y M - - Y Y Y Y - - Y N - (49) 
NtaTopoI Y YD - - MD - - - - ND ND - (54) 
RcaTopoI Y Y - - Y - - - - - N N - (55) 
SauTopoI Y Y - - Y - - - - - N N - (46) 
SsoTopoIII Y M - - N - - - N N N N - (22) 
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Chapter 4 - Phylogenetic Analysis Of Type IA DNA Topoisomerases 
4.1 ABSTRACT 
Prior phylogenetic analysis of topoisomerases has focused on all types of topoisomerases making 
in-depth analysis limited. Here, we present the systematic analysis of over 2000 protein 
sequences across all domains of life (1806 bacterial, 149 archaeal and 130 eukaryal enzymes) of 
type IA topoisomerases. A close examination of only five active site residues, defined as the 
residues spanning from the -1 position relative to the catalytic tyrosine up to the +3 position, 
reveals clues about the evolutionary ties that bind and potential origins of the subfamilies. 
Archaeal topoisomerases contain two predominant active site sequences SYPRT and TYHRT for 
Reverse Gyrases. Less than 3% of the examined bacterial topoisomerases contained a 
comparable TYHRT sequence. Of that group, two-thirds code for a Reverse Gyrase and one-
third code for a TopoIII. Given the prevalence within Archaea and the scarcity within Bacteria, 
the data suggests that Archaea are the likely source of the Reverse Gyrase topoisomerase. The 
predominant bacterial and eukaryotic TopoI sequence is TYMRT and SYPRT, respectively. 
Using only the active site +2 residue, a new system of classification was discovered to 
characterize type IA enzymes. Based on this one amino acid, the classification of an 
uncharacterized enzyme could be ascribed as Reverse Gyrase, TopoI or TopoIII. Insights into the 
significance of these findings for drug development along with the distribution of the DxD and 
GxxQ motifs are discussed herein with an emphasis on Archaea.  
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4.2 INTRODUCTION 
Technology has dramatically advanced science with large-scale analysis that was once 
unimaginable. Calculations that used to require office-sized contraptions operating non-stop for 
days can now be computed within a few seconds using a palm-sized smart phone. From 
molecular modeling to data mining, computational analysis is now a driving force behind basic 
science research with a Congressional mandate that is 24 years old (1). Theories that were once 
deemed unsupportable have been fortified through the contributions of phylogenetics (2). 
Molecular examination of highly conserved genes has yielded insights to the relationships 
between organisms that have no visibly unifying attributes to the naked eye (3). 
But this area of research is far from a scholastic endeavor without practical ramifications. 
In the hopes of improving public health outcomes, molecular epidemiologists have employed the 
same fundamental techniques to determine the predominant HIV-1 subtypes and drive the 
development of subtype-specific vaccines (4, 5). In examining the phylogenetic distribution of a 
selectable marker, it is now possible to determine whether an infectious agent is community-
acquired or of nosocomial origin (6). Using this toolkit, it is now possible to predict the 
therapeutic value of uninvestigated plants based on related characterized sources (7). A novel 
therapeutic agent from a rare plant source presents tremendous ecological burden on Science. 
However, when an abundant homolog with an identical compound can be identified, 
phylogenetic analysis facilitates a fresh solution from a simple tree.  
And while previous phylogenetic work has greatly advanced our understanding of all 
topoisomerases, each class and subtype differ in structure, mechanism and function (8-10). Type 
IA topoisomerases have been identified in all sequenced genomes and have been demonstrated to 
be essential for normal development. In an effort to better classify these molecular machines, we 
have conducted a phylogenomic analysis of sequenced NCBI genomes as of 12/28/2010 in 
Archaea, Bacteria, Eukarya and Viruses. There is a special emphasis on archaeal topoisomerases, 
but properties are revealed about the Last Universal Common Ancestor (LUCA) from each 
domain. We use type IA topoisomerases to demonstrate that a novel method for fast 
classification based on a single amino acid is possible. The driving force behind this works is 
that better classification of topoisomerases leads to a greater understanding of archetypal type IA 
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topoisomerases. General properties that apply to most topoisomerases within a subclass will 
become more apparent. Phylogenetic analysis can guide the development of novel therapeutic 
agents and provide a basis for predicting topoisomerase reactivity based on established 
classifications. 
4.3 METHODS 
We conducted a search within all sequenced genomes (NCBI) and obtained over 6000 hits for 
“topoisomerase”. The results yielded proteins coding for different types of topoisomerases, 
TOPRIM domain containing proteins and various proteins with modest homology (Primases, 
Polymerases, Chromosome Segregation proteins, etc). Type II topoisomerases (Gyrases, TopoIV 
and TopoVI) were eliminated from the list to narrow it down to under 3000. Using an NCBI 
BLASTp cut-off of 100 for the Max Score and a threshold e-value of 1e-10 and a minimum of 
100 Amino Acids of homologous, low homology sequences were excised and a list of 2085 of 
type I topoisomerase protein sequences obtained.  
4.4 RESULTS 
4.4.1 Archetypal Motifs Consensus sequences and invariant residues are packets of 
information that have stood the test of evolution. They reveal attributes of the domains and 
LUCA that scientists and statisticians alike try to predict (2, 11). In the topoisomerases, they 
represent the residues that have been the focus of many classic investigations (see Table 4-1). 
Escherichia coli has long been a model system with wide biological application (12). As the first 
topoisomerase discovered, omega protein (EcoTopoI) has been the source of the most intensive 
investigation within this field (13). With the first notable crystal structure produced, EcoTopoI 
provided a model for further genetic manipulation with residues interacting with the active sites 
receiving the most attention. Interestingly, the vast majority of these residues are highly 
conserved across all domains. The best examples are those within the active site and the DxD 
motif (14). In Figure 4-1, we provide a visual map of previously characterized mutants on the 
crystal structure of EcoTopoI (1ECL) in blue with active site residue highlighted in orange. The 
only residue not represented in this illustration is Cys662 since this crystal structure only 
contains the N-terminal 596 amino acids. 
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4.4.2 Examination of Active Site Signature Sequences Analysis of the signature sequences 
contained in all type IA topoisomerases began with the catalytic site of the domain Archaea. 
Interestingly, 145 out of these 147 sequences contain a catalytic site that is highly conserved. For 
example, all reverse gyrases, except three, contain a signature protein sequence of TYHRT in 
the active site with a consensus of 87%, 98%, 94%, 98%, 96%, respectively. The exceptions 
are Methanothermus fervidus DSM 2088 (YP_004003667.1) and Thermococcus sibiricus MM 
739 (YP_002993945.1) which contain a signature sequence of TYIRT. Methanopyrus kandleri 
AV19 reverse gyrase (NP_613336.1) is the only reverse gyrase that does not contain a catalytic 
site that is homologous. However, the functional protein is expressed from split genes and the 
other subunit does contain the canonical TYHRT (15). 
Sequence analysis of the archaeal TopoIIIs reveals a signature sequence of SYPRT at the 
catalytic core with a consensus of 81%, 98%, 97%,97% and 97%, respectively for each amino 
acid. For all sequences that do not contain a serine in the initial position, threonine is substituted. 
There are two exceptions to this rule. The first is from Candidatus Korarchaeum cryptofilum 
OPF8 [Accession No: YP_001736678.1] which contains SYIGT. As previously suggested, this 
organism appears to have diverged early from all other archaea (16). It is important to note this is 
the only gene in the sub-domain Korarcheota that is represented in this analysis. As a result, this 
may be a signature sequence of topoisomerases in this sub-domain, but cannot be confirmed until 
more genomes are sequenced. 
Of the archaeal TopoIIIs, only Nanoarchaeum equitans Kin4-M contains a split gene [Accession 
No: NP_963610.1 and NP_963339.1] and, therefore, all archaeal Type IA topoisomerases 
contain the signature sequence in the active polypeptide. Given that this organism contains the 
smallest sequenced archaeal genome and that several other peptides within this organism are 
constructed from split genes, it appears that this is an evolutionary strategy beholden to this 
organism. 
As seen in Figure 4-2, there are two predominant bacterial active site sequences – TYMRT & 
TYPR(S/T). The former appears to be a unique signature sequence for bacterial TopoI while the 
latter codes for bacterial TopoIII. Interestingly, the amino acid present between the active site 
tyrosine and the +3 arginine appears sufficient to classify the enzyme as a reverse gyrase 
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(Histidine), TopoI (Methionine) or TopoIII (Proline). No enzymes with Isoleucine or Glutamine 
have been characterized to date.  As a result, whether the mechanism or activity profile of these 
topoisomerases is comparable remains unclear.  
A total of 46 sequences were identified which contain a signature sequence homologous to the 
archaeal reverse gyrases (TYHRT). Worthy of mention is the fact that a small subset of those 
bacterial proteins (19 topoisomerases total) containing this sequence are not reverse gyrases as 
determined by their relative size and BLAST results (data not shown). Moreover, 10 out of these 
19 sequences are known pathogens (see Table 4-2) (17-19). Of the 36 bacterial sequences which 
contained TYIRT, 9 sequences were for proteins encoded in pathogenic organisms (see Table 4-
3). While the biological significance of this discovery is a matter for scientific investigation in a 
separate study, the fact that enzymes from these infectious agents contain this unique signature 
sequence may provide a structural and/or mechanistic marker for drug targeting that has not 
previously been explored. 
While reverse gyrases have been suggested to be a signature protein that reflects a 
hyperthermophilic adaptation to life, their discovery within thermophiles has confused matters 
(20, 21). 
The distribution of sequences presented herein suggests that topoisomerases that contain the 
TYHRT active site originate within the domain Archaea (see Table 4-4). The data shows that 
34.7% of the archaeal sequences examined contain this active site while less than 3% within the 
domain Bacteria contain the sequence. This makes it possible that a HGT from an archaeal 
source permitted Bacteria to obtain this sequence (22). Another possibility is that there is 
selection bias inherent in the manner in which genomes are sequenced. Closer examination of the 
45 proteins with a TYHRT sequence reveals that there are two subclasses within the domain 
Bacteria that do not exist within the domain Archaea.  
One subtype (seventeen sequences that are TYHRT and one that has a TYHRS) contains an 
average amino acid length of 676 amino acids. These TYHRT sequences have greater sequence 
homology with bacterial topoisomerase I while the lone TYHRS peptide [Acc ID: 
YP_003600471.1] from Neisseria gonorrhoeae shares greater sequence homology with bacterial 
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TopoIII [data not shown]. Interestingly, out of these 18 sequences, several known pathogens are 
observed. There is another subtype (28 sequences total) that have an average of 1121 amino 
acids and share greater sequence homology with archaeal reverse gyrase.  
Out of 130 eukaryotic topoisomerases examined, 110 enzymes contain an active site sequence of 
SYPRT while 7 contain TYPRT. These results provide a conclusive motif in eukaryotes for type 
IA enzymes. Sorghum bicolor has three type IA topoisomerases and one of these proteins 
[UniProt ID: C5Z4V5] is the only eukaryotic protein examined with an active signature sequence 
of TYIRT. Sorghum bicolor is susceptible to at least one parasitic agent that has been postulated 
to be involved in HGT (23). Given the distinct eukaryotic GxxQ motif and the unique active site 
motif of this particular topoisomerase compared to the other two orthologs, we suggest the 
presence of this topoisomerase is the result of a HGT.  
For viruses, only 2 genomes within the family Mimiviridae appeared to contain type IA 
topoisomerases: Acanthamoeba polyphaga mimivirus and Cafeteria roenbergensis virus BV-
PW1. Each genome contained a single type IA enzyme [Acc ID: YP_003986717.1  and 
YP_003969716.1] that contains an active site signature sequence of TYMRT. Given the sparse 
distribution and that these viruses have been known to contain genomic elements from all 
domains of a life, we propose that these protein sequences were obtained from a HGT from a 
bacteria that co-infected the eukaryotic host (24, 25). As such, the data suggests that the LUCA 
of viruses does not contain type IA topoisomerases. The results combined with the literature 
suggest a bacterial type IA inhibitor could also target a mimivirus that may be involved in human 
pathology (26). 
4.4.3 Topoisomerase Protein Sequence Length For archaeal Type IA, TopoIII sizes range from 
587-1364 amino acids. The one caveat is that Nanoarchaeum equitans Kin4-M contains a split 
gene of 408 and 172 amino acids. With a total of 580 amino acids, it extends the archaeal range 
from 580-1364 amino acids. For archaeal Reverse Gyrases, the gene size varied from 1030-1711. 
The outliers are the split genes from Nanoarchaeum equitans Kin4-M and Methanopyrus 
kandleri AV19 whose cumulative protein sequence length fall within the indicated range.  
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The overall range of sizes for bacterial type IA topoisomerases is 315-1560. More specifically, 
the bacterial TopoIIIs with an active site of (S/T)YPR(S/T) ranged from 315-1560 amino acids. 
Bacterial TopoIs with an active site of TYMRT span from 593-1242. For bacterial Reverse 
Gyrases, the size range was from 1031-1177. For bacterial non-Reverse Gyrases with the 
TYHRT sequence, the length of 638-729 was observed. For proteins with the TYHRT active 
site sequence, bacterial sequence size provides a clear metric for delineation when the active site 
classification is ambiguous (see Table 4-5). 
For eukaryotic topoisomerases, TopoI enzymes ranged from 590-1243 while TopoIII enzymes 
ranged from 382-2117 amino acids. At 2117 amino acids, Ostreococcus tauri TopoIII 
(OtaTopoIII) is the largest observed topoisomerase III by a wide margin. The next largest 
eukaryotic topoisomerase III is Thalassiosira pseudonana CCMP1335 TopoIII with 1417 amino 
acids. OtaTopoIII has the distinction of having its GxxQ motif at the C-terminal position 1797 
although its active site is even more C-terminal to it at position 1919. Much of the N-terminal 
sequence appears to have alternative functionality with about 1500 amino acids not having a 
known function. To confound matters more, this organism also contains the smallest eukaryotic 
topoisomerase (382 amino acids) with a potentially unique active site of MYNRT. As the 
smallest-identified free-living eukaryote, Ostreococcus tauri has a compacted genome (27). 
Given the density of this genome (density refers to kb per gene), it is possible that this is a 
multifunctional split gene enzyme or that there are various isoforms expressed. 
4.4.4 Gene Duplication Or Distinct Functions? There are 7 sequenced archaeal genomes that 
contain two TopoIIIs. This list includes Methanocella paludicola SANAE, Methanococcoides 
burtonii DSM 6242, Methanohalobium evestigatum Z-7303, Methanohalophilus mahii DSM 
5219, Methanosarcina acetivorans C2A, Methanosarcina barkeri str. Fusaro and 
Methanosarcina mazei Go1 (see Table 4-6). Given the distinct functions of TopoIIIs in other 
domains and the unique phylogenetic clades, the more likely conclusion is that they are essential 
and perform unique cellular roles (see Figure 4-3) (28-31). Thus far, this phenomenon has only 
been documented in the kingdom Euryarchaeota and, more specifically, the phylum 
Methanomicrobia. For that reason, we propose that the name of these enzymes be distinguished 
as alpha and beta. 
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The only sequenced archaeal genomes that contain two Reverse Gyrases are Aeropyrum pernix 
K1, Desulfurococcus kamchatkensis 1221n, Hyperthermus butylicus DSM 5456, Ignicoccus 
hospitalis KIN4/I, Ignisphaera aggregans DSM 17230, Metallosphaera sedula DSM 5348, 
Staphylothermus hellenicus DSM 12710, Staphylothermus marinus F1, Sulfolobus islandicus 
L.D.8.5, Sulfolobus solfataricus P2, Sulfolobus tokodaii str. 7 and Thermosphaera aggregans 
DSM 11486. All of these sequences reside in the phylum Crenarchaeota and domain 
Thermoprotei (see Table 4-7). The amino acid sequence analysis for each organism reveals that 
these proteins appear to be sufficiently different to have evolved independently than to have been 
the result of gene duplication (see Figure 4-4). 
4.4.5 DxD MOTIF 
Out of those 149 peptide sequences analyzed, only one archaeal peptide sequence does not 
contain the DxD motif (see Figure 4-5). This is Nanoarchaeum equitans Kin4-M TopoIII 
[Access No. NP_963718.1] and it is a split gene of a bipartite heterodimer. The other gene from 
this protein does contain the DxD motif. As such, there were 147 archaeal proteins analyzed and 
none lacked this conserved motif.  
From the 130 eukaryotic sequences analyzed, not a single one lacked the DxD motif. The most 
common eukaryotic iteration of this motif is DCDREGE. Lysine (K) is the most common 
substitution for Arginine (R). 
Only 90 peptides out of the 1806 bacterial sequences from 84 different genomes lacked the DxD 
motif. The most common bacterial iteration of the DxD motif is DPDREGE. As illustrated from 
the data, it is common for other acidic residues variations to be present as well such as ExExE 
and DxDxE. These residues have been postulated to interact with the Mg2+ ion necessary for 
relegation (32). Interestingly, the sequences lacking the canonical DxD motif contain a 
homologous motif DAGREGE in almost the exact same location with the most common variant 
containing Serine (S) in place of Alanine (A). The functional and structural significance of this 
unique arrangement is a scientific query worthy of further investigation. 
4.4.6 GxxQ MOTIF 
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Examination of the archaeal alignment revealed several regions that were highly conserved. 
Based on previous reports, the active site and the DxDxE motif within the canonical TOPRIM 
domain were expected to be highly conserved motifs (9, 14). Interestingly, the data demonstrates 
that the region which may interact with the TOPRIM motif based on proximity is also highly 
conserved. In particular, examination of the crystal structure of EcoTopoI (PDB: 3pWT) reveals 
that DxDxE motif is poised for interaction with the DNA substrate. Interestingly, another 
conserved motify GRVQ motif can be seen less than 5 angstroms away. Given its proximity and 
the efforts to characterize the glycine through site directed mutagenesis, this motif requires 
further scientific exploration to explain the functional significance (33, 34). 
Given the proximity to the DNA substrate and highly conserved nature of the GxxQ motif, it is 
possible that it is functionally required for in vivo DNA-protein interaction as well. Within 
Bacteria and Archaea, the predominant sequence of this motif is GRVQ. In Eukarya, there is a 
more variation with GPCQ predominating over GRVQ (see Figure 4-6).  
4.5 DISCUSSION 
The DxD motif sequence is highly conserved in type IA topoisomerases across all domains of 
life. Our analysis provides further evidence that the DxD motif is essential to the in vivo function 
of this protein and present in the LUCA. 
These results suggest that while the active sites for Archaea and Eukarya are more akin, the 
highly conserved GRVQ domain is more akin between Archaea and Bacteria. These subtle 
differences may play a huge role in identifying compounds which selectively act upon 
topoisomerases from one domain versus another. Moreover, the universal presence of the GxxQ 
suggests that it was present in the LUCA. 
The observation that known pathogens harbor topoisomerases with an active site akin to an 
archaeal reverse gyrase and overall sequence homology akin to bacterial type I non-reverse 
gyrase topoisomerases poses an evolutionary riddle. One possible explanation is that there has 
been a unique mutation incorporated into these pathogens that provides utility not needed for 
other organisms. Given the mutually exclusive distribution of the two bacterial subtypes of 
TYHR(T/S) enzymes and the size difference, it appears that they are unique or that there has 
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been an effective mutation of the active site that is not present in most topoisomerases that 
provides functionality within the organism.  
The GRVQ mutation in the reverse gyrase type of enzymes is located in the C terminal akin to 
archaeal reverse gyrases. The THYR(T/S) topoisomerases contain the GRVQ sequence in the N 
terminal akin to bacterial topoisomerases. The relative unique profile of these highly conserved 
domains lends greater credence to the notion that they each have separate origins with the non-
reverse gyrase enzymes having a mutation in the active site from TMYRT to THYRT or from 
TPYRS to THYRS. The latter involves two mutations in the exact same codon position from G-
>U and C->A 
4.6 CONCLUSION 
Using bioinformatics, a novel method for classification of topoisomerases is presented that 
circumvents homology sequencing. Analysis of a single amino acid has been employed. Highly 
conserved motifs and the potential variants have been identified. Questions have also been raised 
about uncharacterized topoisomerases which may contain novel functionality based on their 
active site (TYIRT) and DxD motifs (DAGREGE). 
We have identified potential therapeutic targets for known and suspected infectious agents that 
are implicated in benign conditions such as diarrhea and malignant conditions such as bacteremia 
and gastric carcinoma. With multi-drug resistant pathogens becoming a limiting factor in the 
treatment of serious conditions, we state the case for a therapeutic target for organisms that have 
largely overcome our antimicrobial defenses. 
As with higher order eukaryotes, Methanosarcinales are the only sequenced archaeal class with 
two TopoIII enzymes. Given the recent evidence that TopoIII has altered expression in certain 
neoplastic conditions, the characterization of archaeal topoisomerases may provide an ideal 
system for the study of eukaryotic TopoIIIs (26). More broadly, the data presented here raises the 
prospect of predicting the drug susceptibility of a given topoisomerase based on conserved 
amino acid sequences. The development of type IA topoisomerase inhibitors may prove to be an 
important factor in human defense against disease. 
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FIGURE 4-1 Three dimensional model of the Escherichia coli topoisomerase I with the 
previously mutated residues highlighted. The amino acids that have been the subject of site 
directed mutagenesis studies have been highlighted in blue with the exception of the catalytic 
tyrosine which is in orange. (A) Crystal of EcoTopoI (PDB: 1ECL) (B) A stick model illustrating 
the mutations alone without GxxQ motif. (C) A stick model illustrating the mutations and the 
GxxQ motif. 
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FIGURE 4-2 ACTIVE SITE DISTRIBUTION ACROSS THE DOMAINS OF LIFE. A bar chart illustrating the frquency of all 
determined variants of the active site sequence in the type IA enzymes examined. The active site is defined as the amino acids in the 
topoisomerase that are in the -1 to +4 from the catalytic tyrosine. Archaea are denoted in blue, Bacteria in red and Eukarya in green. 
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Figure 4-3. Neighbor joining tree using % identity of archaeal TopoIIIs.  
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Figure 4-3. (cont.) 
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Figure 4-3. (cont.) The GenBank accession numbers are in brackets. All sequenced genome queries for 
archaeal TopoIII topoisomerases obtained from the NCBI Database as of Dec 28, 2010. Multiple 
sequence alignment performed with MUSCLE using default settings. AboTopoIII, Aciduliprofundum 
boonei T469 TopoIII [YP_003482708.1]; AfuTopoIII, Archaeoglobus fulgidus DSM 4304 TopoIII 
[NP_070633.1]; ApeTopoIII, Aeropyrum pernix K1 TopoIII [NP_148170.1]; AprTopoIII, Archaeoglobus 
profundus DSM 5631 TopoIII [YP_003400026.1]; AsaTopoIII, Acidilobus saccharovorans 345-15 
TopoIII [YP_003815866.1]; CKoTopoIII, Candidatus Korarchaeum cryptofilum OPF8 TopoIII 
[YP_001736678.1]; CmaTopoIII, Caldivirga maquilingensis IC-167 TopoIII [YP_001539953.1]; 
CMeTopoIII, Candidatus Methanoregula boonei 6A8 TopoIII [YP_001404020.1]; DkaTopoIII, 
Desulfurococcus kamchatkensis 1221n TopoIII [YP_002428729.1]; FplTopoIII, Ferroglobus placidus 
DSM 10642 TopoIII [YP_003436042.1]; HboTopoIII, Halogeometricum borinquense DSM 11551 
TopoIII [YP_004037536.1]; HbuTopoIII, Hyperthermus butylicus DSM 5456 TopoIII [YP_001013109.1]; 
HjeTopoIII, Halalkalicoccus jeotgali B3 TopoIII [YP_003737780.1]; HlaTopoIII, Halorubrum 
lacusprofundi ATCC 49239 TopoIII [YP_002564934.1]; HmaTopoIII, Haloarcula marismortui ATCC 
43049 TopoIII [YP_136265.1]; HmuTopoIII, Halomicrobium mukohataei DSM 12286 TopoIII 
[YP_003178822.1]; HsaTopoIII, Halobacterium salinarum R1 TopoIII [YP_001688526.1]; HspTopoIII, 
Halobacterium sp. NRC-1 TopoIII [NP_444190.1]; HtuTopoIII, Haloterrigena turkmenica DSM 5511 
TopoIII [YP_003403017.1]; HutTopoIII, Halorhabdus utahensis DSM 12940 TopoIII [YP_003131625.1]; 
HvoTopoIII, Haloferax volcanii DS2 TopoIII [YP_003534743.1]; HwaTopoIII, Haloquadratum walsbyi 
DSM 16790 TopoIII [YP_657047.1]; IagTopoIII, Ignisphaera aggregans DSM 17230 TopoIII 
[YP_003859870.1]; IhoTopoIII, Ignicoccus hospitalis KIN4/I TopoIII [YP_001434598.1]; MacTopoIII, 
Methanosarcina acetivorans C2A TopoIII [NP_616715.1]; MacTopoIII, Methanosarcina acetivorans 
C2A TopoIII [NP_617416.1]; MaeTopoIII, Methanococcus aeolicus Nankai-3 TopoIII 
[YP_001324231.1]; MbaTopoIII, Methanosarcina barkeri str. Fusaro TopoIII [YP_305639.1]; 
MbaTopoIII, Methanosarcina barkeri str. Fusaro TopoIII [YP_305910.1]; MbuTopoIII,                   
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Figure 4-3. (cont.)Methanococcoides burtonii DSM 6242 TopoIII [YP_564864.1]; MbuTopoIII, 
Methanococcoides burtonii DSM 6242 TopoIII [YP_565420.1]; MevTopoIII, Methanohalobium 
evestigatum Z-7303 TopoIII [YP_003726397.1]; MevTopoIII, Methanohalobium evestigatum Z-7303 
TopoIII [YP_003726445.1]; MfeTopoIII, Methanocaldococcus fervens AG86 TopoIII [YP_003128046.1]; 
MfeTopoIII, Methanothermus fervidus DSM 2088 TopoIII [YP_004003743.1]; MhuTopoIII, 
Methanospirillum hungatei JF-1 TopoIII [YP_502480.1]; MinTopoIII, Methanocaldococcus infernus ME 
TopoIII [YP_003616766.1]; MjaTopoIII, Methanocaldococcus jannaschii DSM 2661 TopoIII 
[NP_248662.1]; MkaTopoIII, Methanopyrus kandleri AV19 TopoIII [NP_614887.1]; MlaTopoIII, 
Methanocorpusculum labreanum Z TopoIII [YP_001030575.1]; MmaTopoIII, Methanococcus 
maripaludis C5 TopoIII [YP_001097306.1]; MmaTopoIII, Methanoculleus marisnigri JR1 TopoIII 
[YP_001046685.1]; MmaTopoIII, Methanohalophilus mahii DSM 5219 TopoIII [YP_003542001.1]; 
MmaTopoIII, Methanohalophilus mahii DSM 5219 TopoIII [YP_003542343.1]; MmaTopoIII, 
Methanosarcina mazei Go1 TopoIII [NP_632207.1]; MmaTopoIII, Methanosarcina mazei Go1 TopoIII 
[NP_635100.1]; MmaTopoIII, Methanothermobacter marburgensis str. Marburg TopoIII 
[YP_003849132.1]; MpaTopoIII, Methanocella paludicola SANAE TopoIII [YP_003357385.1]; 
MpaTopoIII, Methanocella paludicola SANAE TopoIII [YP_003357497.1]; MpaTopoIII, 
Methanosphaerula palustris E1-9c TopoIII [YP_002466356.1]; MpeTopoIII, Methanoplanus 
petrolearius DSM 11571 TopoIII [YP_003895123.1]; MruTopoIII, Methanobrevibacter ruminantium M1 
TopoIII [YP_003423134.1]; MseTopoIII, Metallosphaera sedula DSM 5348 TopoIII [YP_001190937.1]; 
MsmTopoIII, Methanobrevibacter smithii ATCC 35061 TopoIII [YP_001273290.1]; MspTopoIII, 
Methanocaldococcus sp. FS406-22 TopoIII [YP_003458026.1]; MstTopoIII, Methanosphaera 
stadtmanae DSM 3091 TopoIII [YP_447412.1]; MthTopoIII, Methanosaeta thermophila PT TopoIII 
[YP_843026.1]; MthTopoIII, Methanothermobacter thermautotrophicus str. Delta H TopoIII 
[NP_276736.1]; MvaTopoIII, Methanococcus vannielii SB TopoIII [YP_001322681.1]; MvoTopoIII, 
Methanococcus voltae A3 TopoIII [YP_003707397.1]; MvuTopoIII, Methanocaldococcus vulcanius M7 
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Figure 4-3. (cont.) TopoIII [YP_003247065.1]; NeqTopoIII, Nanoarchaeum equitans Kin4-M TopoIII 
[NP_963339.1]; NmaTopoIII, Natrialba magadii ATCC 43099 TopoIII [YP_003480583.1]; NphTopoIII, 
Natronomonas pharaonis DSM 2160 TopoIII [YP_326271.1]; PabTopoIII, Pyrococcus abyssi GE5 
TopoIII [NP_127104.1]; PaeTopoIII, Pyrobaculum aerophilum str. IM2 TopoIII [NP_560414.1]; 
ParTopoIII, Pyrobaculum arsenaticum DSM 13514 TopoIII [YP_001153574.1]; PcaTopoIII, 
Pyrobaculum calidifontis JCM 11548 TopoIII [YP_001056006.1]; PfuTopoIII, Pyrococcus furiosus DSM 
3638 TopoIII [NP_578223.1]; PhoTopoIII, Pyrococcus horikoshii OT3 TopoIII [NP_142581.1]; 
PisTopoIII, Pyrobaculum islandicum DSM 4184 TopoIII [YP_929913.1]; PtoTopoIII, Picrophilus 
torridus DSM 9790 TopoIII [YP_023525.1]; SacTopoIII, Sulfolobus acidocaldarius DSM 639 TopoIII 
[YP_255998.1]; SheTopoIII, Staphylothermus hellenicus DSM 12710 TopoIII [YP_003669180.1]; 
SisTopoIII, Sulfolobus islandicus L.D.8.5 TopoIII [YP_003419463.1]; SmaTopoIII, Staphylothermus 
marinus F1 TopoIII [YP_001041270.1]; SsoTopoIII, Sulfolobus solfataricus P2 TopoIII [NP_342400.1]; 
StoTopoIII, Sulfolobus tokodaii str. 7 TopoIII [NP_377148.1]; TacTopoIII, Thermoplasma acidophilum 
DSM 1728 TopoIII [NP_393542.1]; TagTopoIII, Thermosphaera aggregans DSM 11486 TopoIII 
[YP_003649402.1]; TbaTopoIII, Thermococcus barophilus MP TopoIII [YP_004070852.1]; TgaTopoIII, 
Thermococcus gammatolerans EJ3 TopoIII [YP_002959674.1]; TkoTopoIII, Thermococcus kodakarensis 
KOD1 TopoIII [YP_183504.1]; TneTopoIII, Thermoproteus neutrophilus V24Sta TopoIII 
[YP_001795099.1]; TonTopoIII, Thermococcus onnurineus NA1 TopoIII [YP_002306697.1]; 
TpeTopoIII, Thermofilum pendens Hrk 5 TopoIII [YP_920289.1]; TsiTopoIII, Thermococcus sibiricus 
MM 739 TopoIII [YP_002994394.1]; TvoTopoIII, Thermoplasma volcanium GSS1 TopoIII 
[NP_110538.1]; umeTopoIII, uncultured methanogenic archaeon RC-I TopoIII [YP_686736.1]; 
umeTopoIII, uncultured methanogenic archaeon RC-I TopoIII [YP_686844.1]; VdiTopoIII, Vulcanisaeta 
distributa DSM 14429 TopoIII [YP_003902881.1]; 
126 
 
Figure 4-4. Neighbor joining tree using % identity of archaeal Reverse Gyrases. 
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 Figure 4-4. (cont.) 
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Figure 4-4. (cont.) The GenBank accession numbers are in brackets. All sequenced genome queries for 
archaeal Reverse Gyrase topoisomerases obtained from the NCBI Database as of Dec 28, 2010. Multiple 
sequence alignment performed with MUSCLE using default settings. AboRevGyr, Aciduliprofundum 
boonei T469 Reverse Gyrase [YP_003483322.1]; AfuRevGyr, Archaeoglobus fulgidus DSM 4304 
Reverse Gyrase [NP_069857.1]; ApeRevGyr, Aeropyrum pernix K1 Reverse Gyrase [NP_147880.2]; 
ApeRevGyr, Aeropyrum pernix K1 Reverse Gyrase [NP_147906.2]; AprRevGyr, Archaeoglobus 
profundus DSM 5631 Reverse Gyrase [YP_003400660.1]; AsaRevGyr, Acidilobus saccharovorans 345-
15 Reverse Gyrase [YP_003816678.1]; CKoRevGyr, Candidatus Korarchaeum cryptofilum OPF8 
Reverse Gyrase [YP_001737502.1]; CmaRevGyr, Caldivirga maquilingensis IC-167 Reverse Gyrase 
[YP_001540636.1]; DkaRevGyr, Desulfurococcus kamchatkensis 1221n Reverse Gyrase 
[YP_002428519.1]; DkaRevGyr, Desulfurococcus kamchatkensis 1221n Reverse Gyrase 
[YP_002428926.1]; FplRevGyr, Ferroglobus placidus DSM 10642 Reverse Gyrase [YP_003435231.1]; 
HbuRevGyr, Hyperthermus butylicus DSM 5456 Reverse Gyrase [YP_001012435.1]; HbuRevGyr, 
Hyperthermus butylicus DSM 5456 Reverse Gyrase [YP_001013124.1]; IagRevGyr, Ignisphaera 
aggregans DSM 17230 Reverse Gyrase [YP_003858944.1]; IagRevGyr, Ignisphaera aggregans DSM 
17230 Reverse Gyrase [YP_003860622.1]; IhoRevGyr, Ignicoccus hospitalis KIN4/I Reverse Gyrase 
[YP_001435008.1]; IhoRevGyr, Ignicoccus hospitalis KIN4/I Reverse Gyrase [YP_001435105.1]; 
MfeRevGyr, Methanocaldococcus fervens AG86 Reverse Gyrase [YP_003127391.1]; MinRevGyr, 
Methanocaldococcus infernus ME Reverse Gyrase [YP_003616312.1]; MjaRevGyr, 
Methanocaldococcus jannaschii DSM 2661 Reverse Gyrase [NP_248519.1]; MkaRevGyr, Methanopyrus 
kandleri AV19 Reverse Gyrase [NP_613576.1]; MseRevGyr, Metallosphaera sedula DSM 5348 Reverse 
Gyrase [YP_001191827.1]; MseRevGyr, Metallosphaera sedula DSM 5348 Reverse Gyrase 
[YP_001192298.1]; MspRevGyr, Methanocaldococcus sp. FS406-22 Reverse Gyrase [YP_003457949.1]; 
MvuRevGyr, Methanocaldococcus vulcanius M7 Reverse Gyrase [YP_003247600.1]; NeqRevGyr, 
Nanoarchaeum equitans Kin4-M Reverse Gyrase [NP_963605.1]; PabRevGyr, Pyrococcus abyssi GE5 
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Figure 4-4. (cont.) Reverse Gyrase [NP_126943.1]; PaeRevGyr, Pyrobaculum aerophilum str. IM2 
Reverse Gyrase [NP_559079.1]; ParRevGyr, Pyrobaculum arsenaticum DSM 13514 Reverse Gyrase 
[YP_001152524.1]; PcaRevGyr, Pyrobaculum calidifontis JCM 11548 Reverse Gyrase 
[YP_001055584.1]; PfuRevGyr, Pyrococcus furiosus DSM 3638 Reverse Gyrase [NP_578224.1]; 
PhoRevGyr, Pyrococcus horikoshii OT3 Reverse Gyrase [NP_142736.1]; PisRevGyr, Pyrobaculum 
islandicum DSM 4184 Reverse Gyrase [YP_930753.1]; SacRevGyr, Sulfolobus acidocaldarius DSM 639 
Reverse Gyrase [YP_255499.1]; SheRevGyr, Staphylothermus hellenicus DSM 12710 Reverse Gyrase 
[YP_003669337.1]; SheRevGyr, Staphylothermus hellenicus DSM 12710 Reverse Gyrase 
[YP_003669485.1]; SisRevGyr, Sulfolobus islandicus L.D.8.5 Reverse Gyrase [YP_003419411.1]; 
SisRevGyr, Sulfolobus islandicus L.D.8.5 Reverse Gyrase [YP_003419968.1]; SmaRevGyr, 
Staphylothermus marinus F1 Reverse Gyrase [YP_001040974.1]; SmaRevGyr, Staphylothermus marinus 
F1 Reverse Gyrase [YP_001041125.1]; SsoRevGyr, Sulfolobus solfataricus P2 Reverse Gyrase 
[NP_341957.1]; SsoRevGyr, Sulfolobus solfataricus P2 Reverse Gyrase [NP_342447.1]; StoRevGyr, 
Sulfolobus tokodaii str. 7 Reverse Gyrase [NP_376245.1]; StoRevGyr, Sulfolobus tokodaii str. 7 Reverse 
Gyrase [NP_377224.1]; TagRevGyr, Thermosphaera aggregans DSM 11486 Reverse Gyrase 
[YP_003650407.1]; TagRevGyr, Thermosphaera aggregans DSM 11486 Reverse Gyrase 
[YP_003650443.1]; TbaRevGyr, Thermococcus barophilus MP Reverse Gyrase [YP_004070963.1]; 
TgaRevGyr, Thermococcus gammatolerans EJ3 Reverse Gyrase [YP_002960045.1]; TkoRevGyr, 
Thermococcus kodakarensis KOD1 Reverse Gyrase [YP_182883.1]; TneRevGyr, Thermoproteus 
neutrophilus V24Sta Reverse Gyrase [YP_001793605.1]; TonRevGyr, Thermococcus onnurineus NA1 
Reverse Gyrase [YP_002306713.1]; TpeRevGyr, Thermofilum pendens Hrk 5 Reverse Gyrase 
[YP_919983.1]; VdiRevGyr, Vulcanisaeta distributa DSM 14429 Reverse Gyrase [YP_003902688.1]; 
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FIGURE 4-5 DxD motif distribution across the domains of life. A bar chart illustrating the 
frequency of DxD motifs within type IA topoisomerases. The sum for a given domain does not 
equal 1 because it is possible for any given topoisomerase to have more than one DxD motif. 
Archaea are denoted in blue, Bacteria in red and Eukarya in green. 
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FIGURE 4-6 Distribution of conserved GXXQ motif across all domains. This is a bar chart 
illustrating the relative percentage of each GXXQ motif variant within a given domain. Only 
variants with greater than 1% prevalence are illustrated. Archaea are denoted in blue, Bacteria in 
red and Eukarya in green. 
0.0%
10.0%
20.0%
30.0%
40.0%
50.0%
60.0%
70.0%
80.0%
90.0%
100.0%
GPCQ GQYQ GRAQ GRCQ GRVL GRVQ GSCQ GSFQ GSSQ GTCQ
ARCHAEA BACTERIA EUKARYA
GxxQ MOTIF DISTRIBUTION
132 
 
 TABLE 4-1 Escherichia coli topoisomerase I mutations. 
MUTATION DESCRIPTION REFERENCE 
C662H Structural change with loss of one tightly bound Zn(II) and altered cleavage site preferences.  (35) 
C662S Structural change with loss of one tightly bound Zn(II) and altered cleavage site preferences (35) 
D111A No Effect (36, 37) 
D111A/D113A Right shift of Mg(II) concentrations dependence from 6 to 15-20 mM.for maximal DNA relaxation activity (32) 
D111A/D113A/E115A Loss of DNA relaxation activity (32) 
D111A/E115A Right shift of Mg(II) concentrations dependence from 6 to 15-20 mM.for maximal DNA relaxation activity (32) 
D111N Loss of DNA Relaxation Activity (38) 
D113A Loss of DNA Relaxation Activity (37) 
D113A/E115A No conformational change (32) 
D113N 100x Reduction of DNA Relaxation Activity. Overexpression decreases cell viability. (38) 
D313A No Effect (36) 
D323A No Effect (36) 
E113A No Effect (36) 
E115A No Effect (36, 37) 
E9A Partial loss of DNA relaxation activity (36) 
E9A/D111A Partial loss of DNA relaxation activity (32) 
E9A/D113A Partial loss of DNA relaxation activity (32) 
E9A/D115A Partial loss of DNA relaxation activity (32) 
E9Q Significantly reduces supercoil removal activity. DNA cleavage and rejoining activities unchanged. (36) 
EcTOP67-D111N 18x enhancement in DNA relaxation activity (38) 
EcTOP67-G116S 2.6x enhancement in DNA relaxation activity (38) 
G116N No effect on cell viability (38) 
G116S >1,000x loss in cell viability  (39) 
G194S/P/K/R/N/A Required for DNA cleavage and relaxation activity. Supports a functional role in the enzyme conformational change (33) 
G65N Cell viability reduced at 37°C and 42°C (16) 
G65N/W79S Cell viability reduced at 37°C and 42°C. Reduced DNA relaxation activity even with 7.5x enzyme and unable (16) 
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to completely relax substrate. Cleavage activity also reduced 
H33A No Effect (36) 
H365A Lower DNA binding affinity and slower rate of DNA cleavage while having more cleaved substrate overall. pH dependence reported (36) 
K13A/R Severely reduced the relaxation and DNA cleavage activity (40) 
M320R Cleavage products formation greater than WT in the presence of 2 mM MgCl2 (41) 
M320V No Significant Effect (42) 
Q309A No Effect (36) 
Q197A Loss of relaxation activity (> 100x). Lower DNA binding (3–4x).  (34) 
R136A Mutation of Arg-136 abolished all the enzyme relaxation activity even though DNA cleavage activity was retained. (37) 
R195A/K A - Lower DNA binding (3–4x). Loss relaxation activity (> 500x).  K - Lower DNA binding (2x).Loss relaxation activity (> 50x).  (34) 
R321A DNA cleavage functions with Mg(II) but complete loss of DNA relaxation activity with cleaved covalent intermediate accumulation (36, 37) 
R321F/L/K Partial Loss of DNA relaxation activity (43) 
R321K Partial Loss of DNA relaxation activity (36) 
S10A/T Loss of DNA cleavage and relaxation activity of the enzyme (40) 
S192A/T Little effect on DNA cleavage and relegation. Greater loss with Alanine substitution (34) 
T318A No Effect (36) 
T322A No Effect (36) 
T496A No Effect (36) 
Y319A Completely inactivates the enzyme (16, 36)
Y319F/S Completely inactivates the enzyme (34, 44) 
Y319S Completely inactivates the enzyme (44) 
TABLE 4-1. (cont.) This table contains a list of mutations within the literature that have been characterized. EcTOP67, Escherichia 
coli topoisomerase I 67 kDa fragment containing residues 1-596. Bold is utilized to highlight site directed mutagenesis studies 
conducted on highly conserved motifs of EcoTopoI. 
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ORGANISM NAME LENGTH TYR ACTIVE SITE NCBI ACCESSION NO. 
Acidithiobacillus ferrooxidans ATCC 23270 705 291 TYHRT YP_002425486.1 
Acinetobacter baumannii AB0057 672 286 TYHRT YP_002317671.1 
Campylobacter jejuni subsp. jejuni 81-176 655 288 TYHRT YP_980071.1 
Campylobacter jejuni subsp. jejuni 81-176 655 288 TYHRT NP_863308.1 
Cyanothece sp. ATCC 51142 719 328 TYHRT YP_001806222.1 
Deferribacter desulfuricans SSM1 705 295 TYHRT YP_003497392.1 
Helicobacter pylori 26695 677 298 TYHRT NP_207238.1 
Helicobacter pylori B8 677 298 TYHRT YP_003728508.1 
Helicobacter pylori PeCan4 677 298 TYHRT YP_003927794.1 
Marinobacter aquaeolei VT8 729 285 TYHRT YP_956966.1 
Methylovorus sp. SIP3-4 590 280 SYHRT YP_003052628.1 
Neisseria gonorrhoeae 731 323 TYHRS YP_003600471.1 
Persephonella marina EX-H1 680 291 TYHRT YP_002731728.1 
Pseudomonas aeruginosa PA7 639 298 TYHRT YP_001349815.1 
Pseudomonas aeruginosa UCBPP-PA14 641 298 TYHRT YP_792914.1 
Pseudomonas fluorescens Pf-5 638 298 TYHRT YP_261755.1 
Sulfurihydrogenibium azorense Az-Fu1 675 286 TYHRT YP_002728159.1 
Sulfurihydrogenibium sp. YO3AOP1 683 292 TYHRT YP_001930557.1 
Xylella fastidiosa 9a5c 660 287 TYHRT NP_061659.1 
 
TABLE 4-2. List of bacterial topoisomerases with A (S/T)YHRT sequence. All of the sequences identified contain the DPDRE 
and GRVQ motif. Sequences highlighted in blue are pathogenic. TYR, amino acid position of the active site tyrosine; Length, primary 
amino acid sequence length. 
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ORGANISM NAME LENGTH TYR ACTIVE SITE ACCESSION NO. 
Borrelia turicatae 91E135 845 324 TYIRT NP_671319.1 
Helicobacter pylori B8 686 294 TYIRT YP_001874260.1 
Helicobacter pylori G27 603 260 TYIRT YP_001719085.1 
Helicobacter pylori J99 425 301 TYIRT YP_002469319.1 
Helicobacter pylori J99 686 294 TYIRT YP_001169700.1 
Helicobacter pylori Shi470 644 301 TYIRT YP_386564.1 
Helicobacter pylori SJM180 686 294 TYIRT YP_002436682.1 
Mycoplasma capricolum subsp. capricolum ATCC 27343 643 296 TYIRT YP_001196024.1 
Mycoplasma mycoides subsp. mycoides SC str. PG1 643 296 TYIRT YP_132566.1 
 
TABLE 4-3. List of bacterial topoisomerases that are from pathogenic organisms and that have an active site TYIRT sequence. 
A total of 36 enzymes were identified with this signature sequence in the active site. This table contains an abbreviated list of only the 
9 that are known or suspected pathogens. TYR indicates the amino acid position of the active site tyrosine. Length is the primary 
amino acid sequence length.  
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ACTIVE ARCHAEA (n=147) BACTERIA (n=1806) EUKARYA (n=130) VIRUS (n=2) 
SITE # FREQ (%) # FREQ (%) # FREQ (%) # FREQ (%) 
MYNRT 0 0.0% 0 0.0% 1 0.8% 0 0.0% 
NYPRT 0 0.0% 0 0.0% 1 0.8% 0 0.0% 
SYHRT 1 0.7% 1 0.1% 0 0.0% 0 0.0% 
SYIGT 1 0.7% 0 0.0% 0 0.0% 0 0.0% 
SYIRT 0 0.0% 7 0.4% 0 0.0% 0 0.0% 
SYMRT 0 0.0% 31 1.7% 1 0.8% 0 0.0% 
SYPKS 1 0.7% 0 0.0% 0 0.0% 0 0.0% 
SYPRA 0 0.0% 2 0.1% 0 0.0% 0 0.0% 
SYPRS 1 0.7% 31 1.7% 0 0.0% 0 0.0% 
SYPRT 75 51.0% 111 6.1% 110 84.6% 0 0.0% 
SYPRV 0 0.0% 7 0.4% 0 0.0% 0 0.0% 
TYHRS 1 0.7% 1 0.1% 0 0.0% 0 0.0% 
TYHRT 51 34.7% 45 2.5% 0 0.0% 0 0.0% 
TYIRT 2 1.4% 36 2.0% 1 0.8% 0 0.0% 
TYMRS 0 0.0% 1 0.1% 0  0.0% 0 0.0% 
TYMRT 0 0.0% 948 52.5% 9 6.9% 2 100.0% 
TYNRS 0 0.0% 4 0.2% 0 0.0% 0 0.0% 
TYPRA 0 0.0% 3 0.2% 0 0.0% 0 0.0% 
TYPRS 0 0.0% 229 12.7% 0 0.0% 0 0.0% 
TYPRT 14 9.5% 336 18.6% 7 5.4% 0 0.0% 
TYPRV 0 0.0% 13 0.7% 0 0.0% 0 0.0% 
 
TABLE 4-4 ACTIVE SITE SUMMARY. A table illustrating the prevalence of active site configurations identified for each domain. Numbers in 
red indicate sequences for which the enzymatic profile is unknown. Cells in yellow reflect signature sequences for reverse gyrase enzymes. Cells 
in blue reflect signature sequences for each domain. NOTE: There are only 147 sequences in the domain Archaea because two proteins are split 
proteins. The non-catalytic peptide is not considered in this analysis. 
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DOMAIN 
ACTIVE SITE 
Y?R CLASSIFICATION 
ARCHAEA 
H Reverse Gyrase 
I Unknown 
M TopoI 
N Unknown 
P TopoIII 
BACTERIA     
 H α - If Polypeptide Length < 950, TopoI or TopoIII 
β - If Polypeptide Length > 950, Reverse Gyrase 
I Unknown 
M TopoI 
N Unknown 
  P TopoIII 
EUKARYA 
M Unknown, Likely TopoI 
  P TopoIII 
  
TABLE 4-5 New Classification Schema For Type IA Topoisomerases. Based on our 
bioinformatics results and a review of the literature, a new system of classification is suggested 
based on a single amino acid contained in the active site residue.  
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TABLE 4-6 Taxonomic Rank Of Archaeal Genomes With Two TopoIIIs. 
  
KINGDOM PHYLUM CLASS ORDER FAMILY GENUS SPECIES 
Euryarchaeota Methanomicrobia Methanocellales Methanocellaceae Methanocella Methanocella paludicola SANAE 
Euryarchaeota Methanomicrobia Methanosarcinales Methanosarcinaceae Methanococcoides Methanococcoides burtonii DSM 6242 
Euryarchaeota Methanomicrobia Methanosarcinales Methanosarcinaceae Methanohalobium Methanohalobium evestigatum Z-7303 
Euryarchaeota Methanomicrobia Methanosarcinales Methanosarcinaceae Methanohalophilus Methanohalophilus mahii DSM 5219 
Euryarchaeota Methanomicrobia Methanosarcinales Methanosarcinaceae Methanosarcina Methanosarcina acetivorans C2A 
Euryarchaeota Methanomicrobia Methanosarcinales Methanosarcinaceae Methanosarcina Methanosarcina barkeri str. Fusaro  
Euryarchaeota Methanomicrobia Methanosarcinales Methanosarcinaceae Methanosarcina Methanosarcina mazei Go1 
  
SOURCE: http://www.uniprot.org/taxonomy/ 
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TABLE  4-7 Taxonomic rank of archaeal genomes with two Reverse Gyrases. 
 
KINGDOM PHYLUM CLASS ORDER FAMILY GENUS SPECIES 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Aeropyrum Aeropyrum pernix K1 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Desulfurococcus Desulfurococcus kamchatkensis 1221n 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Ignicoccus Ignicoccus hospitalis KIN4/I 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Ignisphaera Ignisphaera aggregans DSM 17230 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Staphylothermus Staphylothermus hellenicus DSM 12710 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Staphylothermus Staphylothermus marinus F1 
Crenarchaeota Thermoprotei Desulfurococcales Desulfurococcaceae Thermosphaera Thermosphaera aggregans DSM 11486 
Crenarchaeota Thermoprotei Desulfurococcales Pyrodictiaceae Hyperthermus Hyperthermus butylicus DSM 5456 
Crenarchaeota Thermoprotei Sulfolobales Sulfolobaceae Metallosphaera Metallosphaera sedula DSM 5348 
Crenarchaeota Thermoprotei Sulfolobales Sulfolobaceae Sulfolobus Sulfolobus islandicus L.D.8.5 
Crenarchaeota Thermoprotei Sulfolobales Sulfolobaceae Sulfolobus Sulfolobus solfataricus P2 
Crenarchaeota Thermoprotei Sulfolobales Sulfolobaceae Sulfolobus Sulfolobus tokodaii str. 7 
 
SOURCE: http://www.uniprot.org/taxonomy
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Chapter 5 – Discussion and Conclusions 
5.1 The Future 
The prevailing wisdom is that, in order for life to exist on Earth, an organism requires at 
least one type IA enzyme and one type II enzyme (1). Moreover, TopoIII enzymes have been 
demonstrated to be essential for normal growth and development of lower and higher order 
eukaryotes along with Bacteria (2, 3). In spite of this fact, scientific spotlight has remained on 
the non-essential type IB topoisomerases and reverse gyrases due to their cellular and 
phylogenetic distribution, respectively. Type IB enzymes have been suggested to be of viral 
origin because they are found in organelle structures (plastids, mitochondria and nuclei) and 
viruses. TopoIB has a sparse distribution within Bacteria and extremely limited distribution 
within Archaea (4). Along with that, plasmids from hyperthermophiles such as Archaeoglobus 
profundus and Thermotoga sp. RQ7 have been identified which are negatively supercoiled when 
hyperthermophiles were believed to have positively supercoiled genomes produced by reverse 
gyrase (5). With recent experiments illustrating that reverse gyrase is non-essential, the data 
illustrates that current research is not focused on the topoisomerases which are essential for life 
(6). 
5.2 Cleavage Specificity And Beyond  
As more crystal structures become available, it is apparent that teasing out the residues 
responsible for this DNA interaction and the large conformational changes involved in managing DNA 
topology require examination across domains (7, 8). At present, there are 169 structures available for 
topoisomerases within RCSB Protein Data Bank as of 5/28/2012. Of those, only 18 are of archaeal origin. 
Those 18 crystal structures account for only five archaeal topoisomerases: Methanosarcina mazei Topo 
VI, Methanococcus jannaschii TopoVI, Sulfolobus shibatae type II, Methanopyrus kandleri Topo V (type 
IC) and Archaeoglobus fulgidus reverse gyrase (only archaeal type IA topoisomerase crystallized) (9-13). 
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Combining our understanding of each step of catalysis is essential to harnessing the power of 
these molecular machines. Unfortunately, there has been so little attention afforded archaeal TopoIII 
such that no conclusions can be made about the steps of catalysis between the three domains of life. 
Cleavage specificity has played an important role thus far and may fill a crucial gap. 
Some studies have sought to characterize topoisomerases in terms of exact site of cleavage based 
on a limited subset of substrates and substrate topologies. Early experiments with Mlu and Eco 
Topo I illustrated a general preference for cleavage at sites with cytosine at the -4 position 90% 
of the time (14). Dam reverse gyrase was also shown to have a preference for Cytosine at the -4 
position relative to the site of cleavage of linearized pBR322 for the majority of the identified 
sites (15). Similarly, Mycobaterium smegmatis studies revealed a pentanucleotide motif at the 
cleavage site C(G/T)CTT based on the cleavage of random genomic fragments inserted into 
pUC19 (16). These biochemical studies help to define a constant attribute of a specific 
topoisomerase that has been utilized for comparison across domains and crystallization studies 
(see Chapter 2). 
The true benefit of these studies is revealed when higher level studies build upon this 
information to reveal new insights into topoisomerase activity. For example, a novel study in 
Drosophila topoisomerase II was conducted that utilized single molecule FRET to analyze the 
cleavage religation equilibrium of this topoisomerase (17). To accomplish this work, the authors 
utilized a 28-bp oligonucleotides DNA substrate that contained a known cleavage site that was 
identified more than two decades prior (18)! Using this substrate, the authors were able to obtain 
measurements for the opening and closing of the DNA gate of this enzyme along with the 
estimated maximum gate distance. This type of study reflects a monumental advancement of our 
145 
 
understanding of the molecular mechanism of type II topoisomerases based on previously 
published work that is few and far between in the field.  
We have attempted to determine the cleavage site specificity of MacTopoIIIα using 
radiolabeled ssDNA sequences readily available within our laboratory. Despite testing over 30 
different substrates that are less than 40 nt each, we were unable to observe any preference for a 
particular sequence. (Data not shown) Nonetheless, there is a still an exponentially significant 
amount of sequence space not covered. It is important to note that sequence specificity amongst 
type I topoisomerases is not conserved and may reflect evolutionary divergence. Future 
determination of an archaeal strong topoisomerase site (STS) may play a critical role in 
understanding the basic properties of the catalytic mechanism. 
5.3 Genetics 
Since Archaea and archaeal TopoIII have not been directly implicated in any pathogenic state, 
the therapeutic agents available to target this enzyme are nonexistent. And yet, researchers are 
now starting to postulate that Archaea may play an as yet undefined role in the pathogenesis of a 
wide range of diseases (19). For example, there is evidence illustrating that the more severe the 
chronic periodontitis the greater the involvement of Methanobrevibacter species (20). Likewise, 
there is recent work in breast cancer revealing that TopoIII is an independent marker for the 
severity of disease (21). This growing body of evidence provides strong support for the 
continued characterization of archaeal TopoIIIs and the development of drugs that target these 
enzymes.  
Methanosarcinales represent the only completely sequenced archaeal order with two 
TopoIII topoisomerases. As with humans, they are paraphyletic, but the significance is unknown. 
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Given the sequence homology and comparable genetic distribution, understanding the in vitro 
and in vivo role of MacTopooIII enzymes may shed light on our current understanding of the role 
of TopoIII within humans (see Figure 5-1). With the largest sequenced genome, Methanosarcina 
acetivorans C2A is a versatile organism that can survive in various environments such as 
freshwater and marine sediments. With an expanding biochemical toolkit, this archaeon is 
becoming the model of choice (22, 23). Our studies have only begun to probe recombinant 
MacTopoIIIα wild type and mutants for differences in the catalytic activity, the cleavage 
specificity and the role of zinc-binding. 
Analysis of the amino acid sequence of Mac TopoIIIs reveals a catalytic tyrosine at 
residue 317 in MacTopoIIIα and MacTopoIIIβ along with a C-X2-C-X17-C-X5-C-X18-C-X2-H 
motif in the C-terminal domain (see Figure 5-1). The role of the C-terminal domain and Zn2+ 
chelation in the catalytic cycle is one that has not been answered within Archaea and, as 
previously stated, an issue that remains to be fully resolved for topoisomerase in general (see 
Chapter 2). Should this motif serve an enzyme-specific role in catalysis, then it is reasonable to 
postulate that future pharmaceuticals could target this region for medical and/or research 
purposes. 
In Chapter 3, we provided the first investigation into the C-terminal domain of TopoIII in 
Archaea. However, further characterization of MacTopoIIIα with six variants containing either a 
Cysteine-to-Alanine mutation or Histidine-to-Alanine mutation must be produced and 
characterized in order to reveal which residues specifically contribute to binding of zinc. 
Recombinant proteins containing single mutations can be analyzed for the ability to bind Zn2+ 
using Inductively Coupled Plasma-Mass Spectroscopy and the ability to relax negatively 
supercoiled DNA using standard topoisomerase assays. Should this endeavor yield no influence 
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on Zn2+-chelation, then three double mutants could be produced to further probe the role of this 
motif.  
In the preceding chapter, we identified a GXXQ motif which is conserved across all 
domains of life. However, only the Glycine 194, Arginine 195 and Glutamine 197 residues have 
been characterized in the domain Bacteria (24, 25). It is unclear what the exact contribution of 
these residues is to the structure and function of archaeal and eukaryotic topoisomerases. 
Systematic analysis of these residues may reveal information about protein-DNA interaction 
requirements in other domains of life. 
A study on mice, a higher order eukaryote, demonstrated that top3α is essential, but the 
precise cellular function is elusive since knockout mice are embryonically lethal (3). Meanwhile, 
Top3β-/- mice develop normally, but have shorter lifespans over a 25 month period (26). In this 
case, there were no differences in size, weight, and agility relative to the wild-type, but post-
morterm biopsies revealed lesions in multiple organs. Further study of this phenotype revealed 
that there was increase in antibodies against IgG while maintaining normal populations of 
lymphocytes (2). There were anomalous chromosome numbers in somatic cells and a high 
incidence of condensed nuclear morphology suggestive of apoptosis. Longer term studies 
revealed that older Top3 −/− mice become infertile with a high frequency of aneuploidy (27). 
These data provide direct evidence that TopoIII is essential for normal development in 
eukaryotes.  
The essentiality of an archaeal TopoIII gene remains unanswered. The answer to this 
question with each gene represents an opportunity to provide greater resolution on genetic 
redundancy in Archaea. It is important to note that compensatory mutations may arise when a 
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conditional mutant is generated (23). To fully address the question, a conditional mutant must be 
further confirmed with a deletion construct. 
5.4 Conclusion 
The future of topoisomerase research depends upon a paradigm shift within the scientific 
community that emphasizes the importance of TopoIII enzymes as reflected through the number 
and type of investigations conducted. To that end, we have provided the first characterization of 
a mesophilic type IA archaeal topoisomerase. In this study, we conducted an in vitro 
characterization of some of the basic biochemical properties of this enzyme from the well-
characterized active site tyrosine to the unresolved C-terminal.  We have also performed the 
largest phylogenomic analysis of topoisomerases to-date with over 2000 sequences from a single 
class of enzymes. From these studies, we were able to construct a new scheme for 
characterization and provide information on prototypic topoisomerases. We have also revealed 
unique attributes about topoisomerases within pathogenic organisms that had gone previously 
unnoticed. In completing this body of work on type IA topoisomerases, we have illustrated the 
significance of TopoIII and the need for future investigations in the field. 
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Figure 5-1. 
   
HTopoIIIα M E M A L R G V R K V L C V A E K N D A A K G I A D L L S N G R M R R R E G L S K F N K I Y E F D Y H L Y G Q N V T M V  6 0
HTopoIIIβ - - - - - - - M K T V L M V A E K P S L A Q S I A K I L S R G S L S S H K G L N G A C S V H E Y T G T F A G Q P V R F K  5 3
MacTopoIIIα - - - - - - - - - M H L I V T E K N I A A R R I A A I L A P K S P K K E R - - V S G V D V Y R Y E L G K G K S R Q E T A  4 9
MacTopoIIIβ - - - - - - - - M T V V A F A E K N K A A A Q I A S I L G D G E V D K I S - - V E G L P A Y E F K W K - - - - G E E W L  4 6
HTopoIIIα M T S V S G H L L A H D F Q M Q F R K W Q S C N P L V L F - E A E I E K Y C P E N F V D I K K T L E R E T R Q C Q A L V  1 1 9
HTopoIIIβ M T S V C G H V M T L D F L G K Y N K W D K V D P A E L F S Q A P T E K K E A N P K L N M V K F L Q V E G R G C D Y I V  1 1 3
MacTopoIIIα V V G L S G H I V G I D F Q K E Y N N W Q K V D A R A L I D A E I T T T P I N R - - - K I V T A L R T L G K E A D R V T  1 0 6
MacTopoIIIβ V M G L S G H I M N Y D F P E Q Y N K W S E V N P G T L L G V D P E K - - - F V T R A E Y A T A I K K L A K R A D K I I  1 0 3
HTopoIIIα I W T D C D R E G E N I G F E I I H V C K A V K P N L Q - - - - - V L R A R F S E I T P H A V R T A C E N L T E P D Q R  1 7 4
HTopoIIIβ L W L D C D K E G E N I C F E V L D A V L P V M N K A H G G E K T V F R A R F S S I T D T D I C N A M A C L G E P D H N  1 7 3
MacTopoIIIα I A T D Y D R E G E L I G V E A L N I I K K V N P E V P - - - - - F D R V R Y S A I T P K A I D A A F T N P T S V D F D  1 6 1
MacTopoIIIβ L A C D Y D R E G E N I G F E A K T L A E E V T - D V P - - - - - V A R A R F S A L S P K E V R K A F E S P V D P D H N  1 5 7
HTopoIIIα V S D A V D V R Q E L D L R I G A A F T R F Q T L R L Q R I F P E V L A E Q L I S Y G S C Q F P T L G F V V E R F K A I  2 3 4
HTopoIIIβ E A L S V D A R Q E L D L R I G C A F T R F Q T K Y F Q G K Y - G D L D S S L I S F G P C Q T P T L G F C V E R H D K I  2 3 2
MacTopoIIIα L A D A G H S R Q V I D L V W G A A L T R Y I S L A A G R L G - - - - - K M F L S V G R V Q S P T L S L V V D R E K E R  2 1 6
MacTopoIIIβ L A M A A E T R Q I L D L K M G A A F T R F V T L S V R E K A R - - - T K D I L S I G P C Q T P T C G F V Y E R E K A I  2 1 4
HTopoIIIα Q A F V P E I F H R I K V T H D H - K D G I V E F N W K R H R L F N H T A C L V L Y Q L C V E D P M A T V V E V R S K P  2 9 3
HTopoIIIβ Q S F K P E T Y W V L Q A K V N T D K D R S L L L D W D R V R V F D R E I A Q M F L N M T K L E K E A Q V E A T S R K E  2 9 2
MacTopoIIIα N I F V P T P Y W E I H V E L E T K A G E T F S A Q H S T R R F L D K E E A T A V F K K - - L G K K A E L K E I E K G T  2 7 4
MacTopoIIIβ R A F K A K D F W K I T A I F G A - K G G D F E G T H R A G N I H D K E K A A E I F K R L K G A K E G F V V K K T V K E  2 7 3
HTopoIIIα K S K W R P Q A L D T V E L E K L A S R K L R I N A K E T M R I A E K L Y T Q G Y I S Y P R T E T N I F P R D L N L T V  3 5 3
HTopoIIIβ K A K Q R P L A L N T V E M L R V A S S S L G M G P Q H A M Q T A E R L Y T Q G Y I S Y P R T E T T H Y P E N F D L K G  3 5 2
MacTopoIIIα K S D L P P T P F N T T G F I S A A N - S I G L S P A N A M R I A E S L Y T N G Y I S Y P R T D N T V Y P E T L D L R A  3 3 3
MacTopoIIIβ A K T S P P N P L N T T E F L K R A S K F L G I S P E V A L E V A E Q L Y L A G F T S Y P R T E T N K Y A D D F D F K T  3 3 3
HTopoIIIα L V E Q Q T P D P R W G A F A Q S I L E R G G P T P R N G N K S D Q A H P P I H P T K Y T N N - - L Q G D E - - - - - Q  4 0 6
HTopoIIIβ S L R Q Q A N H P Y W A N T V K R L L A E G I N R P R K G H D A G - D H P P I T P M K S A T E A E L G G D A - - - - - W  4 0 6
MacTopoIIIα Q I E I F T E G P - F K E F A D A L L E K A E L V P T R G K K E T T D H P P I Y P A S L A K E S E L K E E E - - - - - W  3 8 7
MacTopoIIIβ L L F D F A R Q K E Y K P F A E S I L S - A P I V P K N G D K D A H D H P P I H P I R V A A K G E I S A A V T I P H A A  3 9 2
HTopoIIIα R L Y E F I V R H F L A C C S Q D A Q G Q E T T V E I D I A Q E R F V A H G L M I L A R N Y L D V Y P Y D H W S - D K I  4 6 5
HTopoIIIβ R L Y E Y I T R H F I A T V S H D C K Y L Q S T I S F R I G P E L F T C S G K T V L S P G F T E V M P W Q S V P L E E S  4 6 6
MacTopoIIIα K V Y E L V V R R F F A T F A G P S T W E T M R L R L E I N A E E F R A N G A R L L E P G W R W Y Y P Y N V P E - D R L  4 4 6
MacTopoIIIβ E V Y D L I A R H F L A N L M P A A V F E K T H L H L Q V R E E P F D S S G T V L K D A G W L E V Y P F E N K K - D K L  4 5 1
HTopoIIIα L P V Y E Q G S H F Q P S T V E M V D G E T S P P K L L T E A D L I A L M E K H G I G T D A T H A E H I E T I K A R M Y  5 2 5
HTopoIIIβ L P T C Q R G D A F P V G E V K M L E K Q T N P P D Y L T E A E L I T L M E K H G I G T D A S I P V H I N N I C Q R N Y  5 2 6
MacTopoIIIα F P E L S E G E I L K V I K K E M L D K E T Q P P G R Y G Q G R L I N I M E E L G L G T K A T R H E I I S K L Y S R A Y  5 0 6
MacTopoIIIβ L P F V E E K E K V D V K K L S N T K S K T S P P K K L T E A E L L T L M D K H G I G T K A T A P T H I E T N K K R G Y  5 1 1
HTopoIIIα V G L T P D K R F L P G H L G M G L V E G Y D S M G Y E M S K P D L R A E L E A D L K L I C D G K K D K F V V L R Q Q V  5 8 5
HTopoIIIβ V T V E S G R R L K P T N L G I V L V H G Y Y K I D A E L V L P T I R S A V E K Q L N L I A Q G K A D Y R Q V L G H T L  5 8 6
MacTopoIIIα I H G N P - - - V Q P T N T S F A V V E T L E K Y S P T I T K P D M T K L L E E N M D L I A E G K I K E D T V L E E S R  5 6 3
MacTopoIIIβ F E T K G - K T V S I L D T G F T L M D G L S L T V P I L V R P D I R A K I E A L I Q E V E D G K K E F E A A L A E G T  5 7 0
HTopoIIIα Q K Y K Q V F I E A V A K A K K L D E A L A Q Y F G N G T E L A Q Q E D I Y P A M P E P I R K C P Q C N K D M V L K T K  6 4 5
HTopoIIIβ D V F K R K F H Y F V D S I A G M D E L M E V S F S P - - - - - - - - - - L A A T G K P L S R C G K C H R F M K Y I Q A  6 3 6
MacTopoIIIα E M L Q Q V F S E L D K N R D K I I E S L Q A G L R E - - - - - - - - - - - - - - D K I I G N C S L C G N E L M I R R S  6 0 9
MacTopoIIIβ A L I K E M Y A Q L E A N K K E L T S N I A G T I K D E A A L E - - - - - - - D K K N Y I G T C K A C G H V L R I V Q T  6 2 3
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Figure 5-1. (cont.) 
 
Figure 5-1. Conserved sequences in the human and Mac TopoIIIs. An alignment of human 
TopoIIIα [AAB03695], human TopoIIIβ [O95985], MacTopoIIIα [NP_617416], MacTopoIIIβ 
[NP_616715]. The residues that are highly conserved (identical for >50% sequences at the 
position) are indicated in black. The residues that are conserved (similar for >50 % sequences at 
the position) are indicated in gray. The active site tyrosine is highlighted in red at amino acid 
position 337,336,317 and 317 respectively. The C-terminal cysteines are highlighted in blue. 
  
HTopoIIIα K N G G F Y L S C M G F P E C R S A V W L P D S V L E A S R D S S V C P V C Q P H P V Y R L K L K F K R G S L P P T M P  7 0 5
HTopoIIIβ K P - - - - - S R L H C S H C D E T Y T L P Q - - - - - - - - - - - - - - - - - - - - - N G T I K L Y K E L R C P L D D  6 7 0
MacTopoIIIα K R G S R F I G C S N Y P N C T F S L P L P K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  6 3 2
MacTopoIIIβ D T G - R F V G C T G Y P D C R N S F P L P K T G - - - - - - - - - - - - - - - - - - - - - A L T V L R S K E C K K G G  6 6 1
HTopoIIIα L E F V C C I G G C D D T L R E I L D L R F S G G P P R A S Q P S G R L Q A N Q S L N R M D N S Q H P Q P A D S R Q T G  7 6 5
HTopoIIIβ F E L V L W S S G S R G K S Y P L C P Y C Y N H P P F R D M K K G - - - - - - - - - M G C N E C T H P S C Q H S - - - -  7 1 7
MacTopoIIIα - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  
MacTopoIIIβ A A V L K V G N K Y N - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -  6 7 2
HTopoIIIα S S K A L A Q T L P P P T A A G E S N S V T C N C G Q E A V L L T V R K E G P N R G R Q F F K C N G G S C N F F L W A D  8 2 5
HTopoIIIβ - - - - - - - - - - - L S M L G I G Q C V E C E S G - - - V L V L D P T S G P K W K V A C N K C N - V V A H C F E N A H  7 6 2
MacTopoIIIα - - - - - - - - - - - - S G Q I V V T D K Q C E T H G L H H I R I I N A G K R P W D L G C P Q C N - - - - - F I E W Q K  6 7 5
MacTopoIIIβ - - - - - - - - - - - - W A V G I G P C F K C E L E K E C Y P P E T V G P C P E C D G S M F L I S F K D S R F L G C T K  7 2 0
HTopoIIIα S P N P G A G G P P A L A Y R P L G A S L G C P P G P G I H L G G F G N P G D G S G S G T S C L C S Q P S V T R T V Q K  8 8 5
HTopoIIIβ R V R V S A D T C S V C E A A L L D V D F N K A K S P - - - - - - - - L P G D - E T Q H M G C V F C D P V F Q E L V E L  8 1 3
MacTopoIIIα T Q K E K Q A Q Q P K K E K P K T I K D I E G - - - - - - - - - - - - - - - - - - - - - - - - - - V G K A T A G K L E E  7 0 9
MacTopoIIIβ R C G Y T H S V P K T G K L T L L D K T C E T C G W K L F R L K E E E K P E L D F C V N R R C P E G R K Y W K Q A G S R  7 8 0
HTopoIIIα D G P N K G R Q F H T C A K P R E Q Q C G F F Q W V D E N T A P G T S G A P S W T G D R G R T L E S E A R S K R P R A S  9 4 5
HTopoIIIβ K H A A S C H P M H R G G P G R R Q - - - - - - - - - - - - - - - - - - - - G R G R G R A R R P P G K P N P R R P K D K  8 5 3
MacTopoIIIα A G I T S V E A L A E A D P - - - - - - - - - - - - - - - - - - - - - - - - - - - I E L A K T I K T S V K K V K T W Q I  7 4 2
MacTopoIIIβ T E P R D Q A K V A A A S S V P A P - - - - - - - - - - - - - - - - - - K V R A G R T P E A K S T P E T R S M P R K A E  8 2 2
HTopoIIIα S S D M G S T A K K P R K C S L C H Q P G H T R P F C P Q N R  9 7 6
HTopoIIIβ M S A L A A Y F V - - - - - - - - - - - - - - - - - - - - - -  8 6 2
MacTopoIIIα S C N G G I V E D L - - - - - - - - - - - - - - - - - - - - -  7 5 2
MacTopoIIIβ S P A S G R V S K L S S T A S R R K E S K - - - - - - - - - -  8 4 3
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